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SUMMARY 
The feasibility of developing immunological and molecular diagnostic tools for routine diagnosis 
of brucellosis under conditions of a less economically and scientifically advanced country in 
general and Mongolia in particular was analysed. Brucellosis is a major healthcare issue in 
Mongolia for both, humans as well as lifestock farming, leading to enormous economic losses 
every year. Diagnosis of the disease is demanding and insufficiently specific with the available 
tests. Using genomic sequences of the most important Brucella strains, new diagnostic 
procedures have been developed by means of molecular biotechnology. They include the 
production of several recombinant proteins as antigens in immunological assays such as 
ELISA. Combining of several of these antigens in a single recombinant fusion protein led to an 
unattained highly specific test for infections caused by Brucella. The genus Brucella includes 
different species (or biovars) carried by different primary animal hosts and being transmitted by 
different routes to humans. Furthermore, the severity of clinical manifestations differs among the 
species necessitating specific  modalities of treatment and making differential diagnosis on the 
species level an important issue. Thus, another part of the study was focused on this topic. By 
means of multiplex nested PCR, a highly sensitive and specific differentiation between the 
major Brucella strains occurring in Mongolia was obtained. The immunological as well as the 
molecular diagnostic principles have been designed to be applicable in laboratory practice 
under limited economical conditions, including simple and inexpensive procedures for antigen 
production and DNA purification. 
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ZUSAMMENFASSUNG 
Ziel der Arbeit war zu versuchen, neue immunologische und molekulare Methoden zur 
routinemäßigen Diagnose der Brucellose unter wirtschaftlich und wissenschaftlich weniger 
privilegierten Bedingung zu entwickeln, wie sie z. B. in der Mongolei vorherrschen.  Die 
Brucellose ist in der Mongolei ein erhebliches Problem, das nicht nur die Gesundheit der 
Bevölkerung betrifft, sondern auch für die Tierzucht relevant ist und dort jedes Jahr zu großen 
ökonomischen Einbußen führt. Die Diagnose der Krankheit ist aufwendig und mit den 
vorhandenen Methoden wenig spezifisch. In der vorliegenden Arbeit wurden unter 
Zuhilfenahme der genomischen Sequenzen der wichtigsten Stämme von Brucella mittels 
molekularbiologischer Methoden neue Diagnoseverfahren entwickelt. Auf der einen Seite waren 
dies verschiedene rekombinante Antigene, die in immunologischen Tests wie dem ELISA zur 
Anwendung kamen. Die Verschmelzung mehrerer solcher rekombinanter Antigene in einem 
einzigen rekombinanten Fusionsprotein führte zu einer bislang unerreicht hohen Spezifität der 
Diagnose der Brucellose.  Das Genus Brucella schließt mehrere  Species (oder Biovare) ein, 
die bei verschiedenen Tierarten vorkommen und auf unterschiedliche Weisen auf den 
Menschen übertragen werden. Die Schwere der klinischen Manifestationen hängt von der Art 
des Erregers ab und bedingt unterschiedliche therapeutische Maßnahmen. Daher ist es wichtig, 
die Art der Erreger durch eine Differentialdiagnose zu identifizieren. Ein weiterer Teil der Arbeit 
befaßt sich daher mit diesem Problem. Mit Hilfe von Multiplex-PCR wurde eine sehr 
empfindliche und spezifische Differenzierung zwischen den wichtigsten in der Mongolei 
auftretenden Brucella-Stämmem erzielt.  Sowohl das immunologische als auch das molekulare 
diagnostische Nachweisverfahren wurden so entwickelt, daß sie unter den bezüglich der 
Finanzierung und der wissenschaftlichen Laborausstattung limitierten Voraussetzungen der 
Mongolei durchführbar sind. Dies betrifft z. B. die Verwendung einfacher und kostengünstiger 
Methoden für die Produktion der Antigene für die Immundiagnose und für die Reinigung von 
DNA für PCR-Analysen.  
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1 INTRODUCTION 
1.1 General facts about brucellosis 
Brucellosis is a group of closely related diseases caused by the members of the genus 
Brucella in animals and humans. It is a zoonosis transmittable to humans with a high degree of 
morbidity. More than 500,000 new cases of brucellosis are reported each year, and according to 
World Health Organization, this figure underestimates the magnitude of the problem. There 
were historically a number of synonyms for this infection: Malta fever, Mediterranean fever, 
Gibraltar fever, Cyprus fever, and undulant fever, but in the meantime all infections by species 
of Brucella are referred to as brucellosis. The organism was first isolated in 1887 by Sir David 
Bruce, who recovered a suspect organism from the spleens of British soldiers dying of Malta 
fever, hence the name for this illness. From this point on, it has progressively become clear that 
closely related bacteria caused all of these diseases. Thus, Meyer and Shaw created the genus 
Brucella in 1920 to accommodate these microorganisms.  
Brucellosis is a complex disease and the range of primary hosts of Brucella includes several 
domestic or semi-domestic animals, cetaceans, pinnipeds and some wild rodents. In domestic 
animals the disease manifests by abortion and infertility. Humans usually acquire brucellosis 
from domestic animals through direct contact or consumption of their products and are not 
themselves source of contagion. The disease in humans is rarely deadly, but debilitating with 
possible severe consequences. The high degree of morbidity, for both animals and humans, is 
an important cause of financial loss and represents a serious public health problem in many 
developing countries (Corbel, 1997). 
1.1.2 Brucella  species: taxonomy, structure, biochemical characteristics and 
polymorphisms 
Genus Brucella belongs to class I Alpha-2 Proteobacteria of phylum Proteobacteria. 
Brucellae are Gram-negative, facultative intracellular pleomorphic bacteria that can infect 
humans and many species of animals (Figure 1.1). 
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Figure 1.1 Electron microscopy of B.abortus (Dennis Kunkel Microscopy, Inc., 2004).
 Six classical species were formerly recognized within the genus Brucellae: B. melitensis, 
B. abortus, B. suis, B. neotomae, B. ovis and B. canis. Two new species were isolated from 
marine animals B. pinnipedialis and B. ceti in mid 1990s (Foster et al., 2007), while recently, a 
novel species, Brucella microti has been detected and isolated from common vole (Scholz et al., 
2008). This classification is mainly based on differences in pathogenicity and host preference. 
Although the six classical species can be differentiated by conventional phenotypic tests, they 
show a high degree of homology in their DNA-DNA hybridization assays (>90 % identity) 
suggesting that the Brucella genus should comprise a single species, B. melitensis, with the 
remaining species considered as biovars. However, molecular genotyping revealed that 
Brucella species display significant DNA inter-specific polymorphisms, justifying the current 
classification. Since the epidemiology and the severity of the diseases in humans is influenced 
by the Brucella type and its source (Corbel et al, 2000), the practical approach in classification 
is also of great importance. In general, B. abortus is associated with cattle, B. melitensis with 
sheep and goats, B. suis with swine, B. ovis causes infections specific for sheep and has not 
been implicated in human diseases, B. canis is usually associated with diseases in dogs but 
occasionally causes human brucellosis, and B. neotomae has been isolated on few occasions 
and has never been implicated in human diseases. The pathogenicity for humans of other 
Brucella species (B. pinnipedialis, B. ceti, and B. microti) still has to be clearly established. 
 The most common Brucella species to affect humans is B. melitensis, the most 
pathogenic species producing the most intense symptoms, the greatest tissue damage, and the 
most frequent incidence of localization in body organs, systems and tissue. 
           3 
The taxonomic identity of the organisms in the genus can be discriminated based on 
their metabolic and antigenic properties. Further, these properties differentiate the species into 
a number of biotypes, primarily based on: their production of H2S, CO2 requirement for growth, 
phage typing, and the ability to grow in a medium containing dyes, such as basic fuchsin or 
thionin, and the agglutination by mono-specific antiserum (Table 1.1). 
 
Species 
 
 
Bio-
type 
CO2  
req’t 
H2S 
prod’n 
Growth on 
media 
containing 
Agglutination 
with 
monospecific 
antisera 
 Lysis by phage† 
       at RTD 
    thionin* fuchsin* A M R Tb Wb Bk Fz 
             
B. abortus 1 (+)‡ + - + + - - L L L L 
 2 (+) + - - + - - L L L L 
 3** (+) + + + + - - L L L L 
 4 (+) + - +*** - + - L L L L 
 5 - - + + - - - L L L L 
 6** - (-)‡ + + + - - L L L L 
 9 - + + + - + - L L L L 
             
B. suis 1  - + + -**** + - - NL L L PL 
 2 - - + - + - - NL L L PL 
 3 - - + - + - - NL L L PL 
 4 - - + (-) + + - NL L L PL 
 5 - - + - - + - NL L L PL 
             
B. melitensis 1 - - + + - + - NL NL L NL 
 2 - - + + +  - - NL NL L  NL 
 3 - - + + + + - NL NL L  NL 
             
B.ovis  + - + (+) - - + NL NL NL NL 
             
B.canis  - - + - - - + NL NL NL NL 
             
         NL    
B. neotomae  - + - - + - - or L L L 
         PL    
 
Table 1.1 Differentiation of Brucella species and biotypes (Stack JA and MacMillan AP, 
1998).                              
                        L = Confluent lysis        PL = Partial lysis     NL =   No lysis 
 * Concentration  =  1/50 000 w/v 
 † Phage R will lyse non-smooth Brucella abortus at RTD 
  Phage R/O will also lyse B. ovis at RTD 
 ‡ (+) = Most strains positive    (-) = Most strains negative 
 ** For more certain differentiation of B. abortus Type 3 and Type 6,  
  thionin at 1/25 000 (w/v) is used in addition.  Type 3 = + , Type 6 = - . 
 *** Some strains of this biovar are inhibited by basic fuchsin 
 **** Some isolates may be resistant to basic fuchsin, pyronin and safranin O 
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The three major species of Brucella affecting humans (B. melitensis, B. abortus and B. 
suis) contain two major surface antigens (designated as A and M), but the relative proportion of 
each antigen varies considerably from a species or a biotype to another.  The antigen variations 
are due to the organisms’ O-polysaccharide structure in the LPS, according to recent studies 
(Iriarte et al., 2004). The genomes of the classical Brucella species and their biotypes are 
comprised of two chromosomes, the only exception being B. suis biotype 3 strain 686 with a 
single chromosome. The larger chromosome is about 2.1 Mbp and contains the bacterial origin 
of replication. The smaller chromosome is approximately 1.2 Mbp and includes plasmid 
replicating functions (Halling et al., 2004).  
Several molecular genotyping methods have been used to show that Brucella species 
display significant DNA polymorphisms, justifying current species classification (Cloeckaert, 
Vizcaino, 2004). The polymorphisms include: the variability in the genome organization, 
distribution of insertion sequences (IS) and the polymorphisms in genes encoding surface, 
cytoplasmic and periplasmic protein antigens. The studies also revealed intra-biotype DNA 
polymorphisms. 
Studies of Brucella proteome (secretome and cellular proteome) have up to now 
uncovered a number of differences not only between B. abortus and B. melitensis, but also 
between the wild and attenuated strains of B. melitensis (Eschenbrenner et al., 2006). 
1.1.3 Virulence and pathogenesis 
Brucella infection primarily occurs through inhalation or ingestion  of organisms via the 
nasal, oral, and pharyngeal cavities (Boschiroli et al., 2001).  Bacteria also can invade the host 
organism directly into the bloodstream through wounds and mucosae. Following infection, the 
bacteria are transported, either free or within phagocytic cells, to the regional lymph nodes. The 
spread and multiplication of Brucella in lymph nodes, spleen, liver, bone marrow, mammary 
glands, and reproductive organs occurs via macrophages. B. melitensis, B. abortus, B. suis, 
and B. canis can infect humans and the pathological manifestations of brucellosis in humans 
are meningitis, endocarditis, spondylitis, and arthritis. The Brucella replication in the host is 
mainly due to their ability to avoid defence mechanisms of the host and proliferate within 
macrophages. Thus, these organisms not only resist killing by neutrophils following 
phagocytosis (Riley and Robertson, 1984) but also replicate inside the macrophages and non-
phagocytic cells. In addition, survival in the macrophages is considered to be responsible for 
establishment of chronic infections and allows the bacteria to escape the extra-cellular 
mechanisms of host defence such as complement and antibodies.  
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Brucella preferentially infects macrophages, in which they modify phagocytosis, 
phagolysosome fusion, cytokine secretion, and apoptosis. This complex host-pathogen 
interaction is controlled by virulence genes which produce virulence factors. The most important 
of them are: LPS, cyclic glucans, OMPs, periplasmic enzymes, heat shock proteins, type IV 
secretion system (VirB operon), and the two-component regulatory system BvrS/R. Also 
important role in the  virulence of this organism play some specific features as erythritol and iron 
metabolism which partly explains its tissue specific localisation in the case of animal infections. 
  
 
 
Figure 1.2 Intracellular trafficking of Brucella in macrophages. Following an LPS-
dependent, lipid raft-mediated entry, Brucella is found in an early BCV (5–10 min p.i.) that 
interacts with early endosomes (purple), transiently acquiring Rab5 [13] and EEA-1 [11]. BCVs 
then mature into acidic intermediate vacuoles that accumulate LAMP-1, but not Rab7 [11], 
avoiding interactions with late endosomes and fusion with lysosomes via LPS and cyclic ß-
glucan-dependent mechanisms [2,28]. Intermediate BCVs (blue) interact with ER exit sites 
(ERES; 2–8 h p.i.; [12]). Such interactions require the VirB type IV secretion system and lead to 
fusion between BCVs and the ER (8–12 h p.i.), generating an ER-derived organelle permissive 
for bacterial replication (12 h p.i. onwards; green [11]). Vacuoles containing VirB-deficient 
Brucella cannot sustain interactions and fuse with the ER. They ultimately fuse with lysosomes 
(red). Replicative BCVs exclude LAMP-1 and acquire various ER markers, (calnexin, 
calreticulin, sec61ß, PDI) as a result of membrane exchange with the ER. Bacterial replication is 
thought to occur through fission of the BCV into two daughter BCVs via further accretion of ER 
membranes (Celli J., 2005). 
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In the initial stage of infection, Brucella’s surface structures (LPS, proteins) bind to lipid 
rafts and several membrane receptors of macrophages. After phagocytosis, the cyclic-AMP/pkA 
pathway is activated in these cells, followed by phosphorylation of transcription factors. In 
epithelial cells, the bacterium recruits actin filaments in order to be vacuolized. In host cells, by 
preventing phagosome-lysosomal fusion, Brucella arrives at ER, the compartment that 
constitutes its replicating niche (Fig 1.2). 
  During intracellular trafficking, a cascade of genes is activated in Brucella in order to 
resist harsh environmental conditions of the phagosome. Finally, the accumulated bacteria are 
disseminated to other host cells. 
1.1.4 Immune response 
Brucella spp. are able to survive phagocytosis by several ways of intracellular life 
including the ability to prevent phagolysosomal fusion in specialized phagocytes such as 
macrophages and dendritic cells and by activation of a set of genes in response to the acidic 
environment (Cheers et al., 1979). Because these organisms are located intra-cellularly, an 
effective immune response includes mainly cell-mediated mechanisms. Immunity is largely 
based on production of interferon-?, which is controlled by IL-12, while its effective functioning 
for activation of macrophages depends on TNF-a. It is likely that depending on the stage of 
infection, both CD4 and CD8 cells make INF- ? in immune response. Both reactive oxygen 
intermediates and nitric oxyde contribute to control within macrophages and INF- ? serves to 
increase anti-Brucella activities.  
Although many aspects of the immunobiology of brucellosis have become clear, this field 
still needs to be elucidated further. 
Both innate and adaptive immune responses take part in Brucella infection. Innate 
immunity is induced in early stage of infection playing role to reduce the initial number of 
bacteria and to provide the environment for generating Th1 response in the host.  
Complement is activated by classical and lectin pathways and results in deposition and 
complement-mediated killing of Brucella. The mechanism of activation mainly depends on the 
type of the infecting strain (smooth or rough). Rapid phagocytosis of bacteria by neutrophils 
occurs after opsonisation, however, most of Brucella survive. Using resistance mechanisms 
against bactericidal systems inside the cell, Brucella is transported to lymphoid tissues by 
neutrophils. A significant role in brucellosis play NK cells providing cytotoxity against infected 
cells. However, in some cases they fail to do so, promoting chronicity of infection. The 
bactericidal functions in macrophages are ROIs and RNIs (reactive oxygen/nitrogen 
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intermediates), which are induced by INF- ? and TNF-a.  ROIs are suggested to be the main 
toxic agent. The macrophages have the ability to kill intracellular Brucella immediately after 
phagocytosis, but often intracellular bacteria survive and multiply by activating virulence genes 
and factors. Characteristic chronic granulomatous lesions (Figure 1.3) develop in infected 
tissues where macrophages, neutrophils and lymphocytes respond to proteins and saccharides 
of Brucella.  
 
 
Figure 1.3 Brucella granuloma in liver.  
(Image: http://upload.wikimedia.org/ Brucella_granuloma.jpg). 
Sequentially, neutrophils appear first in response to Brucella, followed by macrophages 
and then lymphocytes. 
Adaptive immune response to Brucella infection consists of antibody production, T cell 
activation, and cytokine activity. During infection, antibodies against LPS and a variety of 
bacterial proteins are detectable. The production of IgM or IgG antibodies at low concentrations 
in naturally infected species appears to promote lysis of Brucella by the classical complement 
pathway.  Higher antibody levels of IgG present during active infection prevent bacterial lysis 
and likely promote phagocytosis of bacteria by macrophages enhancing bacterial intracellular 
localization (Ko and Splitter, 2003). 
Optimal protection against intracellular bacteria is achieved by a coordinated interaction 
between different T cell subsets, CD4 and CD8, respectively. Another subset,  ?d T cells, 
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activated by non-peptide antigens, control the increase in the number of intracellular Brucella 
organisms by secreting TNF-a and IFN-? to activate macrophage bactericidal function and by 
lysing the infected cells through cytotoxicity. Cytokines playing an essential role in brucellosis 
are IL-12, IFN-?, and TNF-a. IL-12 is a key cytokine produced by B cells and macrophages, and 
leads to Th1 immune responses in the host that will ultimately induce the secretion of IFN-? 
from T cells. The roles of other cytokines in infection need further studies. 
1.1.5 Clinical spectrum of Brucella infection 
The presentation of brucellosis is characteristically variable. The incubation period is 
often difficult to determine but is usually from 2 to 4 weeks. The onset may be insidious or 
abrupt. The sub-clinical infection is common. 
In the simplest case, the onset is influenza-like, with fever reaching 38° to 40°C. Limb 
and back pains are unusually severe, however, and sweating and fatigue are marked. The 
leukocyte count tends to be normal or reduced, with a relative lymphocytosis. Hepatomegaly is 
reported in 20-60 %. On physical examination, splenomegaly may be the only finding. If the 
disease is not treated, the symptoms may continue for 2 to 4 weeks. Many patients will then 
recover spontaneously but others may suffer a series of exacerbations. These may produce an 
undulant fever in which the intensity of fever and symptoms recur and recede at about 10 day 
intervals. Anemia is often a feature. True relapses may occur months after the initial episode, 
even after apparently successful treatment.  
Most affected persons recover entirely within 3 to 12 months but some will develop 
complications marked by involvement of various organs, and a few may enter an ill-defined 
chronic syndrome. Complications include arthritis, endocarditis, mycotic aneurysms, often 
sacroiliitis, and spondylitis (in about 10 percent of cases), central nervous system effects 
including meningitis (in about 5 %), uveitis, and, occasionally, epididymoorchitis. In contrast to 
animals, abortion is not a feature of brucellosis in pregnant women. Hypersensitivity reactions, 
which may mimic the symptoms of an infection, may occur in individuals who are exposed to 
infective material after previous, even sub-clinical, infection. 
Organ systems involvement:  
Skeletal System 
Arthritis is said to be the most common localized complication of brucellosis. 
Osteoarticular manifestations of brucellosis are reported in 20-60 % of patients. In contrast to 
adults, in whom sacroiliitis predominates, childhood brucellosis most often affects large 
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peripheral joints and usually with monoarticular involvement (hips, knees, and ankles). 
Spondylitis is more common in elderly patients, and may result in paraspinal abscesses. 
Osteomyelitis involving the long bones have also has been reported but is less common in 
children than adults. 
Gastrointestinal System 
Brucellosis, like typhoid-fever, is an enteric fever in which systemic symptoms generally 
predominate over complaints localized to the gastrointestinal tract. Nausea, vomiting, anorexia, 
weight-loss, diarrhea or constipation followed with abdominal discomfort occurs in 30-60 % of 
the patients. A case of a child infected with B.melitensis in whom acute ileitis developed has 
been reported. The liver is probably always involved, but serum levels of hepatic enzymes are 
elevated only mildly. B. suis can cause suppurative abscesses involving the liver and spleen. 
Hepatic lesions are resolved with antibmicrobial therapy and cirrhosis does not occur. 
Splenomegaly occurs in 35 % of the paediatric patients.  
Neurobrucellosis 
Neurologic manifestations of brucellosis include meningitis, encephalitis, 
meningovascular complications, parenchymatous dysfunctions, peripheral neuropathy/ 
radiculopathy, Guillain-Barre's syndrome, brain abscess and psychosis. Central nervous system 
involvement occurs in less than 5 % of patients and usually presents as acute or chronic 
meningitis. Meningitis can be the presenting manifestation or it can occur late in the course of 
brucellosis. There is little to distinguish it clinically from meningitis caused by other bacteria, 
except for the lack of sings of meningeal irritation. Examination of cerebrospinal fluid (CSF) 
reveals lymphocytic pleocytosis with elevated protein content, and low to normal glucose level. 
Cultures of CSF are positive in less than one-half of cases, but antibodies are present in the 
majority of the cases in the CSF.  
1.1.6 Treatment 
The essential element in the treatment of all forms of brucellosis is the administration of 
effective antibiotics, and treatment should be implemented at an early stage. Treatment regimes 
usually consist of combination of at least two agents; however, the optimum antibiotic therapy is 
still disputed (1st International Conference on Emerging Zoonoses, 1997). The full treatment 
lasts 7 to 12 weeks. A shorter duration of treatment is associated with higher relapse rates. 
Additionally, severely ill patients should be treated in a hospital. In those patients with 
complications, additional treatment is necessary including, in some cases, surgical intervention. 
           10 
The appropriate antibiotic therapy for brucellosis has been studied to some degree. 
Doxycycline (100 mg PO bid for 6 weeks) is the most appropriate monotherapy in simple 
infection; however, relapse rates approach 40 % for monotherapy treatment. Rifampin (600-900 
mg/d) usually is added to doxycycline for a full 6-week course. In patients with spondylitis or 
sacroiliitis, doxycycline plus streptomycin (1 g/d IM for 3 weeks) was found to be more effective 
than the doxycycline/rifampin combination. Streptomycin currently is favoured over rifampin for 
combination therapy of any significant infection. In paediatric patients older than 8 years, 
doxycycline (5 mg/kg/d for 3 weeks) plus gentamicin (5 mg/kg/d IM for the first 5 d) was the 
recommended therapy. For children younger than 8 years, trimethoprim / sulfamethoxazole 
(TMP-SMZ) for 3 weeks and a 5-day course of gentamicin were most effective. TMP-SMZ also 
was effective in treating pregnant women, either as a single agent or in combination with 
rifampin or gentamicin. 
Fluoroquinolones have a high relapse rate when used as monotherapy. 
Fluoroquinolones added to doxycycline have no advantage over the other regimens described, 
but may be preferred in an area where resistance to rifampin is high. No uniform 
recommendation exists for treatment of meningitis or endocarditis; however, TMP-SMZ plus 
rifampin remains the preferred combination. In endocarditis, early replacement of the infected 
valve is recommended, along with medical therapy. Corticosteroids are recommended in CNS 
infection, but data supporting their utility are lacking.  
1.1.7 Control and prevention 
Most human brucellosis originates from an infected animal. Human to human infection is 
rare. Prevention includes health education and pasteurization of milk.  
However, education campaigns alone have never succeeded in fully eliminating these 
risks to humans (Robinson A, 2003). Attempts at vaccinating people at risk have resulted in 
effective protection, but also provoked severe reactions when given to sensitised individuals, or 
when administered incorrectly (Schurig et al, 2002). As a result, vaccination of humans is no 
longer routinely used; the ultimate prevention of human infection remains the elimination of the 
brucellosis in animals. Currently, methods used to prevent infections are test and slaughter 
(T&S) of sero-positive animals, vaccination, hygiene measures, and management. Various 
factors influence the choice of methods used such as husbandry system, climate, nomadic 
livestock breeding, prevalence of brucellosis among various animal species, and control 
programme resources available. 
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T&S is not realistic in the majority of places where B. melitensis is endemic (Banai, 
2002). Therefore, until the disease prevalence is significantly reduced, whole herd immunisation 
should precede T&S activities. Experts advise a shifting away from immunisation to a T&S 
policy only after the individual prevalence rate is no greater than 2-3 % and the herd prevalence 
is 5-10 % (Food and Agriculture Organisation of the United Nations, Rome, Italy, 1992c). 
One of the ultimate goals of Brucella research is to achieve its eradication or to prevent 
its expansion. Prevention of human brucellosis is dependent on control of the disease in 
domestic livestock, mainly through mass vaccination. In many countries, the use of B. abortus 
strain vaccines (S19, RB51) in cattle and B. melitensis strain Rev-1 vaccine in goats and sheep 
has resulted in the elimination or near-elimination of brucellosis in these animals. Studies are 
ongoing to develop an effective vaccine against B. suis  and B. ovis. Since the treatment of 
animal brucellosis is very expensive, the mass vaccination of livestock should encouraged. 
Animal owners should be taught about the importance of vaccination of their animals. In spite of 
the clinical efficacy and cost effectiveness of vaccination, the limited availability of vaccines and 
lack of awareness has led to the persistence of brucellosis in most areas of developing 
countries. The lack of human vaccines and effective control measures make it necessary for the 
doctors and other health care workers to take protective measures. Protective clothing / barriers 
while handling stillbirths / products of conception and cultures can reduce occupation-related 
brucellosis. The avoidance of un-pasteurised dairy products prevents infection in the general 
population. Control and prevention of this disease needs not only coordinated activities of public 
health and veterinary institutions, but also a government control in order to establish and 
implement programmes for this purpose. 
Vaccination of livestock along with proficient animal health services, good animal 
management, intensive breeding, control of movement and trade of animals are the key to 
eradication of brucellosis. 
All vaccines used in vaccination of livestock are live attenuated rough strains. While 
vaccines for livestock are primarily aimed at interruption of transmission, the goal of human 
vaccination, which is under intensive investigation and development, is prevention of the 
disease. It is generally recognized that the prevention of human brucellosis is best achieved by 
control or eradication of the disease in animals. However, in some parts of the world this is not 
feasible and attempts have been made to control the disease by vaccination. Although several 
human vaccines have been tested to date, none is completely satisfactory. Attempts were made 
towards developing vaccines based on live-attenuated or mutant strains, protein subunits, and 
killed bacteria. While subunit vaccines contained different parts of bacterial cell (polysaccharide-
protein, lipoprotein, intracellular enzymes etc.), the attenuated live vaccine strains were selected 
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on basis of virulence and LPS structure. These vaccines also differ in their routes of 
administration. The main disadvantage of these vaccines is the short-duration immunity, 
reactogenity and ability of some live strains to cause disease. Intensive investigations on 
effectiveness of DNA vaccines and live mutation-introduced strains are under way. The basic 
premise of DNA vaccines involves the introduction of gene(s) encoding protein antigens 
responsible for stimulating a protective immune response (Robinson, 1997). Use of mutants 
either lacking virulent properties or over-expressing immunogenic antigens are under study as 
well. 
1.1.8 Epidemiology of brucellosis worldwide 
Brucellosis is a zoonosis distributed worldwide. In developed countries, the animal 
disease has been brought under control, consequently reducing number of human cases. The 
human morbidity is usually high in areas where the disease is endemic in livestock, thus 
showing that the occurrence of human brucellosis mainly depends on animal reservoir. Humans 
are infected either by direct contact with infected animals and their products or by consumption 
of contaminated milk and dairy products. Direct contact implies that a person working or living in 
a place where the animal species susceptible to Brucella infection exist, and in close contact 
with animals potentially infected by brucellosis either by milking the animals or processing raw 
animal products like milk, meat or skin. In this case the actual route of infection is through skin 
abrasions and inhalation of aerosols. 
In parts of the world where the Brucella infection is endemic in livestock, the incidence of 
human brucellosis remains high. However, in areas where Brucella spp. infection is present but 
the pasteurization of raw milk is practiced and dairy products are made from pasteurized milk, 
disease occurs at lesser frequencies. In these areas brucellosis is regarded as occupational 
hazard for persons who routinely work with animals and handle their raw products (Nicoletti, 
1989). On the other hand, in areas where the quality control of dairy products is not enforced or 
the consumption of un-pasteurized milk and dairy products is a common nutritional habit, 
brucellosis occurs at relatively higher rate and causes a serious threat to public health. The 
route of infection in this case is mucosa of the digestive tract. Poor hygienic conditions in 
developing countries also contribute to the spread of the disease. However, due to growing 
international tourism, the numbers of reported cases of brucellosis in developed countries, 
where the disease was previously brought under control, is on the rise. Although the cases of 
human brucellosis are registered, the official figures do not fully reflect the number of people 
that are infected annually, underestimating the scope of the problem. Some cases often remain 
unrecognized due to inaccurate diagnosis and the consequent treatment as other diseases. 
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The epidemiology of human brucellosis, the most common zoonotic infection worldwide, 
has drastically changed over the past decade because of various sanitary, socioeconomic and 
political advances, as well as development of international travel. Several areas traditionally 
considered to be endemic - e.g. France, Israel, and most of Latin America - have achieved 
control of the disease. Nonetheless, new foci of human brucellosis have emerged, particularly in 
Central Asia, while the situation in certain countries of the Near-East (e.g. Syria) is rapidly 
worsening. Furthermore, the disease is still present, in varying trends, both in European 
countries and in the USA. Figure 1.4 depicts the incidence of human brucellosis worldwide. 
Table 1.2 shows the countries with the highest annual incidence of human brucellosis from 
2000 onwards, as well as the incidence for selected other countries.  
These changes in epidemiology of brucellosis reflect alterations in socioeconomic 
parameters, improvements in recognition and notification systems, outcomes of ongoing 
eradication programmes of animal brucellosis, and the evolution of the “global village” through 
international tourism (G.Pappas et al., 2006). 
 
 
 
Figure 1.4 Worldwide incidence of human brucellosis (http://infection.thelancet.com). 
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Table 1.2 List of countries with annual incidence of human brucellosis from 2000 onwards. 
Annual cases per million of population (Pappas et al., 2006). 
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1.1.9 Brucellosis in Mongolia 
Mongolia, situated in Central Asia between Russia and China, has a population of 2.7 
million people and an average population density of 1.5 persons per sqare kilometre Major 
political and healthcare changes began in 1990, when Mongolia ceased to be under the Soviet 
control and stopped receiving developmental aid as one of the Eastern Bloc satellites. Since 
that time, its economy has been changing from a centrally planned socialist system to a free 
market economy with healthcare delivery reflecting that transition. 
Although progress is being made, Mongolia continues to struggle with poor 
transportation and communication, and limited material (including laboratory) facilities. Financial 
difficulties remain a major challenge as the country seeks to develop economic self-sufficiency 
and deliver modern health care to its people.  
Approximately 23 % of Mongolia’s population lives in rural areas and leads a nomadic or 
semi-nomadic way of life. In Mongolia, livestock rearing and milk production are important 
branches of the economy, employing approximately 50 % of the population. Their diet is heavily 
dependent on meat and dairy products, reflecting the importance that large domesticated 
animals have played in the country’s history. In the past decade, the number of livestock has 
increased from 26 million to over 40 million, including 17.02 million sheep, 18.2 million goats, 
2.4 million cattle, 2.1 million horses, and 350,500 camels (National Statistical Office of 
Mongolia, 2007, p.78). Not surprisingly, brucellosis remains one of the major veterinary and 
public health problems in Mongolia. The Brucella seroprevalence rate in cattle in 1987 ranged 
from 3.8 % to 35 % before a vaccination program (Denes B., 1997) but now appears to be 
approximately 5 % -10 % with some focal areas being close to 50 % (Andrea Mikolon, 2000). 
Seroprevalence in sheep and goats is less, approximately 2 %. 
Factors influencing transmission 
Traditional Mongolian practices have controlled food borne transmission of brucellosis 
from animal to human: milk was mostly not drunk in its natural state, but transformed to various 
typical drinks or foodstuffs, which have a preventive effect on the transmission of brucellosis. 
Naturally, animal husbandry has played an important role in the transmission of brucellosis 
between animals and from animal to humans. Even though modern husbandry methods have 
been introduced, such as dairy cattle farming, the bulk of animal production largely remains 
nomadic or semi-nomadic to this day. Crucial factors in this setting, from an epidemiological 
point of view, are the close contact between animal and human, some specific management 
practices and habits concerning hygiene (Roth, 2006). 
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Since the birthing season of most life stock falls on early spring in Mongolia, close 
human-animal contact usually occurs when herders bring the new born animals into their 
dwellings in order to protect from freezing. Furthermore, the winter shelters are crowded and the 
faeces become contaminated when abortions due to Brucella infection occur. These faeces are 
consequently transformed into fine dry dust, creating a dangerous source of airborne infection. 
 Specific management practices in Mongolia such as keeping various kinds of animals, 
especially goats and sheep, together in pastures and watering places also promotes 
transmission of the disease. Herders do not practice grazing control or fencing, thus making 
possible transmission of pathogens not only between domestic animals, but also between 
livestock and wildlife. Animal movement from various parts of the country to slaughterhouses in 
Ulaanbaatar is frequent, favouring the spread of animal diseases. The fact that animals are 
frequently mixed and regrouped further contributes to the spread of brucellosis. 
Beside above factors, the situation is exacerbated by inadequate water resources in 
rural areas during the birthing season, when abortions and mass-parturition take place, leading 
to negligible hygienic measures. No adequate  measures are practiced to protect against 
contact infections and to disinfect or clean equipment and shelters as well. 
Routes of transmission 
Early studies on transmisson of brucellosis (Dashdavaa, 1969) recognised the 
importance of animal and food borne transmission for human infection. Further studies 
confirmed that 94.3 % ± ?0.6 % of human infections were caused by animal contact and 5.7 % ± 
0.5 % by alimentation (Baldandorj, 1972). The importance of contact transmission has again 
been confirmed by later studies: 89.2 % of human infection was due to direct animal contact 
(62.1 % of these during animal birthing season), 4.3 % was due to contact with contaminated 
animal products and only 6.5 % of the human infection had been identified as food borne 
(Dashdavaa  et al, 1981). Thus the main risk group has been identified: people having close 
contact to animals or working with animal products. 
In the 1970s, scientific studies attested that 39 % of the herders were infected with 
brucellosis, 6.6 % of the students of Agriculture Institute and 2.2 % of the workers of the plants 
processing wool, leather or meat (Damdinsuren , 1972). Most of the herders were breeding 
small ruminants or cattle (Baldandorj , 1972). A survey in urban settings showed very high 
brucellosis prevalence among workers in plants processing animal products (50.8 % ± ?6.2 % 
seropositive by allergic test; 20.3 % ±? 3.0 % by standard tube agglutination test (SAT) and 
complex fixation test (CFT) and a relatively low prevalence of 1.9 % among unprofessional city 
residents (Baldandorj T, 1972). Surveys conducted in late 1980s reported that 13.5 % of the 
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herders were sero-positive (Ministry of Agriculture, 1991), and confirmed the severe 
contamination of persons working in high risk professions: 28.7 % of the persons working in 
slaughter houses were infected with brucellosis, 17.8 % working in dairy cattle farms, 19.6 % 
working in leather industry and 22.5 % working in the wool industry (Enkhbaatar  et al, 2004). 
This situation seemed to become even worse in the late 1990s, when a survey conducted in 
1996 among 42,000 members of the high risk group (herders, veterinarians etc.) showed that 
30.9 % of them were infected (Ministry of Food and Agriculture, 1996). 
Epidemiological characteristics 
“The morbidity in human population clearly coincides with the lambing and kidding 
season, where 80 % of all cases of human infections are recorded” (Kolar J., 1970). It is 
concordant with other analyses showing that 70 % of new human infections occurred between 
March and July (Baldandorj, 1972). However, intense human infections have been documented 
in autumn as well (Tserendash, 1972). Thus apart from the birthing season, a further 
opportunity of humans to be infected is also associated with milking or slaughtering of infected 
animals, both more prevalent in the late summer and autumn. 
The strains isolated from aborted foetuses and milk (Baldandorj, 1972) were biotypes I 
of B. abortus in cattle (Gombosuren, 1982) and all three biotypes (1,2, and 3) of B. melitensis in 
small ruminants (Tserendash, 1972) (Cvjetanovic et al, 1968). Human studies from 1964 to 
1966 and 1975 to 1976 confirmed that most infections in humans in Mongolia were caused by 
B. melitensis (Dashdavaa et al, 1981) (Gombosuren, 1982). The analysis of patients diagnosed 
with brucellosis, between 1958 and 1969, showed that about 70 % had chronic brucellosis at 
the time of diagnosis (Baldandorj , 1972). By the early 1970s, 86.7 % of the brucellosis patients 
had chronic disease (Damdinsuren, 1972). Brucellosis was often diagnosed too late, probably 
due to limited access to healthcare facilities for diagnosis and treatment. More recently, 
between 1999 and 2001, 47.8 % of the brucellosis patients, treated at the Infectious Disease 
Centre in Ulaanbaatar (capital city), suffered from the chronic form of brucellosis, and a survey 
among 250 physicians resulted in 56.4 % of the cases being chronic in their consultancies (16 
% acute, 20 % sub-acute) (Badarch, 2001). This high proportion in chronic cases reflected the 
poor quality of access to healthcare and diagnosis (Erdenchimeg et al, 2001). 
As of 2001, approximately 8,000 human cases of chronic brucellosis were reported in 
Mongolia, and 1,000–1,500 new cases have been reported yearly since 1996 (National 
Statistical Office of Mongolia, 2007) as compared with approximately 100 cases annually in the 
United States. 
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Most chronic patients appear to have chronic skeletal disease diagnosed by clinical 
features, x-ray findings, and positive serologic results. Cultures are rarely done because of lack 
of appropriate safeguards for this level III pathogen but are performed occasionally. 
Attempts to control this zoonotic infection have been unsuccessful because of an 
inconsistent strategy varying from vaccination of livestock to the destruction of infected animals. 
After numerous surveys in the 1960s, the World Health Organization (WHO) came to the 
conclusion that livestock vaccination was the only effective way to control brucellosis. The 
production of livestock vaccines was successfully established in 1970s and a country-wide 
mass-vaccination program of livestock planned for 11 years started in 1975. The vaccination of 
livestock successfully reduced human incidence of brucellosis to less than one case per 10,000 
per year (Kolar, 1977). The vaccination program was interrupted in the early 1980s due to the 
end of the WHO assistance and democratic reforms followed by the discontinued economic 
dependence on the former Soviet Union in 1990. As a consequence, human brucellosis re-
emerged. A large survey conducted during 1990–95 among herdsmen and other people who 
worked with animals showed that 16 % of the examined population were infected (Mongolia 
Health Sector Review, WHO, 1999). In 1999 the WHO conducted meetings with the Ministry of 
Health and the National Medical University to further assess the health impact of brucellosis in 
the country and make recommendations for its control. As a result, a whole-herd vaccination 
strategy covering 10 years was developed to start in 2000 (Mikolon, 1999). 
According to recent reports (Health Sector Report, 2007, Mongolia), the human 
brucellosis level is presently about 60 cases per 100,000, and high incidence in animals 
continues to cause significant economic losses. Therefore, better control of brucellosis may 
have far-reaching effects for the Mongolian public health and economy by reducing morbidity 
and opening up new international trade opportunities for livestock. 
1.2 Diagnostic methods for brucellosis  
1.2.1 Clinical diagnosis 
The clinical picture in human brucellosis can be misleading, and cases in which 
gastrointestinal, respiratory, dermal, or neurologic manifestations predominate are not 
uncommon. Thus, owing to its heterogeneous and poorly specific clinical symptomatology, the 
diagnosis of brucellosis always requires laboratory confirmation.  
 
 
           19 
1.2.2 Laboratory diagnosis 
For laboratory diagnosis of brucellosis specimens can be either of clinical or 
environmental origin. Clinical specimens best suited include: blood, sera, infected tissues and 
abscess material; bone marrow and tissue from spleen or liver, CSF, pleural fluid and even 
urine. Environmental samples can be milk, meat and other animal products. 
Routine biochemical and hematological laboratory tests also overlap with those of many 
other diseases. Leukopenia or a normal white blood cell count is more common than 
leukocytosis. Normocytic anaemia is frequently present. Sometimes there is thrombocytopenia. 
Liver tests may be abnormal and a liver biopsy or bone marrow specimen can often (± 75 %) 
show granulomatous lesions. The cerebrospinal fluid can be abnormal with an increased 
lymphocyte count, raised CSF protein and normal glucose concentration. 
Generally, laboratory tools include isolation and identification of Brucellae from clinical 
samples, detection of antigen, demonstration of genome and demonstration of Brucella specific 
antibodies. Following diagnostic methods are applied for diagnosis of human brucellosis: 
Bacterial culture confirmed by light microscopy of Gram stained samples and urease 
test. 
Immunoassay tests, which include: Rose Bengal test (RBT), Standard tube agglutination 
tests (SAT), Coombs test, Brucellacapt, radioimmunoassay, ELISA. 
Nucleic acid detection tests which include mainly PCR based tests. 
In Mongolia, the diagnosis of human brucellosis is primarily based on serological 
findings obtained from the Rose Bengal serum agglutination tests. Commercial ELISA tests, 
using LPS as an antigen, are also available. Veterinary laboratories are relatively more 
advanced in respect to culturing, typing and subtyping of Brucella species compared to human 
medical laboratories.  
Definitive diagnosis of human brucellosis is made on the basis of medical history, 
physical examination and serological tests. Bacterial culture is not routine and no data are 
currently available on the use of the method in Mongolia. Imaging is also performed in order to 
detect involvement of internal organs such as spleen and liver. Electrocardiography is not a 
routine procedure for diagnosis of brucellosis, however is occasionally used for revealing 
possible endocarditis as complication of the disease. No recent data are available on 
predominance of Brucella species causing human brucellosis. 
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1.2.2.1 Bacterial culture 
The isolation and identification of Brucella considered to be “ golden standard “ in 
diagnosis of brucellosis and is a proof of definite diagnosis.  
From humans the organism is most commonly isolated from blood or bone marrow, but 
may be isolated from  liver,  spleen, cerebrospinal fluid or focal abscess. 
 
 
 
 
Figure 1.5 Brucella spp. Colony Characteristics. The bacteria grow slowly on most standard 
laboratory media (e.g. sheep blood, chocolate and trypticase soy agars). The morphology of 
colonies is pinpoint, smooth, entire translucent, and non-hemolytic at 48h. 
(Image: http://phil.cdc.gov/PHIL_Images/03182002/00014/PHIL_1902_lores.jpg). 
 
Specimen are inoculated in media at 35-37°C and need 5 % CO2. Standard blood media 
may be used for blood or bone marrow specimens, other specimens may use Trypticase soy 
agar with 5 % sheep blood agar (Figure 1.5), MacConkey agar, or Martin Lewis agar (Alton et 
al., 1988). Media for cultures are broth, solid, and 2 phase systems. Specific media include 
antibiotics for selectivity. Beside classical isolation procedures, there are newly developed 
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methods and growth systems such as lysis centrifugation method and automated blood culture 
systems.  
After culturing the samples are stained with Gram's stain and observed using light 
microscopy (Figure 1.6); suspicious cultures are tested with further biochemical tests. These 
tests allow not only identification of Brucella as genus, but also further differentiation as 
biotypes.  
 
 
 
Figure 1.6 Gram-stained Brucellae under light microscopy. 
(Image: http://phil.cdc.gov/PHIL_Images/03182002/00013/PHIL_1901_lores.jpg). 
1.2.2.2 Immunological methods 
Serological tests, such as Rose Bengal Plate Agglutination Test (RBPT) (Bercovich, 
1998, Diaz-Aparicio et al., 1994), standard tube agglutination test (SAT), Coombs test (Orduna 
et al., 2000, Bercovich, 1998), immunocapture agglutination test (Brucellacapt) (Orduna et al., 
2000), latex agglutination, complement fixation test, ELISA, lateral flow assay - a simplified 
version of ELISA, dipstick assay (Smits et al., 1999), fluorescence polarization assay (FPA) 
were mainstray of laboratory diagnosis for many years. Generally, all these tests use whole cell 
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or LPS as antigen and are applied for presumptive diagnosis. From above methods the first 
three are used frequently for diagnosis of human brucellosis, while others usually applied for 
diagnosis of animal disease, and differentiation of vaccinated from non-vaccinated animals.  
Rose Bengal test that applies stained B. abortus antigen to detect serum antibodies is 
mainly used for screening purposes and is usually followed by one of more specific confirmatory 
assays. 
Contamination of food also is matter of concern of public health sector. The milk ring test 
is a serological test for lacteal anti-Brucella IgM and IgA bound to milk fat globules in cow or 
goat milk . (Bercovic, 1998). 
Antibodies usually begin to appear in the blood at the end of the first week of disease, 
IgM appearing first followed by IgG. Immunological methods used for diagnosis of brucellosis 
are based on antigen-antibody interaction, and antibodies can be either IgG or IgM, depending 
on the phase and stage of disease.  
Generally immunoassays for diagnosis of brucellosis are suggested to lack specificity 
among population in endemic areas and individuals professionally exposed to Brucella.  It is 
also known fact that these methods have limitations in the early phases of disease and in 
patients with relapses. One of serious drawbacks is the cross-reaction with other bacteria.   
Antigens used in assay can also differ, representing whole killed cells, lysates or purified 
parts of bacteria. Most frequently used components are protein fractions of lysed bacteria, 
fractionated or complete LPS. The lipopolysaccharide O-side chain of smooth Brucella species 
seems to be the immunodominant antigen that elicits a long lasting serological response (Baldi 
et al., 1996). However, it is known fact that diagnostic tests based on lipopolysaccharide O-side 
chain antibodies can generate false-positives due to cross-reaction with antigens from other 
gram-negative bacteria (Weynants et al., 1996).  
In recent years, several Brucella protein antigens have been genetically and  
antigenically characterized, and recombinant technology has  been used for the development of 
novel immunoassays based on recombinant antigens for serological diagnosis of infections. 
Most of these diagnostic formats employed a single recombinant protein.  
Single recombinant proteins such Omp31, Omp25, Aminopeptidase N, BP26, P15, P17 
and P39 have been shown to carry immunodominant epitopes useful for serological diagnosis of 
animal brucellosis (see Results). They all proved to be specific, but general drawback was the 
lack of sensitivity. In order to increase sensitivity of test, steps were made towards the 
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development of a multiprotein diagnostic reagent (Letesson et al., 1997), suggesting that 
combination of several immunoreactive protein antigens would rather cover the spectrum of 
antibody response.  
1.2.2.3 Molecular methods 
The development of PCR has offered a new dimension in the diagnosis of different 
microorganisms, enabling to perform tests in just few hours. In principle, identification of 
Brucella at the genus level is sufficient to initiate therapy, however, further differential diagnosis 
at the species / biovar level is useful for elucidation of epidemiological aspects in order to take 
appropriate actions. Besides, molecular approach can be effectively used for disease follow-up, 
thus ensuring the recovery or monitor relapses. 
 The earliest assays were designed to exploit a single unique genetic locus that was 
highly conserved in Brucella. The advantage of these types of assays is that they tend to be 
simple and easy to perform, both sensitive and specific, rapid, and inexpensive. Such tests are 
useful for screening or for identification on the genus level, when species or biovar designations 
are not critical.  
The first published PCR-based diagnostic assay was reported by Fekete et al. (1990). 
This assay was based on the amplification of a 635-bp sequence from a gene encoding a 43-
kDa outer membrane protein of B. abortus strain S19. The authors were able to demonstrate 
that the assay was specific to Brucella, applicable to all species and biovars, and very sensitive 
(less than 100 bacteria). In the following years many genus-specific PCR assays were 
developed, targeting regions and genes  such as 16SrRNA (Romero et al.,1995), BCSP31 
(Serpe et. al., 1999), omp2a and omp2b (Leal-Klevezas et. Al., 1995), and IS711 (Halling et. al., 
1993). One of this type of assays was later included in a more complex assay for detection and 
differentiation of four different bacterial pathogens: C. burnetii, B. melitensis, B. anthracis, and 
Y. pestis (McDonald et al., 2001). 
As a result of applying adequate vaccines and consequent diagnosis, some countries 
have successfully eradicated some or all Brucella species from their livestock. The majority of 
other countries still endemic for brucellosis including Mongolia, have government-supported 
eradication or control programs. For reasons, such as differences in host preference, in the 
husbandry of host species, in modes of transmission, in pathogenicity to humans, in geographic 
distribution, and in the behaviour of reservoir hosts, the governmental regulatory policies for 
brucellosis are usually species-specific. By this way, correct identification of the species 
involved is essential for the initiation of appropriate action.  
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Epidemiological trace-back is an important component of any disease eradication or 
reduction program. In epizootic events, finding the source of infection and identifying possible 
points of transmission are key elements in preventing further spread of disease. Due to high 
genetic homogeneity among species of Brucella, strain identification is a difficult task. Classical 
bacteriology allows for identification of only a small number of subtypes below the species level. 
Furthermore, certain subtypes may dominate a geographic area. For example, when bovine 
brucellosis had a significant presence in the USA, about 85 % of infections were caused by B. 
abortus biovar1. Thus, differential PCR-based assays are particularly useful for epidemiological 
trace back, or for species-specific eradication programs.  
PCR assays differentiating between Brucella species and/or biovars tend to be more 
complex and consequently more difficult to perform because appropriate target sites are rare in 
Brucella due to the remarkable homogeneity of the genus (Verger et al., 1985). 
Discrimination of multiple species simultaneously utilises one of two approaches. The 
first approach includes complex reaction mixtures containing multiple primer pairs, each 
targeting a unique species-specific DNA sequence polymorphism. The second approach uses a 
single primer pair to amplify a DNA sequence containing internal species-specific 
polymorphism. Subsequently, the internal polymorphism is confirmed by some other method 
downstream.  
Based on these two approaches, multiplex PCR assays for identification and 
differentiation of Brucella species and/or biovars such as AMOS (Bricker et al., 2003), and 
BaSS (Ewalt et al., 2003) were developed. PCR-RFLP assays, targeting omp2 (Ficht et al., 
1990; Cloeckaert et al, 1995), omp25 (Cloeckaert et al., 1995), omp31 (Vizcaino et al., 1997), 
dnaK (Cloeckaert et al., 1996) genes were also successfully developed to differentiate the 
Brucella species. 
Several alternative molecular approaches have also been developed in recent years 
exploiting regions of hypervariability for strain identification. Restriction mapping (McGillivery, 
1998), pulsed gel electrophoresis (Allardet-Servent et al., 1988), ribotyping (Rijpens et al., 
1996), IS-RFLP typing (Bricker et al., 2000) were all successful in identifying the variations to 
some degree. Additional methods such as arbitrary-primed PCR (Tcherneva et al., 2000), 
repetitive element PCR (REP-, ERIC-PCR) (Gillings et al., 1997), infrequent restriction site-PCR 
(IRS-PCR) (Cloeckert et al., 2003), ELISA-PCR were also developed and introduced in 
laboratory practice with certain success. 
More recently, promising results in the typing of Brucella strains for epidemiological 
trace-back were obtained using variable number of tandem repeats analysis (VNTR), the 
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methods being multilocus VNTR (MLVA) analysis (Bricker et al., 2003) and the hypervariable 
octameric oligonucleotide finger-prints (HOOF-Prints) as its variant. 
Recent improvements in PCR technology have made it possible to amplify and detect 
DNA targets simultaneously by real-time PCR (Redkar et al., 2001).  
1.3 Goals and objectives of the study 
The methods currently used in diagnosis of human brucellosis in Mongolia and other 
endemic countries are limited. The clinical picture of brucellosis is non-specific and may show 
great variability causing difficulties in diagnosis and consequent treatment. 
Blood cultures are still the "gold standard" for microbiological diagnosis with good 
sensitivity for acute infections with B. melitensis. However, this sensitivity is markedly reduced in 
cases of long-term clinical courses or in patients infected by B. abortus and B. suis and it is a 
time-consuming process, which requires experience and skills for laboratory personnel 
(Yagupsky, 1999). 
The sensitivity of serological tests using bacterial extracts as antigen is relatively high, 
but specificity is generally low in endemic areas due to high titre of antibodies in the healthy 
population (Ariza et al., 1992). In addition, most of these tests cross-react with other bacterial 
infections. 
Molecular methods appear to be promising in the field of diagnosis, especially in the 
follow-up of patients and epidemiological trace-back. Analysis of the complete genome 
sequences of several Brucella species contributed tremendously in this respect. However, the 
assays described in the literature so far appear to be too complex and need to be modified to 
meet conditions of less wealthy countries. 
The goal of this study was to develop and establish an appropriate procedure for definite 
diagnosis of human brucellosis in Mongolia and to elucidate some epidemiological aspects and 
routes of transmission of the disease. For this purpose the following objectives were targeted: 
To develop pathogen DNA extraction and purification procedures from direct clinical 
samples in a simple and cost-effective way. 
To choose specific sets of primers, and to establish conditions of nested PCR in order to 
increase both specificity and sensitivity of the assay. 
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To elucidate epidemiological factors and routes of transmission of the disease by developing 
species-specific PCR in order to determine the prevalent species of human brucellosis in 
Mongolia. 
A second goal was to improve immunodiagnosis of the disease. Since immunological 
methods used for screening and diagnosing human brucellosis in Mongolia lack specificity, or 
are too expensive, it was attempted to search for new and better Brucella-specific recombinant 
antigens for use in immunoassays. In addition, a test system appropriate for conditions 
prevailing in Mongolia should be developed which had to meet such minimum criteria as: 
To be simple and easy to perform. 
To be both sensitive and specific. 
To be rapid. 
 And to be inexpensive. 
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2 MATERIALS AND METHODS 
2.1 Instruments 
Electroporation system 
Electroporator Equibio Easyject Prima Thermo Electron Corporation, Milford, MA, USA   
Gel electrophoresis systems 
Horizontal minigel system (8 x 8 cm) AGS, Heidelberg, Germany 
Vertical minigel chamber (8 x 10 cm) Keutz, Reiskirchen, Germany 
Power supply EPS 500/400   Pharmacia, Freiburg, Germany 
Shakers 
Horizontal shaker GFL 3020   Gesellschaft für Labortechnik, Burgwedel, 
      Germany 
Certomat R     Braun, Melsungen, Germany 
Vortex Genie 2    Scientific Industries, Bohemia, NY, USA 
Centrifuges 
Cooling centrifuge Beckman J2-21,   Beckman Instruments, Summerset, USA 
                                                                     (with Rotors: JA 14 and JA 20) 
Microfuge: Biofuge Pico   Heraeus Instruments, Hanau, Germany 
Multifuge 3     Heraeus Instruments, Hanau, Germany 
Waterbath  
GFL Wasserbad 1013    Gesellschaft für Labortechnik, Burgwedel, 
                           Germany 
Thermocyclers 
T1 Thermocycler 96    Biometra GmbH, Göttingen, Germany 
Primus 96     MWG Biotech AG, Ebersberg, Germany 
Sonifier 
Sonoplus HD70     Bandelin, Berlin, Germany 
Photographic equipment 
UV Transilluminator     Herolab GmbH, Wiesloch, Germany 
Polaroid MP-4 Land Camera   Polaroid Corporation, Cambridge, MA, USA 
Film: Polaroid 667 Professional   Polaroid Corporation, Cambridge, MA, USA 
Microplate reader 
Bio Rad Model 3550-UV                       Bio Rad, Munich, Germany 
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2.2 Materials 
2.2.1 Chemicals 
Acrylamid      Serva, Heidelberg, Germany 
Agarose for gel electrophoresis   Sigma-Aldrich, Munich, Germany 
Ammoniumpersulfate (APS)    Serva, Heidelberg, Germany  
Ammoniumsulfate     Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin      Sigma-Aldrich, Munich, Germany 
Adenil Triphosphate (ATP)    Carl Roth GmbH, Karlsruhe, Germany 
Biorex 70 resin     BIO-RAD Laboratories, Hercules, USA 
Bovine serum albumin fraction V (BSA)  Carl Roth GmbH, Karlsruhe, Germany 
5-Bromo-4-chloro-3-indolylphosphate (BCIP) Gerbu, Wiesloch, Germany 
Coomassie Brilliant Blue R250   Serva, Heidelberg, Germany 
Dithiothreitol (DTT)     Biomol, Heidelberg, Germany 
Ethidium bromide     Serva, Heidelberg, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Serva, Heidelberg, Germany 
Guanidiniumhydrochlorid (GHC)   ICN Biomedicals, Germany 
Heparin sepharose     Pharmacia-LKB, Upsala, Sweden 
Hydrogen peroxide 30 % (w/v) (H2O2)   Sigma-Aldrich, Munich, Germany 
Isopropyl-ß-D-thiogalactopyranose (IPTG)   Gerbu, Wiesloch, Germany 
Kanamycin      Sigma-Aldrich, Munich, Germany 
ß-Mercaptoethanol     Serva, Heidelberg, Germany 
Nitro blue tetrazolium (NBT)    Gerbu, Wiesloch, Germany 
N,N-dimethylacetamine (DMA)    Sigma-Aldrich, Munich, Germany 
N,N,N‘,N‘- Tetramethylethylendiamine (TEMED) Serva, Heidelberg, Germany 
Phenylmethylsulphonylfluoride (PMSF)  Carl Roth GmbH, Karlsruhe, Germany 
Polyethyleneimine     Sigma-Aldrich, Munich, Germany 
Polyethylenglycol (Mr 3500-4500)   Carl Roth GmbH, Karlsruhe, Germany 
Sodiumdodecylsulfate (SDS)   Carl Roth GmbH, Karlsruhe, Germany 
Tetracycline      Sigma-Aldrich, Munich, Germany 
Tetrabutylammonium borohydride (TBABH)  Sigma-Aldrich, Munich, Germany 3,3’,5,5’-
Tetramethylbenzidine (TMB)    Gerbu, Wiesloch, Germany 
Tween-20 (polyoxyethylen sorbitan monolaureat) Serva, Heidelberg, Germany 
Triton X-100      Merck, Darmstadt, Germany 
Tris (hydroxymethyl) aminomethane   Carl Roth GmbH, Karlsruhe, Germany 
Urea       ICN Biomedicals, Germany 
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DNA size marker 
Plasmid pSP 64 was cleaved a) with Hind III, b) with Dra I and c) with Hinf I. The 
individual cleavage assays were mixed in the relation 1:2:4 with respect to the amount of 
plasmid DNA, resulting in the following fragment sizes (base pairs): 
 
                                                                 
                                                                   
 
 
 
 
 
 
 
Protein size marker 
Protein marker I (14-116 kDa)    AppliChem GmbH, Darmstadt, Germany                       
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65 
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Silica suspension for purification of nucleic acids 
 50 g of silica (SiO2) powder (Sigma No. S 5631) were suspended in 250 ml of water, 
centrifuged for 3 min at 5000 x g, the milky supernatant was discarded, the sediment 
resuspended in another 250 ml of water and centrifuged again. The procedure was repeated 3-
5 times more until supernatant became clear. The sediment was suspended in one volume of 
water and kept in 2 ml aliquots at -20°C. 
Nitrocellulose membrane 
Protran BA 85,  Schleicher & Schuell Bioscience, Dassel, Germany 
Metal affinity resin  
TALON®         BD Biosciences, Palo Alto, CA, USA 
2.2.2 Bacterial strains 
 Escherichia coli XL1-Blue    recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1  
      lac [F´ proAB, lacIZ .M15 Tn10 (Tet)] 
 Escherichia coli XL1-Blue/pREP  recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1  
      lac [F´ proAB, lacIZ .M15 Tn10 (Tet)]/pREP(Kan) 
 
                                     
2.2.3 Bacterial DNAs (Brucella and other strains)  
 DNA samples from Brucella species type strains were kindly provided by professor G. 
Baljer, Institute for Hygiene and Infectious Diseases of Animals, University of Giessen. DNA 
from following type strains were used in experiments: B. abortus 544, B. melitensis 16M, B. suis 
1330, B. ovis 63/290. 
 DNA-s from following additional pathogens were used for cross-reativity tests;  
Haemophilus ducreyi (DSMZ, strain 8925, ATCC 33940) 
Treponema pallidum (Prof. H-J. Wellensieck, University of Giessen, Germany) 
Chlamydia trachomatis (Dr. E. Domann, University of Giessen, Germany) 
Mycobacterium tuberculosis (Medical Microbiology Deptartment, University of Giessen) 
Listeria monocytogenes (Prof. T. Chakraborty, University of Giessen) 
Streptococcus pneumoniae (DSMZ strain 20566) 
Streptococcus agalactiae (DSMZ strain 2134) 
Bordetella pertussis (DSMZ strain 5571) 
Bordetella parapertussis (DSMZ strain 13415) 
Salmonella enteritidis (strain RKI 7271/03, Robert Koch Institut,  Wernigerode) 
Escherichia coli, EHEC strain (isolate from Dr. E. Domann, University of  Giessen) 
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Yersinia enterocolytica (serovar O:9), (DSMZ strain 9499) 
Neisseria gonorrhoeae (DNA from Dr. T. Meyer, MPI für biophysikalische Chemie, 
 Göttingen)  
2.2.4 Antisera 
Sera from Brucellosis patients were obtained from the Brucellosis department of the 
National Center for Contagious Diseases (NCCD), Health Sciences University of Mongolia.     
Additional sera were obtained from different departments of NCCD, including 
departments for Respiratory and Sexually Transmitted Diseases. 60 control sera were derived 
from German blood donors in the Academic Hospital at the University of Giessen, Germany. 
Phosphatase- and peroxidase-conjugated goat anti-human IgG and IgM antibodies were 
bought from Dianova GmbH, Hamburg, Germany. 
2.2.5 Enzymes 
Restriction enzymes 
Enzyme U / µl Buffer Target sequence Company 
Bam HI 20 NEB 2 + BSA G?GATCC New England Biolabs® 
EcoRI 20 NEB 2 + BSA G?AATTC New England Biolabs® 
Hind III 20 NEB 2 + BSA A?AGTCC New England Biolabs® 
Pst I 20 NEB 3 + BSA CTGCA?G New England Biolabs® 
Kpn I 10 NEB 1 + BSA GGTAC?C New England Biolabs® 
Xho I 20 NEB 2 + BSA C?TCGAG New England Biolabs® 
 
Other enzymes  
Enzyme Activity Company 
T4 DNA ligase 1 Weiss-U / µl New England Biolabs® 
Taq polymerase 5 U / µl Self-made (see below) 
Proteinase K 0,3 U / µl Sigma / Alldrich® 
RNase A 0,5 Kunitz-U / µl Sigma / Alldrich® 
Lysozyme 100 U / µg Sigma / Alldrich® 
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2.3 Buffers and solutions 
2.3.1 Buffers and solutions for protein gel electrophoresis 
Tris-glycin electrophoresis buffer (TG): 
25 mM Tris; 192 mM glycin 
0,1 % SDS 
Sample buffer (SB) 
50 mM Tris-HCl (pH 6.8) 
2 % SDS 
10 % glycerol 
1 % ß-mercaptoethanol 
12.5 mM EDTA 
0.025 % bromphenol blue 
 
Coomassie Blue staining solution  
50 % ethanol 
10 % acetic acid 
0.12 % Coomassie Brilliant Blue  
 
 
Destaining solution 
7.2 % acetic acid  
5 % ethanol 
 
 
 
2.3.2 Buffers and solutions for DNA gel electrophoresis 
Agarose gel electrophoresis buffer (E-buffer)  
40 mM Tris/acetate (pH 8,0)  
40 mM Na acetate 
2.0 mM EDTA 
 
 
 
Acrylamide gel electrophoresis buffer (TBE-buffer) 
90 mM Tris/borate pH 8.3  
2.5 mM EDTA 
 
 
6 x SB buffer (10 ml) 
2 ml 1M Tris-HCl pH 6,8 
0.8 g SDS 
0.4 ml glycerol 
0.4 ml ß-mercaptoethanol 
1 ml 0.5 M EDTA 
1 ml 0.1 % bromphenol blue 
add H2O to 10 ml 
 
Destaining solution 
375 ml acetic acid 96 % 
250 ml ethanol 99. 6 % 
add H2O to 5 litre 
Coomassie Blue staining solution 
2.4 g Coomassie Blue  
1 litre ethanol 99.6 % 
200 ml acetic acid 96 % 
add H2O to 2 litres 
20 x E-buffer 
193.8 g Tris-OH 
131.2 g Na acetate 
160 ml 0.5 M EDTA 
adjust pH 8.3 with acetic acid 
add H2O to 2 litre 
10 x TBE-buffer  
108 g Tris-OH 
55 g boric acid 
40 ml 0.5M EDTA  
adjust pH 8.0 with acetic acid 
add H2O to 1 litre 
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Loading buffer 
20 mM Tris/HCl pH 7.5  
50 % glycerol  
0.02 % bromphenol blue  
0.02 % xylene cyanol blue  
20 mM EDTA 
 
 
Ethidium bromide staining solution 
1 µg ethidium bromide / 100 ml E-buffer 
 
 
 
 
2.3.3 Buffers and solutions for methods of molecular biology 
TE buffer 
10 mM Tris/HCl pH 7.5 
0.1 mM EDTA  
 
 
T4 Ligase buffer 
30 mM Tris-HCl (pH 7,5) 
10 mM MgCl2 
10 mM dithiothreitol (DTT) 
10 % polyethyleneglycol (PEG) 
1 mM ATP 
100 µg /ml bovine serum albumin (BSA) 
 
 
 
Restriction enzyme cleavage buffer NEB 1 
10 mM BisTris Propane-HCl 
10 mM MgCl2 
1 mM dithiothreitol (DTT) 
 
 
Restriction enzyme cleavage buffer NEB 2 
10 mM Tris-HCl 
10 mM MgCl2 
50 mM NaCl 
1 mM dithiothreitol (DTT) 
Loading buffer 
0.2 ml 1 M Tris/HCl pH 7.5 
5 ml glycerol 
0.2 ml 10 mg/ml bromphenol blue 
0.2 ml 10 mg/ml xylene cyanol 
blue 
0.4 ml 0.5 M EDTA 
Staining solution 
400 ml 1 x E-buffer 
40 µl 10 mg/ml ethidium bromide 
solution 
2 x T4 ligase buffer (1 ml) 
30 µl 1 M Tris-HCl 
10 µl 1 M MgCl2 
10 µl 1 M dithiothreitol  
200 µl 50 % polyethyleneglycol  
10 µl 0.1 M ATP 
20 µl BSA (5 mg/ml) 
720 µl H2O  
10 x NEB 2 
0.1 ml 1 M Tris/HCl pH 8.0 
0.1 ml 1 M MgCl2 
0.1 ml 5 M NaCl 
0.1 ml 100 mM dithiothreitol 
TE buffer (100 ml) 
1 ml 1 M Tris/HCl pH 7.5 
20 µl 0.5 M EDTA 
add H2O to 100 ml 
10 x NEB 1 
0.1 ml 1 M BisTris Propane/HCl 
pH 8.0 
0.1 ml 1 M MgCl2 
0.1 ml 100 mM dithiothreitol 
0.6 ml H2O 
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GuHCl lysis buffer (50 ml) 
24 g GuHCl  
2 ml 1 M Tris/HCl pH 7.0 
2 ml of 0.5 M EDTA  
0.5 ml Tween 20 
RBC lysis buffer (500 ml) 
4.1 g NH4Cl 
0.6 g NH4HCO3 
0.5 g KCl 
0.1 ml 0.5 M EDTA 
Restriction enzyme cleavage buffer NEB 3 
50 mM Tris-HCl 
10 mM MgCl2 
100 mM NaCl  
1 mM dithiothreitol (DTT) 
2.3.4 Buffers for total DNA extraction 
GuHCl lysis buffer (DNA extraction buffer) 
5 M Guanidinum hydrochloride (GuHCl) 
40 mM Tris/HCl pH 7.0 
20 mM EDTA  
1 % Tween 20  
Ethanol washing buffer 
70 % ethanol 
10 mM TrisHCl pH 7.0 
RBC lysis buffer: 
300 mM NH4Cl 
30 mM NH4HCO3 
30 mM KCl 
0.1 mM EDTA 
2.3.5 Buffers for alkaline lysis/silica method for plasmid preparation    
Solution 1 
100 mM Tris/HCl pH 7.5 
10 mM EDTA 
 
Solution 2 
200 mM NaOH  
1 % SDS  
 
Solution 3 
3 M Na acetate 
2 M acetic acid 
 
 
 
 
 
GuHCl lysis buffer, GuHCl washing buffer, and ethanol washing buffer needed for the 
consequent purification steps are shown above. 
 
10 x NEB 3 
0.5 ml 1 M Tris/HCl pH 8.0 
0.1 ml 1 M MgCl2 
0.2 ml 5 M NaCl 
0.1 ml 100 mM dithiothreitol 
Solution 2 
4 ml 5 N NaOH 
10 ml 10 % SDS 
86 ml H2O 
Solution 3 
60 ml 5 M Na acetate 
11.5 ml glacial acetic acid 
28.5 ml H2O 
Solution 1 
10 ml 1 M Tris/HCl pH 7.5 
2 ml 0.5 M EDTA 
88 ml H2O 
 
Ethanol washing buffer 
70 ml ethanol 
1 ml 1M tris/HCl pH 7.0 
29 ml H2O 
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2.3.6 Buffers for purification of His -tagged proteins with TALON® 
Protein lysis buffer 
6 M guanidinium hydrochloride (GuHCl) 
40 mM Tris/HCl pH 8.0 
250 mM NaCl 
 
 
Protein washing / equilibration buffer 
8 M urea 
40 mM Tris/HCl pH 8.0 
250 mM NaCl 
 
 
 
Protein elution buffer 
8 M urea  
40 mM Tris/HCl pH 7.0 
250 mM NaCl 
250 mM imidazol 
 
2.3.7 Buffers for immunoassays 
TBS-buffer 
10 mM Tris-HCl pH 8.0 
150 mM NaCl 
 
TBST-buffer 
10 mM Tris-HCl pH 8.0 
150 mM NaCl 
0.05 % Tween 20 
 
Antigen dilution buffer 
1 x TBS 
0.2 % Tween 20 
10 % glycerol 
1 mM  DTT 
 
Ab dilution buffer 
1 × TBST 
1 % BSA 
1 mM  DTT 
Washing/equilibration buffer 
48 g urea 
4 ml 1M Tris/HCl pH 8.0 
5 ml 5 M NaCl 
add H2O to 100 ml 
adjust pH to 8.0 
Elution buffer 
48 g urea 
4 ml 1M Tris/HCl pH 7.0 
5 ml 5 M NaCl 
1.7 g imidazol 
add H2O to 100 ml 
adjust pH to 7.0 
Lysis buffer  
57.3 g GuHCl 
4 ml 1M Tris/HCl pH 8.0 
5 ml 5 M NaCl 
add H2O to 100 ml 
adjust to pH 8.0 
20 × TBST buffer (2 litres) 
200 ml 1 M Tris/HCl pH 8.0 
175 g NaCl 
10 ml Tween 20 
add H2O to 2 litres 
20 × TBS buffer (2 litres) 
200 ml 1 M Tris/HCl pH 8.0 
175 g NaCl 
add H2O to 2 litres 
Antigen dilution buffer (100 ml) 
5 ml 20 x TBS 
2 ml 10 % Tween 20 
10 ml glycerol 
1 ml 1M DTT 
82 ml H2O 
Ab dilution buffer (100 ml) 
5 ml 20 x TBST 
1 g BSA 
1 ml 1M DTT 
93 ml H2O 
           36 
AP buffer 
100 mM Tris-HCl pH 9,5 
100 mM NaCl 
5 mM  MgCl2 
 
NBT solution 
50 mg/ml NBT (nitro blue tetrazolium)  
in 70 % dimethylformamide, keep at -20°C 
 
BCIP solution 
50 mg/ml BCIP (5-Bromo-4-Chloro-3-Indolylphosphate)  
in 100 % dimethylformamide, keep at -20°C 
 
AP colour developing solution 
60 µl BCIP solution and 60 µl NBT solution 
dissolved in 10 ml of AP buffer (stable for 1 hour) 
 
ELISA Washing buffer (1 x PBS): 
0.1 M phosphate buffer (pH 7.2) 
0.15 M NaCl 
2.5 mM KCl  
 
Blocking buffer 
1 % milk powder 
1x PBS 
 
Buffer A for ELISA assay 
0.2 M potassium citrate pH 4.0  
before use, add 25 µl of 30 % H2O2 to  
8 ml of this stock solution 
 
Solution B for ELISA assay 
41 mM tetramethylbenzidine (TMB)  
8.2 mM TBABH in N,N-dimethylacetamide (DMA) 
(absolute, H2O content < 0.01 %)  
 
Substrate working solution for ELISA 
Immediately before use, 
add 200 µl solution B to 8 ml buffer A 
with freshly added H2O2 
 
Stop solution for ELISA assay 
1 M H2SO4 
AP buffer (200 ml) 
20 ml 1M Tris-HCl pH 9,5 
4 ml 5 M NaCl 
1 ml 1 M MgCl2 
175 ml H2O 
Buffer A (100 ml) 
2.2 g citric acid 
2.5 g  tri-Na citrate (Mr = 294) 
pH = 4.0 ± 0.1 
Solution B: 
100 mg TMB  
20 mg TBABH 
10 ml DMA 
Stop Solution: 
5.4 ml 98 % H2SO4 
add H2O to 100 ml  
Blocking buffer 
1 g milk powder  
100 ml 1 x PBS 
10 x PBS (1 litre) 
90 g of NaCl 
14.4 g of Na2HPO4 
2.4 g of KH2PO4 
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2.4 METHODS 
2.4.1 DNA purification 
Isolation of nucleic acids using guanidinium-hydrochloride/silica 
The following procedure is appropriate to isolate total DNA (1-5 µg) from a variety of 
bacteria, eukaryotic cells, or homogenised tissue (10 to 20 mg).  500 µl of guanidinum DNA 
extraction buffer (5 M GuHCl, 40 mM Tris/HCl pH 7.0, 20 mM EDTA, 1 % Tween 20) were 
added to 10-20 µl sedimented cells, vortexed and incubated for 10 min at 65°C.  After 2 min 
centrifugation at 13.000 rpm in a minifuge, the supernatant was transferred to a new tube and 5 
µl of silica suspension were added, mixed with vortex and incubated for 5 min at room 
temperature.  The sample was centrifuged for 30 s at 13.000 rpm, the pellet resuspended in 300 
µl 70 % ethanol washing buffer, centrifuged for 30 s at 13.000 rpm and the supernatant 
removed. The pellet was washed in the same way three more times with ethanol washing buffer 
(70 % ethanol, 10 mM TrisHCl pH 7.0).  The last pellet was centrifuged again and residual 
ethanol was removed. 5 µl of TE buffer were added, incubated for 5 min at 55°C and 
centrifuged for 1 min at 13.000 rpm.  The supernatant was collected and the pellet eluted with 
another 5 µl TE buffer. The supernatants were combined. 
Alkaline lysis/silica method for plasmid preparation 
The plasmid DNA purification procedure is a combination of the alkaline lysis protocol 
originally published by Ish-Horowicz and Burk (1981) and the above described silica adsorption 
method.  It can be used for mini plasmid preparations (1.5 ml cultures) as well as for bigger 
preparations (50 ml cultures or more).  In the following, the volumes of the different solutions 
needed in each step are given for mini plasmid preparations and for 50 ml cultures in brackets. 
1.5 ml [50 ml] of over night culture were centrifuged for 3 min.  The supernatant was removed 
by aspiration and the pellet resuspended in 100 µl [2 ml] of Solution 1. 10 µl [100 µl] of RNase A 
(5 mg/ml; kept at -20°C in 50 % glycerol) were added, and the sample was incubated at room 
temperature for 2 min. 200 µl [4 ml] of Solution 2 were added, quickly mixed (it is important not 
to vortex) and incubated for 2 min at room temperature (RT). Then, 150 µl [3 ml] of Solution 3 
was added and again well mixed (without vortexing) and incubated for 1 min. The sample was 
centrifuged at 13.000 x g for 10 min at RT and the supernatant transferred to a new tube. Then, 
400 µl [7 ml] of DNA extraction buffer and 7 µl [100 µl] of silica suspension were added.  
The sample was mixed by vortexing, incubated at RT for 5 min, centrifuged for 1 min and 
the supernatant removed. To the pellet, 400 µl [7 ml] of ethanol washing buffer were added. The 
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sample was mixed by vortexing, centrifuged for 1 min and the supernatant discarded. The 
washing steps were repeated twice. Finally, the wet silica was centrifuged again for 1 min and 
the residual washing buffer removed completely. To elute the DNA, silica particles were 
resuspended in 20 µl [200 µl] TE buffer, incubated 10 min at 55°C, centrifuged for 2 min and the 
supernatant collected in a new tube. Silica was eluted once more with 20 µl [200 µl] TE buffer 
(only vortexed, not incubated at 55°C), centrifuged and the supernatants combined. 
DNA purification from agarose gels 
To purify DNA fragments from agarose gels the following protocol (Vogelstein et al., 
1979) was used.  The corresponding part of the gel was cut out under UV illumination, and 
incubated with 2-3 volumes of 4 M NaI at 60°C until the agarose was molten.  5-10 µl of silica 
suspension were added and incubated at room temperature for 5 min.  After centrifugation for 
30 s, the silica pellet was washed three times with ethanol washing buffer and the DNA eluted in 
the minimal volume of TE buffer as described above. 
Buffy coat DNA extraction 
 2-3 ml of citrate or EDTA-blood were centrifuged for 15 minutes at 1000 x g. Then, 
supernatant plasma was collected and kept in the refrigerator.  The yellow thin “buffy coat” layer 
on top of the sedimented erythrocytes was collected with a pipette (200 to 300 µl) and 
transferred to an Eppendorf tube.  1.2 ml of RBC lysis buffer were added, mixed shortly by 
vortexing, incubated 10 minutes at room temperatures, inverting the tube several times.  
Afterwards, the tube was centrifuged 1 minute at 2000 x g, and the supernatant removed.  A 
pellet of 10-20 µl was obtained and mixed with DNA extraction buffer.  DNA was extracted as 
described above.   
 
2.4.2 Purification of recombinant Taq DNA polymerase 
Taq DNA polymerase was purified from a recombinant strain of E. coli (E. coli XL-1 
Blue/pQE-Taq) expressing an exonuclease-free mutant of the enzyme. The strain was 
constructed previously in the laboratory of Prof. E. Beck, University of Giessen (unpublished 
results). The thermostable enzyme can also be purified without the cooling steps described in 
the following protocol.  
1 litre of LB medium containing 25 µg/ml kanamycin and 50 µg/ml ampicillin was 
inoculated with 100 ml of an over night culture of XL-1 Blue pQE-Taq cells.  The cells were 
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grown at 37°C with optimal aeration for 1-2 hours.  At an OD600 of 1.8, 1 ml of 1 M IPTG was 
added and then the culture vigorously shaked for another 4 hours.  Cells were harvested by 
centrifugation (yield ~5 g) and frozen at -20°C. Freezing of the cells can be omitted, but is 
recommended if the enzyme preparation is not performed immediately.  The cells were 
resuspended in 15 ml TMN buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA, 20 mM (NH4)2SO4) 
together with 8 mg of lysozyme (from 10 mg/ml stock solution) and incubated for 15 min at 20-
25°C.  After adding 200 µl of 10 % Triton X-100 and 200 µl of 10 % Tween 20, the culture was 
mixed and incubated at 80°C for 20 min in a 50 ml screw-cap Falcon tube.  After the heating 
step, 250 µl of 100 mM PMSF were added to prevent proteolytic degradation. 
DNA was sheared by 1 min sonification (it is also possible to do it by repeated pressing 
through a syringe first with a 1 mm diameter needle and then with smaller needles) and 
centrifuged 15 min at 20.000 x g at 4°C.  The supernatant (~15 ml) was collected and 0.6 ml of 
5 M NaCl (0.2 M final concentration) were added.  
The DNA was precipitated with polyethyleneimine (PEI) by adding dropwise 500 µl of 5 
% PEI solution, mixing and incubating in ice for 10 min.  The sample was centrifuged at 10.000 
x g for 5 min.  4 aliquots of 500 µl of supernatant were transferred to Eppendorf tubes each and 
mixed with increasing amounts (2-8 µl) of 5 % PEI solution.  They were incubated 5 min on ice, 
centrifuged and the amount of pellet compared. The minimal amount of PEI to precipitate DNA 
quantitatively was determinated and added to the bulk extract (usually 100-200 µl; use 1/100 
volume of 5 % PEI solution in excess). The suspension was left 20 min on ice and centrifuged 
at 20.000 x g for 20 min. The supernatant was collected and diluted 6 fold with KTA buffer (20 
mM Tris/HCl pH 8.5, 10 mM beta-mercaptoethanol, 10 % (w/v) glycerol, 0.1 mM EDTA, 0.05 % 
Triton X 100, 0.05 % Tween 20). 
The excess of PEI was removed by passing the extract through a 2 ml BioRex 70 
column equilibrated in KTA buffer + 30 mM ammonium sulphate. A disposable 4 ml plastic 
column (International Sorbent Technology, Hengoed, Mid Glamorgan, UK) was used.  The 
column was rinsed with 2 ml KTA buffer and the flow-through loaded on another plastic column 
containing 2 ml heparin sepharose equilibrated with KTA buffer, 30 mM ammonium sulphate.  
The column was washed first with 50 ml KTA buffer, 40 mM ammonium sulphate. Thereafter, 
the column was washed with 20 ml KTA buffer, 40 mM ammonium sulphate, 50 % glycerol. Taq 
DNA polymerase was eluted with KTA buffer, 150 mM ammonium sulphate, 50 % glycerol. 0.5 
ml fractions were collected and 3 µl aliquots analysed on a 12.5 % SDS polyacrylamide gel.  
The enzyme was found in fractions 4 to 7. The enzyme was stored at -20°C. For long term 
storage, Tween 20 to 1 % final concentration was added. The yield was approximately 30.000 
units of enzyme at a concentration of 80 units/µl in the peak fraction. 
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2.4.3 Standard cleavage assay 
 Cleavage of DNA with BamHI and HindIII in the same assay was performed with NEB2 
buffer, and 5 mg / ml BSA solution was added to final concentration 500 µg / ml and incubated 
for 1 to 2 hours at 37°C.  For PstI, NEB3 as well NEB1 for KpnI  buffers were used under the 
same conditions. In general, 20 U of each restriction enzyme were used to cleave 
approximately 5µg of plasmid DNA in a 50 µl assay.  
2.4.4 Standard ligation assay 
 Ligation of fragments to be cloned in expression vectors was performed in 10 µl 
volume by T4 ligase (1 Weiss-U / µl) with ligation buffer containing 5 % PEG. To assay 
containing 1 µg (final concentration 0.1 µg / µl) of previously cleaved plasmid, 3 µg of fragment 
DNA was added to final concentration 0.3 µg / µl. Thus, 1:3 ratio of plasmid and fragment DNA 
amount was kept per 10 µl of assay. The ligation assay was incubated over night at 12ºC, and 
used the next day, after purification with silica, for the transformation of the electroporation 
competent cells.   
2.4.5 Transformation of E. coli cells by electroporation 
Transformation by electroporation was performed essentially as described by Sambrook 
et al. (1989).  5 ml of a fresh pre-culture (over night culture is not recommended) were taken to 
inoculate 200 ml pre-warmed LB medium.  The cells were grown at 37°C until OD600 of 0.6 was 
reached. The culture was chilled on ice as quickly as possible and the cells centrifuged for 5 
min at 10.000 x g.  The pellet was resuspended in 25 ml ice-cold water. Centrifugation and 
resuspension were repeated two times and finally the pellet was resuspended in 400 µl ice-cold 
water and 10 % glycerol (final concentration) added.  The cells were aliquoted in 40 µl portions 
and kept frozen at -70°C. 
For transformation, 40 µl competent frozen cells were thawn on ice. 10 µl of silica 
purified ligase assay were added and the tube left in ice for 1 min. The cells were transferred in 
a pre-cooled 2 mm electroporation cuvette and electroporated at 2500 V.  Immediately after, 1 
ml of LB medium was added, the cells were transferred into an Eppendorf tube and incubated 
for 1 h at 37°C. 100 µl of the content of the Eppendorf tube were spread in one half of an agar 
plate containing selective antibiotics.  The rest of the cells was centrifuged, resuspended in 
approx. 100 µl of medium and spread on the other half of the plate.  The agar plate was 
incubated over night at 37°C. 
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2.4.6 Expression and purification of His-tagged proteins 
Expression and purification of His-tagged proteins was performed as described by 
Hochuli et al. (1988). The recombinant protein antigens were cloned in pQE-30 (Qiagen, Hilden, 
Germany).  The vector joins a histidine tag to the N-terminus of the recombinant protein (see 
Figure 2.4-1). Expression from the strong phage T5 promotor of this vector is regulated by a lac 
repressor provided in excess by the plasmid pREP (maintained in the cells by kanamycin 
selection).  
 Transformed with such vector E. coli XL-1Blue/pREP cells were grown in LB medium 
containing 50 µg/ml ampicillin and 25 µg/ml kanamycin up to density of 5 x 108 cells per ml 
(OD600 = 0.8-1.0). Then IPTG was added to a final concentration of 1 mM, and the cells (250 ml 
culture in a 1 litre Erlenmeyer flask) were further incubated under vigorous agitation on a shaker 
for 3-4 hours at 37°C. The sediment of cells after centrifugation were at -20°C. Next day, the 
cells were thawn, resuspended in 10 ml of Protein lysis buffer and incubated for 30 min at RT, 
shaking from time to time. The cell lysate was centrifuged for 20 min at 20.000 x g in a cooling 
centrifuge, the supernatant transferred to a 50 ml Falcon tube containing 1 ml suspension (0,5 
ml packed volume) of TALON® (equilibrated in Protein washing buffer). The solution was mixed 
gently in a rotating wheel for 1 hour and centrifuged for 1 min at 3.000 x g in a swinging bucket 
centrifuge. The supernatant was removed carefully and 50 ml of Protein washing buffer were 
added. The solution was mixed gently in a rotating wheel again for 5 min, centrifuged for 1 min 
at 3.000 x g and the supernatant was removed carefully. The washing steps were repeated two 
times. The resin was then suspended in 4 ml of Protein washing buffer and loaded on a 
disposable plastic column.  
The column was rinsed with 5 ml of washing solution and the proteins eluted by adding 
stepwise 0.5 ml of Protein elution buffer. 2 min pause were taken between each elution steps in 
order to concentrate the protein outflow.  Aliquots of 3 µl and 15 µl of each of the 0.5 ml 
fractions were analysed with SDS PAGE.  Protein concentration was determined by the 
Bradford assay (Bradford, 1976). 
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--------------------T5 promotor/lac operator---------- 
CTCGAGAAATCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATAGATTCA    60 
 
-------------------------->          >---RBS---> 
       >--pQE-forw primer-> Eco RI                     Met 
ATTGTGAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAGAAATTAACTATGAGA   120 
 
           His-tag       BamH I                      Sal I 
GGATCGCATCACCATCACCATCACGGATCCGCATGCGAGCTCGGTACCCCGGGTCGACCT   180 
 
       HindIII 
GCAGCCAAGCTTAATTAGCTGAGCTTGGACTCCTGTTGATAGATCCAGTAATGACCTCAG   240 
 
                                                  <-- 
AACTCCATCTGGATTTGTTCAGAACGCTCGGTTGCCGCCGGGCGTTTTTTATTGGTGAGA   300 
 
 <-pQE-rev primer 
ATCCAAGCTAGCTTGGCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATC   360 
 
 
Figure 2.4-1 Multiple cloning site of the pQE-30 expression vector. Recognition sites of  
some restriction enzymes (red), histidine-tag (green), ribosome binding site (RBS),  hybridation sites 
of pQE forward and reverse primers (blue), metionine codon (violet) and T5 promotor and lac operator 
(orange) at the beginning of the sequence are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.7 Line blot 
The line blot is a simple immunoassay similar to the well known Western blot and was 
performed essentially as described by Klinkert et al., 1991.  In contrast to the Western blot, 
antigens are not electrotransferred but applied manually to the nitrocellulose membrane.   
Preparation of antigen test stripes 
Antigen was applied to nitrocellulose sheets as a line with a 1.0 mm tip of an ink pen (Rotring 
Radiograph, Rotring GmbH, Hamburg, Germany), using a ruler as a guide. Alternatively, a 200 
µl plastic pipette tip was used whose opening was squeezed with pliers to reduce the speed of 
flow. The antigen solution was prepared by mixing recombinant antigen (in 7 M urea as eluted 
from the TALON column) with different amounts of antigen dilution buffer (1xTBS, 0.2 % Tween 
20, 10 % glycerol, 1 mM DTT). The concentration of protein is in the range of 0.1 - 0.01 mg/ml, 
however, the appropriate dilution has to be determined empirically for each batch of antigen by 
serial two-fold dilutions. The concentration just not yet reactive with negative control sera is 
correct. Lines of individual antigens were placed 0.5 cm apart. Non-specific binding sites were 
blocked by placing the air-dried nitrocellulose sheet in TBS buffer, 1 % Tween 20 for 1 hour. 
Sheets were then washed in TBST, cut perpendicularly to the antigen lines in 4 mm stripes, 
dried and stored at ambient temperature.  
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Immunodetection 
The nitrocellulose stripes were re-hydrated in TBST and incubated in disposable 
incubation trays (Schleicher & Schuell, item No. 10448017) with 0.5 ml of a primary antibody 
solution (patient or control serum) diluted 1:100 - 1:200 in Ab dilution buffer (1 × TBST, 1 % 
BSA, 1 mM DTT) for 0.5-1 hours at room temperature or over night at 4°C on a shaker.  The 
antibody was removed from the solution and saved at 4°C.  The nitrocellulose stripes were 
washed three times for 10 minutes each with TBST and 0.5 M NaCl.  Then, they were incubated 
with goat anti human IgG conjugated to alkaline phosphatase (Dianova, Hamburg, Germany; 
1:7000 diluted in Ab dilution buffer) for 1-2 hours at room temperature on a shaker. Finally, the 
stripes were washed three times for 10 minutes in TBST and once with AP buffer (100 mM Tris-
HCl pH 9.5, 100 mM NaCl, 5 mM MgCl2).  The "disposable" incubation trays can be re-used 
many times when washed carefully with detergent using a brush. 
AP staining protocol 
To visualise the bound AP-conjugated antibodies, the following method was used.  An 
AP colour developing solution was prepared just before use by adding 60 µl BCIP solution (50 
mg/ml BCIP in 100 % dimethylformamide) and 60 µl NBT solution (50 mg/ml NBT in 70 % 
dimethylformamide) to 10 ml of AP buffer.  The membrane stripes were added to the AP colour 
developing solution with the protein side up and it was waited for colour to develop on the 
membrane. When bands became clearly visible, the membranes were transferred to 10 mM 
Tris-HCl pH 8.0, 1 mM EDTA to stop the reaction.  After drying at room temperature, the test 
stripes were photographed, or scanned into a computer. 
2.4.8 ELISA 
Flat-bottom 96 well microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were 
incubated over night at 4°C with 0.1 ml of antigen diluted in PBS to a concentration of 1 ng/ml. 
The wells were washed three times with 0.35 ml PBS each and then incubated with 0.2 ml 
blocking buffer (1 % milk powder in PBS) for 1 hour at ambient temperature. The blocked plates 
were washed three times with 1 x PBS, dried and stored at room temperature. For long term 
storage (more than one month), the antigen-coated plates were sealed in plastic sheets. 100 µl 
of serum samples diluted 1:200 in blocking buffer were added to each well and incubated for 1 
hour at room temperature. The plates were washed three times with 1 x PBS, the wells filled 
with a 1:5.000 dilution of goat anti human IgG-HRP (horseradish peroxidase) conjugate 
(Dianova, Hamburg, Germany) and incubated again for 1 hour at room temperature. The plates 
were washed three times with PBS as before, then 75 µl of HRP substrate working solution 
           44 
were added to each well, incubated at room temperature, and the staining reaction stopped 
after 30 minutes with 100 µl of 1 M sulphuric acid and the results read at 450 nm. The HRP 
substrate working solution was prepared immediately before use as follows: 25 µl of a 30 % 
solution of H2O2 and 200 µl of 41 mM 3,3',5,5'-tetramethylbenzidine, 8.2 mM 
tetrabutylammonium borohydride in N,N-dimethylacetamide were added to 8 ml of 0.2 M 
potassium citrate buffer pH 4.0 (Frey et al., 2000).  
2.4.9 PCR procedures 
Standard PCR conditions 
For all PCR assays, the same Taq DNA polymerase buffer was used. It is prepared as a 
10 x buffer and has the following composition: 
1 x Taq buffer  
40 mM Tricine-KOH (pH 8.7 at 25°C) 
15 mM K acetate 
3.5 mM acetate 
0.1 % gelatine 
0.05 % Tween 20 
 
 
Standard PCR reaction assay 
 Using efficient standard thermocyclers such as T1 thermocycler 96 from Biometra, or 
Primus 96 from MWG Biotech which are appropriate for 200 µl reaction tubes, have a heated lid 
and heating/cooling rates of at least 2-3°C/s, highly reproducible results were obtained with 
assays as small as 10 µl. A standard PCR reaction mixture had the following composition: 
1 µl 10 x Taq buffer 
1 µl mixture of 4 dNTPs (2.5 mM each)  
0.5 µl 10 µM forward primer 
0.5 µl 10 µM reverse primer 
1 µl template DNA  
5.8 µl H2O 
0.2 µl Taq DNA polymerase (5 units/µl) 
 
The standard program of the thermocycler was set as follows: 
step 1:    2 min at 94°C (denaturing of DNA template) 
10 x Taq buffer (10 ml) 
4 ml 1 M Tricine-KOH 
1.5 ml 1 M K acetate 
350 µl 1 M acetate 
2.5 ml 4 % heated gelatine solution  
500 µl Tween 20 
1.15 ml H2O 
           45 
step 2:    35 cycles of [94°C 20 s, 60°C 1 min, 72°C 1 min] 
step 3:    5 min 72°C (optional, to fill-in the DNA ends completely) 
The same conditions were applied for nested PCR. 1 µl of a 1:10 dilution (with H2O) of 
the result of first PCR assay was used as DNA template. 
2.4.10 Gel electrophoresis 
Agarose gels 
Agarose gel electrophoresis was performed according to standard procedures 
(Sambrook et al. 1989).  Plasmid DNA and PCR fragments were analysed on horizontal 1 % or 
2 % agarose gels using a Tris/acetate electrophoresis buffer (E-buffer).  To check migration of 
the DNA fragments, the samples were mixed with 20 % loading buffer containing 50 % glycerol 
and marker dyes. In 1 % agarose gels, bromphenol blue migrates at the position of 200 bp, 
whereas xylenecyanol blue migrates at the position of 300 bp.  The gels were stained for 20 min 
with ethidium bromide staining solution.  Then they were rinsed with tape water, the DNA bands 
visualised on an UV transilluminator and photographed by a Polaroid camera.  Alternatively, a 
simple digital camera in combination with a yellow filter was used.  
Polyacrylamide gels 
 For the analysis of proteins, discontinuous polyacrylamide gels (10 x 8 x 0.1 cm) 
containing SDS (Lämmli, 1970) were prepared in different concentrations according to the 
following recipe:  
       Stacking gel      Separating gel  
                       10 ml       16 ml        16 ml 
Stacking gel buffer: 
125 mM Tris-HCl (pH 6.8) 
0.1 % SDS 
 
 6 % 12,5 % 15 % 
40 % Acrylamide /  
1.3 % bisacrylamide solution  
1,5 ml 5,0 ml 6,0 ml 
4 x buffer 2,5 ml 4,0 ml 4,0 ml 
H2O 6,0 ml 7,0 ml 6,0 ml 
Ammonium persulphate 10 µg 10 µg 10 µg 
TEMED  15 µl 20 µl 20 µl 
4 x Stacking gel buffer 
12.14g Tris-OH 
8 ml 10% SDS  
adjust pH 6.8 with HCl (~8 ml HCl 37 %) 
add H2O to 200 ml 
           46 
Separating gel buffer: 
 
375 mM Tris-HCl (pH 8.8)  
0.1 % SDS 
 
 
 
2.4.11 Serological tests for brucellosis 
RBT and the SAT were performed according to standard procedures. For the RBT, 
undiluted serum samples  (30 µl) were mixed with an equal volume of Rose Bengal Slide 
Screening Test antigen (Biotech Laboratories, UK) on a white agglutination card. Results were 
rated negative when agglutination was absent and 1+ to 4+ positive according to the strength of 
the agglutination. The SAT was performed by preparing two-fold serial dilutions of the serum 
sample starting at a dilution of 1:20 in the wells of a microtiter plate and the addition of an equal 
volume of stained Brucella abortus  antigen MM101 (Linear Chemicals, UK). The mixtures  were 
incubated for 24 hours at 37°C and read by visual inspection. Positive results at dilutions 1:160 
were considered consistent with brucellosis. 
 
4 x Separating gel buffer  
45.43 g Tris-OH 
10 ml 10% SDS  
adjust pH 8.8 with HCl (~6 ml HCl 37 %) 
add H2O to 250 ml 
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3 RESULTS 
Brucellosis, an important disease worldwide, is preventable in principle and occurs in the 
parts of the world where animal and/or human health services are scarce or nonexistent. 
Mongolia is one of the countries where herds are large, animals breed extensively, and nomadic 
transhumance and other migration practices are economic necessities. Due to these key 
conditions, the control and eradication of brucellosis is a daunting task, necessarily requiring the 
development of inter-sectorial programs, including the routine screening of rural and 
professionally exposed risk groups for this disease in the population. Estimation of the actual 
incidences of brucellosis is an important issue of the country’s health sector in order to control 
and prevent the disease.  
For a disease that has been known for such a long time, several challenges still remain 
from the diagnostic point of view. Since the symptoms of brucellosis are non-specific, definite 
diagnosis cannot be established without help of laboratory tests. Although value of 
immunological tests cannot be questioned, they still need much refinement due to lack of 
specificity caused by cross-reactivity with other bacteria. The discrimination of false positives 
can also be ambiguous upon vaccination (in animals) and in diagnosing relapses (in humans), 
since the lipopolysaccharide O-chain of smooth Brucella species seems to be an 
immunodominant antigen that elicits a long lasting serological response (Baldi, 1996). 
Furthermore, these diagnostic tests also generate false positives due to cross-reaction with 
antigens from other Gram-negative bacteria (Weynants, 1996). Therefore, the identification of 
antigens that could potentially be useful for specific immuno-diagnoses is an important issue in 
brucellosis research.  
It was attempted to address the above predicament by developing the following 
improved methods: First, PCR-based assays for diagnosing and differentiating brucellosis on 
the genus and/or species level as a direct indicator of infection, and second, immunodiagnostic 
tests using recombinant proteins as antigens, as an indirect indicator for infection and 
confirmatory test. At the same time, it was attempted to develop the new immunoassays for 
more specific screening by using recombinant proteins instead of bacterial lipopolysaccharide or 
whole bacterial cells as antigens. 
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3.1 Clinical specimens  
As a prerequisite to establish new diagnostic procedures, peripheral blood samples of 
500 suspected brucellosis patients were collected in disposable Sarstedt syringes containing 
EDTA. After centrifugation, both plasma and leukocytes purified from crude buffy coat collected 
from the top of the sedimented red blood cells were used.  
Two groups of individuals were studied for PCR tests. The first group included patients 
with suspected disease on the basis of a clinically positive history, physical examination, 
positive in RBT and in confirmatory SAT, whereby a titre 1:160 was considered consistent with 
brucellosis. The discrimination between acute and chronic brucellosis was not made in this 
group. The samples were collected before hospitalization of the patients to the brucellosis 
department of National Center for Contagious Diseases (NCCD) of Mongolia. The second group 
consisted of 240 individuals that showed negative RBT and SAT. This group had neither clinical 
nor serological findings for brucellosis (negative control group).   
DNA extracted from buffy coat of the seropositive samples was analysed with two 
different Brucella genus-specific nested PCR assays (detecting the genes of 16S rRNA and 
pcaC) as described in more detail below. Approximately 80 % of the samples positive by RBT 
and SAT were also positive in both of these PCR assays. These samples were considered as 
true Brucella-positive and further used for establishing new immunological tests. 
Choosing positive history of disease, RBT, SAT, and PCR results as criteria, next 100 
patient samples were selected as true positives for immunological assays with recombinant 
antigens. 50 additional true negative along with 50 ambiguous samples were included in these 
assays. True negative samples were selected on the basis of negative history, PCR, serological 
assay (RBT, SAT) results, while ambigouous sera derived from patients with no epidemiological 
evidence of brucellosis and negative PCR results, but positive for RBT and SAT.  
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3.2. Molecular methods: PCR 
In order to establish a highly specific test for Brucellosis a number of genus- and/or 
species-specific PCR assays were designed. In view of fact that Brucella is found mainly inside 
of macrophages and monocytes in the circulating blood, genus-specific PCR assays were 
performed with DNA extracted from crude leukocyte preparations of all of the Mongolian patient 
samples described above. The DNA extraction procedure is described in the Materials and 
Methods section. In the following, the results for 100 from the 500 immunologically positive 
patient samples with seven different PCR assays developed in this work are described. 
The sets of primers used were either specific to the genus Brucella as a whole or for 
individual species of Brucella known as the most frequent causative agents of human 
brucellosis: B. melitensis, B. abortus and B. suis, respectively. All primers were designed based 
on Genbank genomic sequence data (Brucella melitensis M16 chromosomes I and II: NC 
003317 and MC 003318; Brucella abortus bv. 1 str. 9-941 chromosomes I and II: NC 006932 
and NC 006933; Brucella suis ATCC 23445 chromosomes I and II: NC 010169 and 010167). 
Optimal primer sequences within selected genomic regions were searched by the primer design 
software "Primer3" developed by the Whitehead Institute for Biomedical Research, Cambridge 
MA, USA (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). To facilitate performance of 
the assays, a uniform annealing temperature of 60°C was selected for all primers. Some of the 
primers were taken from the literature as indicated. Primer sequences, target genes and regions 
used in the PCR assays are shown in Table 3.1. 
In order to check the reliability of the assays, different tests were used in parallel, two for 
general verification of the presence of Brucella, and three multiplex PCR assays for the 
discrimination of the species. To reach maximal sensitivity and specificity, all assays were 
designed as nested PCRs, employing an outer set of primers for the primary PCR cycles, and a 
different inner set of primers in secondary cycles. For initial screening, primers were selected to 
amplify part of the 16S rRNA gene which has the identical sequence in all Brucella strains. A 
second set of primers specific for the genus Brucella was designed using the 
carboxymuconolactone decarboxylase gene pcaC as template (Ratushna et al., 2006).  
To identify the individual Brucella strains, three species-specific PCR assays were 
performed in parallel. In these assays, primers were used that recognised either genes 
occurring exclusively in one particular species each, or primers that led to species-specific 
differences in fragment size for the same gene. As species-specific targets, the following genes 
were selected: (i) the outer membrane transporter (OMT) gene (BruAb2_0168) for B.  
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Table 3.1 Diagnostic PCR primers 
Primer Sequence Product size  b Specificity 
Primers for genus specific PCRs 
16S-out-F 
16S-out-R 
16S-inn-F 
16S-inn-R 
AGATTTATCGGCAAATGATCG 
CCGGTCCAGCCTAACTGAA 
TTATCGGCAAATGATCGGC 
GTAAACACCCCGACGGCTA 
(809) 
 
606 
all 
Brucella species 
PcaC-out-F 
PcaC -out-R 
PcaC -inn-F 
PcaC -inn-R 
TCAGGCGCTTATAACCGAAGa 
ATCTGCGCATAGGTCTGCTTa 
TATAACCGAAGCGGCATGG 
TAGGTCTGCTTGGCGATCTT 
(261) 
 
247 
all 
Brucella species 
Primers for species-specific single PCRs    
OMT-out-F 
OMT-out-R 
OMT-inn-F 
OMT-inn-R 
TGCAGCTCACGGATAATTTGa 
ACACCTTGTCCACGCTCACa 
AGCTCACGGATAATTTGACCAC 
CCAGCATAATGGAACAGGTG 
(783) 
 
715 
B. abortus 
GNTR-out-F 
GNTR-out-R 
GNTR-inn-F 
GNTR-inn-R 
ATTCCCGAAAGCCGATAGAG 
GTCCTTTCAAACGCCGTCTA 
CCGAAAGCCGATAGAGTTTGa 
TCTACACCACGCTGAAGTCGa 
(182) 
162 
 
(393) 
373 
B. melitensis 
 
 
B. abortus, B. 
suis, B. canis 
HlyD-out-F 
HlyD-out-R 
HlyD-inn-F 
HlyD-inn-R 
GATGTTTTCCACTTGCGTCAC 
TCGGCCTGTGGATCTATTTC 
TTCCACTTGCGTCACTGTTC 
ATGTGAGCGAGGATGATTCC 
(593) 
 
584 
B. suis 
(except of 
biovar 40) 
Primers for IS711-based multiplex PCR  
IS711-out-R 
IS711-inn-R 
AlkB-out-F 
AlkB-inn-F 
ChrI-112-out-F 
ChrI-112-inn-F 
dUTPH-out-F 
dUTPH-inn-F 
GAAAACATTGACCGCATTCAT 
TTCATGGGTTTCGTCCATCT 
TCACCAAATATATCCTGCACCA 
ATGGCGACGTGGTTGTCT 
TCATGACACCCAAACTTAGCC 
ACCCAAACTTAGCCATGGTG 
GCCCCACCAGATGAGAAA 
CCGGGCTTTTCTCTATGACA 
 
 
(226) 
189 
(384) 
361 
(303) 
254 
common 
reverse primers 
 
 
 
B. abortus 
B. melitensis 
B. suis 
Primers for EIBE-based multiplex PCR  
EIBE-out-F 
EIBE-out-R 
EIBE-inn-F 
EIBE-inn-R 
TGTGCCAGCTTCGTTGTAAGa 
TGATAGCGCCAGACAACAACa 
GCGCTGTTGATCTGACCTTG 
GTCTGGGATCGCTGGTCTT 
(722)  480 
(596)  354 
(470)  228 
B. suis  
B. abortus  
B. melitensis 
 
a Ratushna et al., 2006. 
b product size in base pairs. The product size of the first PCR is given in parantheses 
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abortus leading to a 715 bp product for B. abortus exclusively, (ii) the transcriptional regulator 
GNTR family gene (BMEII0204) leading to a 162 bp product for B. melitensis and a 343 bp 
product for the stains B. abortus, B. suis and B. canis , and (iii) the gene for HlyD family 
secretion protein (BRA0439) leading to a 585 bp product for B. suis exclusively (Ratushna et al., 
2006).  
In other discriminatory tests, a multiplex PCR targeting the insertion sequence IS711 
and flanking regions was applied using three strain-specific forward primers and one common 
reverse primer (Bricker et al., 1994). All Brucella species contain at least 5 and as many as 35 
copies of this element distributed throughout their genomes (in B. abortus, B. canis and B. suis 
6-8, in B. melitensis 7-10, in B. ovis more than 28). 
Finally,  the species-specific polymorphism of the immunoglobulin-binding protein EIBE 
was used in a third discriminatory test, which led to a different sizes of amplification products 
with the different strains (Ratushna et al., 2006).  
The PCR assays targeted the same genes as described in the above references, but in 
most cases different primer sequences were selected which appeared to be more appropriate 
according to the Primer3 software used. Furthermore, a second set of inner primers for nested 
PCR was designed for each test.  
To facilitate performance of the assays, a uniform annealing temperature of 60°C was 
selected for all primers. Primers described in the literature fitting this condition were used 
without any changes. Nested primers ("inner" primers) were designed for each set of "outer" 
primers in order to improve sensitivity and specificity. The assays with the IS711-specific 
primers as well as with the EIBE gene-based primers were performed as multiplex PCRs in 
both, the primary amplification step with the "outer" primers as well as in the second 
amplification step with the inner primers. One microliter of the product of the primary PCR 
assays served as DNA template for the secondary nested PCR assays. The primary PCRs  did 
normally not lead to visible bands upon gel electrophoresis after ethidium bromide staining, due 
to the low initial amount of the target DNA in the samples. However, after nested PCR, the 
resulting DNA bands became clearly visible. In case of the assays discriminating the different 
species B. mellitensis, B. abortus and B. suis, the inner primers had been selected in such a 
way that a clear assignment of fragment length to the bacterial strain could be made. 
All these PCR assays were first established using Brucella reference strains B. abortus 
544, B. melitensis 16M and B. suis 1330  obtained from professor G. Baljer, Institute for 
Hygiene and Infectious Diseases of Animals, University of Giessen. Electrophoretic separation 
on 2 % agarose gels led to acceptable resolution of all of the resulting PCR products, even 
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though 6 % PAA gels allowed better discrimination of the smaller DNA bands. However, 
preparation of PAA gels for analysis of hundreds of PCR products appeared to be too 
demanding for routine assays. After it became clear that all PCR assays performed well with the 
reference strains, the same tests were performed with DNA samples from patients with clinical 
manifestations who had been positive in the immunological assays RBT and SAT.  
Figure 3.1 shows exemplarily the results of six different assays with the same 18 patient 
samples (nested PCR only), a negative control with buffer alone and the positive controls using 
DNA from the three reference strains. The seventh experiment, the single species PCR with the 
B. suis specific primers HylD is not shown, because it was negative with all samples except of 
the B. suis positive control.  In the same experiment, 100 patient samples were tested in 
parallel. It turned out that 80 out of the 100 patient samples (80 %) revealed detectable levels of 
Brucella DNA by applying nested PCR with 16S rRNA- and PCA-specific primers (Figure 3.1, 
panels A and B). All samples were processed for further PCR tests that were designed to 
differentiate Brucella at the species level. These tests revealed that 64 out of the 80 PCR-
positive cases (80 %) were due to B. abortus, whereas the remaining 16 cases (20 %) were due 
to B. melitensis. No B. suis-specific DNA was detected amongst the samples analysed (Figure 
3.1, panels C to F). All assays were repeated 3 times for each set of primers with identical 
results. The complete results with all 100 patient samples are listed in Table 3.2. 
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Figure 3.1 Comparison of the different Brucella-specific PCR assays. Each panel shows the 
products of nested PCR obtained with patient samples 1-18 after electrophoresis on 2% agarose 
gels. Lanes (-), A, M and S show products with the negative control, B. abortus 544, B. melitensis 
16M, B. suis 1330 DNAs, respectively. A: carboxymuconolactone decarboxylase (pcaC)-specific 
primers, leading to a 247 bp fragment with all Brucella strains; B: 16S rRNS-specific primers 
leading to a 606 bp fragment with all Brucella strains;  C: B. abortus-specific primers derived from 
the outer membrane transporter (OMT) gene, leading to a 715 bp fragment; D: B. melitensis-
specific primers derived from the transcriptional regulator GNTR family gene, leading to a 162 bp 
fragment for B. melitensis and a 343 bp fragment for other Brucella strains. E: insertion sequence 
711 (IS711)-specific primers, leading to a 361 bp fragment with B. melitensis, a 254 bp fragment 
with B. suis , and a 189 bp fragment with B. abortus; F: immunoglobulin-binding protein (EIBE)-
specific primers, leading to a 480 bp fragment with B. suis, a 354 bp fragment with B. abortus, 
and a 228 bp fragment with B. melitensis. The expected positions of the DNA bands are marked 
in red for genus-specificity, Blue for B. melitensis, yellow for B. abortus and green for B. suis. 
Data for the B. suis-specific PCR are not shown because there were no positive results except for 
the B. suis-specific control. 
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1 - - - - - - -  51 - - - - - - - 
2 - - - - - - -  52 + + a a - + - 
3 + + m m + - -  53 + + a a - + - 
4 - - - - - - -  54 + + a a - + - 
5 - - - - - - -  55 - - - - - - - 
6 + + a a - + -  56 - - - - - - - 
7 + + a a - + -  57 + + a a - + - 
8 + + a a - + -  58 - - - - - - - 
9 + + a a - + -  59 + + a a - + - 
10 + + a a - + -  60 - - - - - - - 
11 + + m m + - -  61 + + a a - + - 
12 + + a a - + -  62 + + a a - + - 
13 + + a a - + -  63 + + a a - + - 
14 + + a a - + -  64 - - - - - - - 
15 + + a a - + -  65 + + m m + - - 
16 + + a a - + -  66 + + a a - + - 
17 - - - - - - -  67 + + m m + - - 
18 + + m m + - -  68 + + a a - + - 
19 + + a a - + -  69 + + a a - + - 
20 + + m m + - -  70 + + m m + - - 
21 + + a a - + -  71 + + a a - + - 
22 + + a a - + -  72 + + a a - + - 
23 + + m m + - -  73 - - - - - - - 
24 + + m m + - -  74 + + a a - + - 
25 + + m m + - -  75 + + a a - + - 
26 + + a a - + -  76 + + a a - + - 
27 + + a a - + -  77 + + a a - + - 
28 + + a a - + -  78 - - - - - - - 
29 + + a a - + -  79 + + m m + - - 
30 + + m m + - -  80 + + a a - + - 
31 + + a a - + -  81 + + m m + - - 
32 + + a a - + -  82 + + a a - + - 
33 + + a a - + -  83 + + a a - + - 
34 - - - - - - -  84 + + a a - + - 
35 + + a a - + -  85 + + m m + - - 
36 + + a a - + -  86 + + a a - + - 
37 - - - - - - -  87 - - - - - - - 
38 + + m m + - -  88 + + a a - + - 
39 + + m m + - -  89 + + a a - + - 
40 + + a a - + -  90 + + a a - + - 
41 + + a a - + -  91 + + a a - + - 
42 + + a a - + -  92 + + a a - + - 
43 + + a a - + -  93 + + a a - + - 
44 + + a a - + -  94 - - - - - - - 
45 + + a a - + -  95 + + a a - + - 
46 + + a a - + -  96 + + a a - + - 
47 + + a a - + -  97 + + a a - + - 
48 + + a a - + -  98 - - - - - - - 
49 - - - - - - -  99 + + a a - + - 
50 + + a a - + -  100 - - - - - - - 
         
100 80 80 
16 
m 
64 a 
16 
m 
64 a 
16 64 0 
 
Table 3.2 Results of the different PCR assays. The results for the individual patients are 
marked as follows: +, = positive , - = negative, m = positive for B. melitensis, a = positive for B. 
abortus. 
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3.3 Establishing immunodiagnostics 
Most commercial kits for diagnosis of brucellosis employ LPS or crude antigens, 
obtained by different methods of lysates of bacterial cultures. Serological assays for screening 
such as RBT and SAT use suspensions of killed whole bacteria. All assays have high 
sensitivity, which is needed for screening, but have the disadvantage of being not specific 
enough. The recombinant protein antigens, on the other hand, although showing high rates of 
specificity, fail to be sensitive enough and lead to false negative reactions. However, this 
disadvantage could be eliminated either by selecting more appropriate recombinant protein 
antigens, or combining several of such antigens in a single immunoassay. As individual 
recombinant antigens are usually not recognized by all patients sera due to the genetic 
heterogeinity of the immune system, it was decided to search for additional potential diagnostic 
antigens in the genomes of Brucella strains and to test their performance in immunological 
assays.   
3.3.1 Selection of diagnostic antigens 
The search of antigens was first based on published data of other groups, and since this 
approach did not lead to satisfactory results, exploration of available genomic data for 
potentially immuno-reactive pathogen proteins was performed in addition. The corresponding 
genomic sequences were obtained from different DNA data banks, preferentially from the NCBI 
collection of complete bacterial chromosomes (http://www.ncbi.nlm.nih.gov/Genbank). Brucella 
Bioinformatics Portal (BBP) (Xiang et al., 2006), a bioinformatics resource portal developed for 
Brucella research community was also of a great help in this study. Up to now, the genomes of 
following species and biovars have been released: B. melitensis 16M, B. melitensis biovar 
abortus 2308, B. abortus biovar 1 strain 9-941, B. abortus S19, B. suis ATCC 23445, and B. 
suis 1330. DNA sequences of other Brucella strains (B. canis, B. ovis, B. neotomaea) were not 
included in the search. 
The genomic data of these Brucella strains were analysed giving preference to outer 
membrane proteins and taking an account their feasibility of expression as a recombinant 
protein in E.coli. Also the complexity of corresponding gene was analysed in order to detect 
cleavage sites and their interference with cleavage sites of expression vector. Besides, the 
sequences were checked for codons rarely used in E.coli and for their specificity to genus 
Brucella. The similarity of the sequences with other organisms was checked with the BLAST 
program (http://www.genedb.org/genedb/ blast.jsp).   
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The sequence information extracted from literature and different genomic data bases 
was used to clone the following 10 antigens. The abbreviations used for these antigens in the 
text are shown in bold face letters. 
1. B.abortus bacterioferritin, P15 (Denoel et al., 1995). 
2. B.abortus 17-kDa protein, P17 (Hemmen, F., et al., 1995). 
3. B.abortus 39-kDa cytoplasmic protein, P39 (Denoel et al., 1997). 
4. B.abortus 26 kDa periplasmic protein, BP26 (Rosetti et al., 1996). 
5. B.melitensis Omp31outer membrane protein, Omp31 (Cassatro et al., 2003) 
6. B.abortus Omp25 outer membrane protein, Omp25 (Cloeckaert, 1996). 
7. B.melitensis 16M membrane alanine aminopeptidase, AminopepN   
  (Contreras-Rodriguez et al., 2006). 
8. B.abortus outer membrane lipoprotein-related protein, LP. 
9. B. abortus hypothetical omp62289852 , Baomp852. 
10. B.abortus outer membrane efflux protein, Baompeff. 
The majority of the genes selected by this way had been described at a certain extent in 
the literature as indicated. However, most of these proteins were described as potential 
diagnostic antigens only, and only few of them had been tested extensively for 
immunodiagnosis of human brucellosis. 
The general strategy for testing the listed antigens in immunoassays was to test them 
first individually and, depending on their immuno-reactivity, to combine individual selected 
antigens in a single chimeric fusion protein for two reasons: first to simplify the production and 
thereby optimise the purification of the recombinant antigen, and second, to increase both 
specificity and sensitivity of the assay. By this way, a fusion antigen was produced at the end. 
Its performance was experimentally tested in immunoassays and the results were compared 
with published data from existing diagnostic procedures.  All protein antigens were well 
expressed in E. coli XL1-Blue/pREP, except LP which seems to be detrimental for  E. coli cells, 
since it could be produced only in small quantities even using a synthetic gene containing 
optimised translational codons. 
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3.3.2 Synthesis of recombinant antigens: example of cloning by PCR 
amplification of P15 antigen 
P15 was one of the antigens cloned first. The gene sequence, which encodes for 15 kDa 
bacterioferritin, was derived from B. abortus  chromosomal sequence as shown in Figure 3.2. 
The protein coding sequence was amplified by PCR using primers derived from its genomic 
sequence (GeneBank NC_006932).  
 
In order to simplify cloning of different recombinant antigens, the same restriction sites 
were used at the beginning (BamHI) and at the end (HindIII) of the open reading frames for all 
constructions. To use this cloning strategy, the BamHI and HindIII restriction sites should not 
occur within the open reading frames. For this purpose, a search for these sites within the 
 
P-15 bacterioferritin 
 
Coding sequence: 
        1 cgcggccgtt gctgtggctg cttcccaaat gtcgtagaaa ccatcataag ggtgactgaa 
       61 gaatactatc ttcgtcgcaa ccaaatggac gaaaacatta tccagttcat ggatcgtgtg 
      121 cgttctctac gagataaatt cgggagttca tggaatgaaa ggcgaaccaa aggtcatcga 
      181 gcggcttaac gaggcactgt ttcttgagct cggtgcggta aaccagtatt ggctgcacta 
      241 ccgtcttctc aacgattggg gttacacgcg ccttgcaaag aaggaacgcg aggaatccat 
      301 cgaggaaatg catcacgccg acaagctgat tgatcgcatt atcttccttg aaggctttcc 
      361 gaacctccag accgtttcgc cgttgcgcat tggccagaat gtgaaggaag ttctcgaagc 
      421 tgacctcaag ggtgaatatg acgctcgcgc ttcgtataag gaatcgcgcg aaatctgcga 
      481 caagctcggc gactatgtgt cgaagcagct tttcgacgaa cttctggccg atgaagaagg 
      541 ccatatcgac ttccttgaaa cccagcttga ccttctcgcc aagatcggcg gagaacgcta 
      601 tggccagctt aacgcggcgc ccgccgacga agctgagtaa gcctgtttca atctgtcttg 
 
Primers: 
BAp15-for: ATAGGATCCatgaaaggcgaaccaaaggt(BamHI) 
BAp15-rev: TATAAGCTTtaagctggccatagcgttct(HindIII) 
 
Translation: 
       1 MKGEPKVIER LNEALFLELG AVNQYWLHYR LLNDWGYTRL AKKEREESIE EMHHADKLID  
      61 RIIFLEGFPN LQTVSPLRIG QNVKEVLEAD LKGEYDARAS YKESREICDK LGDYVSKQLF  
     121 DELLADEEGH IDFLETQLDL LAKIGGERYG QLNAAPADEA E  
 
 
Figure 3.2 Cloning of P-15 bacterioferritin of B. abortus.  The coding sequence as 
extracted from GeneBank is shown above. Start and stop codons are marked in bold face, the 
location of the primers used for PCR amplification are underlined. The lower part of the figure 
shows the protein sequence. In the recombinant protein, the N-terminal sequence is fused to a 
hexameric histidine sequence which serves for purification by affinity chromatography. The last 
9 amino acids of the original B. abortus protein are not contained due to suboptimal nucleotide 
sequences for efficient PCR priming. 
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TTT F 0.58      TCT S 0.17      TAT Y 0.59      TGT C 0.46 
TTC F 0.42      TCC S 0.15      TAC Y 0.41      TGC C 0.54 
TTA L 0.14      TCA S 0.14      TAA * 0.61      TGA * 0.30 
TTG L 0.13      TCG S 0.14      TAG * 0.09      TGG W 1.00 
 
CTT L 0.12      CCT P 0.18      CAT H 0.57      CGT R 0.36 
CTC L 0.10      CCC P 0.13      CAC H 0.43      CGC R 0.36 
CTA L 0.04      CCA P 0.20      CAA Q 0.34      CGA R 0.07 
CTG L 0.47      CCG P 0.49      CAG Q 0.66      CGG R 0.11 
 
ATT I 0.49      ACT T 0.19      AAT N 0.49      AGT S 0.16 
ATC I 0.39      ACC T 0.40      AAC N 0.51      AGC S 0.25 
ATA I 0.11      ACA T 0.17      AAA K 0.74      AGA R 0.07 
ATG M 1.00      ACG T 0.25      AAG K 0.26      AGG R 0.04 
 
GTT V 0.28      GCT A 0.18      GAT D 0.63      GGT G 0.35 
GTC V 0.20      GCC A 0.26      GAC D 0.37      GGC G 0.37 
GTA V 0.17      GCA A 0.23      GAA E 0.68      GGA G 0.13 
GTG V 0.35      GCG A 0.33      GAG E 0.32      GGG G 0.15 
 
Figure 3.3 Genetic standard code of Escherichia coli. Codons are 
followed by the amino acid they code for, and the corresponding usage 
frequencies. Codons marked in red present the lowest frequencies, and 
another group of condons with low frequencies in orange.  Stop codons are 
indicated with an asterisc. Modified from Maloy et al., 1996 
 
 
genomic sequence was performed in each case using “The Sequence manipulation Suite” 
software (http://www.bioinformatics.org/sms2/, Stothard, 2000). The Baompefflux protein 
contained these two restriction sites in the N-terminal coding part and was therefore cloned as 
partial fragment including approximately 30 % of the C-terminal sequence only. However, in the 
other genes no such interfering BamHI and HindIII restriction sites were contained and the open 
reading frames of the proteins were cloned in most cases completely, omitting the start codon 
(AUG). This was done to prevent internal translation initiation at this site upon fusion with the 
histidine affinity tag sequence encoded by the vector plasmid. The stop codons at the C-
terminal end were excised in most cases as well, to allow later fusion of different antigens to 
polyproteins. In some cases the HindIII restriction site at the end of the gene was substituted by 
a KpnI or PstI site, depending on the occurence of these sequences inside the open reading 
frame.  
There is substantial experimental evidence that the presence of non-optimal codons 
(i.e., those translated by rare tRNAs) in a sequence can reduce the translation rate of proteins 
(Robinson et al., 1984; Bonekamp et al., 1985), which is one of the strategies for the regulation 
of protein expression in bacteria (Grantham et al., 1981). The codon frequencies in the 
Escherichia coli are shown in Figure 3.3.  
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All genes cloned were checked for the presence of these rare E. coli codons.  Luckily, all 
of them, with the exception of the LP gene, used preferentially abundant  E. coli codons for 
translation. PCR primers for amplification of the corresponding coding sequences were 
designed first manually and their utility thereafter was checked according to the criteria of the 
Primer3 computer program (Rozen et al., 2000, http://frodo.wi.mit.edu/ primer3/input.htm). This 
helped to select appropriate annealing temperatures and to predict whether the selected 
primers were compatible with efficient priming.  
Genes containing BamHI or HindIII restriction sites within the open reading frame were 
cloned in a way that only the largest possible fragments without these sites were included. PCR 
primers to amplify the largest possible fragment were designed by means of the Primer3 
program. Restriction sites BamHI (g|gatcc) and HindIII (a|agctt) for cloning in the vector plasmid 
were added manually to the primers. The computer-predicted forward and reverse primers led 
usually to succfessfull amplification of the predicted DNA fragments using the selected 
annealing temperatures and the corresponding DNAs of either B. melitensis or B. abortus  as 
templates.  
The forward and reverse PCR primers designed for cloning of P15 consisted of 29 bp 
each with the following sequences (restriction sites are underlined). 
BAp15-for: ATAGGATCCatgaaaggcgaaccaaaggt  (BamHI) 
BAp15-rev: TATAAGCTTtaagctggccatagcgttct  (HindIII) 
                        
 
 
 
Figure 3.4 Amplification of P15 by PCR. A product of 457bp size was produced by  
BAp15-for and BAp15-rev  primers. 
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3.3.3 Cloning in pQE-30 vector and protein expression 
In order to insert the P15 gene into the pQE-30 expression vector, “sticky ends” were 
created by digesting the eluted PCR fragment with BamHI and HindIII restriction enzymes and 
subsequent ligation with the pQE vector cleaved with the same enzymes.  After purification with 
silica to remove polyethyleneglycol and salts, the plasmid DNA was electroporated into 
competent E. coli cells that were thereafter selected on agar plates containing ampicillin and 
kanamicine. Resulting colonies were checked for the presence of the insert sequence by PCR, 
using the primers P15 forward and pQE reverse, the latter being located in the vector 
downstream from the insertion site. By this way, false positive results due to the presence of the 
non-ligated PCR fragment were avoided. One of the positive clones was selected for growth 
and protein purification. 
The remaining recombinant antigens were cloned using basically the same procedure 
with  minor differences such as using restriction enzymes other than HindIII at the end of open 
reading frame due to occurrence of this site inside of the coding sequence of the gene. In case 
of P17, P39 and Omp31, Omp25, and Baomp852, the HindIII cleavage site was replaced by 
either KpnI or PstI, respectively. The genes, primers and translation products of all recombinant 
antigens are listed in the Appendix section. 
In case of the LP antigen, a very weak expression was observed only. Therefore it was 
decided to use a synthetic gene (ordered from GENEART, Regensburg) that substituted rare 
codons of E. coli by more frequently used ones. However, the new construct did not result in a 
better expression, the possible reason being therefore rather the toxicity of an excess of the 
protein to E. coli. Nevertheless it was possible to obtain sufficient amounts of this antigen for 
testing in immunological assays. 
All recombinant proteins were expressed in E. coli XL1-Blue/pREP and purified by 
affinity chromatography in preparative scale as described in the Materials and Methods section. 
As an example, the elution profile from the TALON affinity purification of recombinant P-15 
antigen analysed on an analytical SDS polyarcrylamide gel is depicted in Figure 3.5. 
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Figure 3.5 Analysis of P-15 purification by analytical SDS-PAGE gel electrophoresis. The 
first three fractions contain the highest concentration of the antigen.  
The other recombinant antigens were expressed and purified in the same way. Aliquots 
of the purified proteins are shown in Figure 3.6. 
      
 
Figure 3.6 SDS PAGE analysis of all recombinant Brucella antigens. The left lane contains 
a protein size maker. Lanes 1 to 15 correspond to the following recombinant antigens:  
1. Baompefflux, 2. P15, 3. LP, 4. P17, 5. Omp31, 6. Omp25,  
7. Baomp852, 8. BP26, 9. omp852-bp26, 10. P39, 11. Baomp852-BP26, 12. BP26-P39,  
13. P15-P39, 14. Triple fusion P15-bp26-P39, 15. Aminopeptidase N. 
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3.3.4 Specificity and sensitivity of the antigens 
The efficiency of the purified recombinant antigens for immunodiagnosis was tested 
using an immunoblot technique called "line blot" (described in the Materials and Methods 
section).  Because the line blot compares the reactivity of different antigens and of different 
concentrations of these antigens in a single assay, this step allowed to reach two objectives: (1) 
to determine the optimal concentration of the antigens in immunoassays, and (2) to determine 
the reactivity with brucellosis patient sera and control sera, i.e. to detect possible cross-
reactions. To determine the optimal concentration, the antigens were applied in serial dilutions 
on the membrane, then incubated with either brucellosis patient sera or with control sera.  At the 
optimal concentration, an antigen leads to a clear reaction with specific sera, but not with control 
sera. An excessive concentration of the antigen leads to false positive reactions with control 
sera, and a sub-optimal concentration reduces sensitivity of the test.  
The intensity of the detectable reaction depends rather on the affinity of an antigen to 
specific antibodies than on the concentration of these antibodies in patient sera. Some antigens 
had to be used at concentrations as high as 200 µg/ml, while others led to strong positive 
reactions at concentrations less than 1 µg/ml. Some antigens showed a strong background 
reaction with the negative control sera, mainly those that had to be used at high concentrations 
due to their low specific reactivity. As the affinity purification procedure does not remove 
bacterial components such as lipopolysaccharid completely, the high background reaction with 
the control sera may be due to antibodies directed against these components.  E. coli-specific 
antibodies are present in all human sera and prevail even more in sera derived from people in 
developing countries. Bacterial contaminations in the antigen preparations cannot be removed 
completely without great effort. However, the more diluted an antigen can be used in 
immunoassays, the lower the cross-reaction with bacterial contaminations will be.  
The line blot assay was also used to determine the specificity of the immuno-reaction of 
the recombinant antigens (Figure 3.7). Single test stripes were incubated either with individual 
sera derived from the mongolian brucellosis patients, or with sera from patients with other 
infectious diseases but without epidemiological, clinical, or serological evidence of brucellosis. 
In addition, antigens were tested with sera from healthy blood donors from Germany. As can be 
seen from the figure, not all of the brucellosis-positive serum samples reacted with all of the 
antigens, even though a clearly visible signal with selected antigens was detectable in most 
cases. The difference in reactivity of individual patients with specific antigens reflects most 
probably the genetic heterogeneity of individuals with respect to the immune system. 
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Figure 3.7 Specificity of the recombinant antigens determined in line blot. The individual 
antigens have been applied as a line on a nitrocellulose embrane, the membrane was then 
blocked in 1 % Tween 20, cut in 4 mm stripes, and incubated with sera from brucellosis patient 
(stripes 1 – 16), or negative control sera (stripes 17 – 40). Note that not each antigen reacts 
strongly positive with all patient sera, and some antigens lead to cross-reactions with negative 
control sera (P17 and Baompefflux). Human serum in the upper line serves as a control for the 
staining reaction of the alkaline phosphatase conjugated to the second antibody. 
 
After the immuno-reaction of the recombinant antigens had been characterised in the 
line blot assays, they were tested in ELISA assays. Although ELISA assays depend on special 
equipment such as optical readers and washers, they are more appropriate for tests on large 
scale because they can be automated and are quantifiable.  Figure 3.8 shows as an example 
the results of P15 in ELISA with 50 positive brucellosis patient sera and with 50 negative control 
sera. 
Not all of the antigens turned out to be usefull for immonoassays in ELISA. Antigen P17 
reacted with both negative and positive sera, thus rendering it useless for further utilization. The 
antigens Omp25 and Omp31 reacted with some Brucella-negative sera, while being not able to 
detect all positive samples. These antigens were therefore excluded from further experiments 
as well. The antigens P15, P39 and BP26 revealed reasonable reactivity with positive sera, but 
the intensity of signals produced was not so strong therefore the singular use for diagnosis 
appeared to be not efficient. Although they did not produce any false positives, there was a 
minor fraction of false negatives for each of the antigens. Such false negative reactions with 
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individual antigens were observed differently by true positive patient sera, thus reflecting rather 
the genetic heterogeneity of the immune system of the patients than a weakness of interaction 
with the corresponding antigen. In addtion recombinant proteins LP and Aminopeptidase N 
appeared to be usefull for specific diagnosis although the difference in OD values between 
positive and negative controls was not very high.  
 
Figure 3.8 Antigen P15 ELISA with patient sera and control sera. P-15-coated microtitre 
plates were incubated with 50 PCR-positive and 50 negative control sera for one hour, washed, 
reacted with HRP conjugated second antibodies and stained as described in Materials and 
Methods section. Note that except of two of the positive sera, a clear discrimination between 
patients and controls can be observed 
The results for all individual recombinant antigens including fusions (see further) in 
ELISA assays are compiled in Figure 3.9.   
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Figure 3.9  Results of ELISA assays of same 50 positive and 50 negative sera with 
recombinant diagnostic antigens. 1. BP26, 2. P15, 3. Baomp852, 4. Baompefflux, 5. LP, 6. P39, 
7. BP26-P39 fusion, 8. P15-BP26-P39 fusion, 9. AminopepN. 
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It turned out that some of the recombinant antigens showed low immuno-reactivity in 
immunoassays, especially in ELISAs. As shown on graphs although Baompefflux and 
Baomp852 proteins display reactivity to sera at certain extent, they fail to make a clear 
distinction between positives and negatives because of the weak reactivity. Antigen LP displays 
a much higher discriminatory power in this respect, but was still not at the desired level. The 
antigens P15, BP26 and P39 led to a much better distinction of positive and negative sera, 
making them candidates for further development strategy. A possible explanation of weak 
reactivity of individual antigens was either weak binding of the small peptides to the polysterene 
surface of the microtitre plate or / and were removal of them during the washing steps. To 
overcome these problems, it was attempted to combine the smaller peptide antigens to larger 
fusion proteins. 
3.3.5 Fusion of selected antigens 
Results on ELISA with individual antigens clearly showed that only the use of several, 
but not single antigens would lead to sufficient sensitivity in immunoassays. In order to safe 
effort in producing these antigens it was thought that combining of the most reactive 
recombinant antigens to larger fusion proteins could be a reasonable approach. In addition, it 
was possible that the synthetic proteins could adopt – at least in part - a three-dimensional 
conformation that would function as antigenic determinants better in the context of a 
polyprotein. The selected synthetic genes were fused with the help of “adapter” 
oligonucleotides. These adapters served several functions. First, they had to join the 3’ terminal 
HindIII, or PstI site of the anterior antigen in the correct reading frame with the BamHI site of the 
following antigen.  The nucleotide sequence was designed in such way that both restriction sites 
were destroyed by the fusion.  Second, the adapters served as spacers between the different 
antigens. In order to allow a maximum flexibility between the fused antigens, one or two proline 
residues were introduced in the spacer elements. Proline residues are frequently present in 
flexible areas of proteins (e.g. in the "hinge" regions of immunoglobulins). It was assumed that 
such flexible elements would prevent or reduce the interference of secondary structures of the 
individual antigenic regions with each other, and thus facilitate the individual antigenic motives 
to fold in more close to native confromation state. To avoid repeats of homologous sequences 
in the fused genes which could lead to elimination of parts of the construct by homologous 
recombination, different adaptor fragments were constructed. The adapter sequences used are 
shown in the following Figure 3.10. 
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3.3.6 Example of fusion: P15-bp26-P39 
The antigens P15, BP26 and P39 were chosen first to construct a fusion protein since 
they had characteristics as useful antigens, reacting positively with patient sera and giving 
negative results with all negative control sera, by both IgM and IgG-specific  ELISAs. In addition 
they showed significant difference in OD values between the negative and positive samples. 
Cloning of the fusions gene was performed in several steps. First, the coding regions of P15 
and BP26 were fused with the adapter Hind-Bam-AD2. For this purpose, the plasmid pQE-P15 
was cleaved by HindIII and XhoI. Cleavage products were separated by agarose gel 
electrophoresis and the 602 bp band with HindIII and XhoI ends was excised (Fig.3.11). The 
sequence contained the whole P15 gene along with a small fragment of the original pQE vector 
starting at XhoI site (see Figure 2.1). XhoI restriction was chosen for a better orientation and 
detection of fragments on the gel electrophoresis. Simultaneously,  pQE-BP26 was cleaved by 
XhoI and BamHI resulting in a 3987 bp product containing the whole BP26 gene with the rest of 
plasmid pQE.  
 
Hind-Bam-AD1 
 
         HindIII                           BamHI 
 
5' NNN A       AG CTG CCG AGC CTG AGC A       GA TCC NNN 3' 
3' NNN TTC GA       C GGC TCG GAC TCG TCT AG       G NNN 5' 
 
    X   K          L   P   S   L   S   R          S   X 
 
Hind-Bam-AD2 
 
5' NNN A       A GCT ATT CCG CTG AGC A       GA TCC NNN 3' 
3' NNN TTC GA        TAA GGC GAC TCG TCT AG       G NNN 5'     
 
    X   K         A   I   P   L   S   R   S          S   X 
 
 
Pst-Bam-AD1 
           
        PstI 
 
5' NNN CTG CA        T CTG CCG CTG AGC A       GA TCC NNN 3' 
3' NNN G        AC GTA GAC GGC GAC TCG TCT AG       G NNN 5'     
 
    X   L           H   L   P   L   S          R   S   X 
 
Figure 3.10 Adapter sequences used to fuse antigen coding regions.  Nucleotide sequences of the 
adapter oligonucleotides are depicted in complementary form. Residues providing "sticky ends" for the restriction 
site HindIII/PstI and BamHI are underlined. Amino acid sequences encoded by the different adaptors are shown 
below the nucleotide sequences .  
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Figure 3.11 Cleavage of pQE 30 vector containing P15 by XhoI and HindIII. 
In a second step these two fragments were ligated to a single plasmid. Whereas ligation 
of the XhoI sites was normal, the HindIII and BamHI sites were joined by means of the synthetic 
Hind-Bam-AD2 adapter (Figure 3.10). The resulting plasmid containing both genes was 
electroporated into E. coli. Upon antibiotic selection resulting colonies were characterised by 
analytical PCR using the primers BAp15-for and pQE-rev. Correct clones led to amplification of 
a 1213 bp product and were further analysed by restriction digest with BamHI and HindIII upon 
plasmid DNA preparation.  
The next step was to include one more antigene (P39) into the new construct pQE-P15-
AD2-BP26. Using the same strategy, the plasmid was cleaved by XhoI and HindIII again and 
the fragment containing both genes with XhoI and HindIII sites was isolated. Plasmid pQE-P39 
was cut by XhoI and BamHI. The fragments containing P39 and P15-bp26 fusion genes were 
ligated as before, however using a different adapter, Hind-Bam-AD1.  
Using the same strategy, combinations of the following genes were produced and 
consequently expressed in  vector pQE-30: P15 and bp26, omp852 and bp26, P15 and P39, 
bp26 and P39, P15-bp26-P39.  The resulting proteins were produced as described above. They 
were analysed by analytical SDS PAGE as shown in Figure 3.5 lanes 9 and 11-14. 
 
 
 
           69 
3.3.7 Tests of the antigens with human sera samples in ELISA 
A large number of serum samples had been tested in line blots to characterize the 
quality of the recombinant antigens. However, the line blot is not a very practical method for a 
routine diagnostic laboratory.  In most laboratories, ELISA is the method of choice due to its 
capacity to be automated, and the possibility to test large amounts of samples.  Furthermore, 
the results are more objective, since they are quantifiable by photometry.   
Whereas alkaline phosphatase-conjugated second antibodies had been used in the line 
blots, HRP-conjugated second antibodies were used in the ELISA. Alkaline phosphatase 
assays are highly sensitive and the conjugates have the advantage of being very stable during 
storage. However, the tests can be hyper-sensitive leading occasionally to false positive results, 
most probably due to accidental contamination. Phosphatases are ubiquitous and very resistant 
enzymes that are also contained in body fluids such as sweat, saliva etc., thus being easily 
spread by handling reaction tubes and micro-plates even wearing gloves. For this reason, HRP-
conjugated second antibodies were used in ELISA tests including the corresponding colour 
assays. Peroxidase assays are widely used and have the same sensitivity as alkaline 
phosphatase assays. However, they have the disadvantage that the enzymatic activity is not as 
stable as the activity of phosphatase, i.e. the conjugates have a limited halftime. At the other 
hand, there is a much lower risk of contamination since peroxidases occur less frequently in the 
nature than phosphatases, . 
To obtain more exact values in the ELISA tests, double measurements were performed 
on each sample, with the mean value calculated thereafter thus reducing intra-assay variation. 
To discriminate positive versus negative results, a cut off value is established by using the 
following equation: 
Cut off = average of negative controls + 2 to 5 x standard deviation (SD) of negative 
controls. 
To determine how many SD have to be used in the formula, a test was performed with a 
large number of Brucella positive and negative sera and the cut off value was calculated at 2, 3, 
4, or 5 x SD. Several false positives were found using 2 x SD while several false negative were 
observed when 4 x SD was used. In contrast, neither false positive nor false negative results 
were obtained using 2 x SD for the aminopeptidase N, and for Lp and 3 x SD for the triple fusion 
antigen P15-bp26-P39 indicating an optimal discrimination at these ranges. When the SAT 
negative patients’ sera from Mongolia were used as negative controls, a slight increase in the 
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cut off values was observed as compared to the values obtained with the German negative 
control sera.   
In order to find the optimal conditions to perform the ELISA with the antigens (LP, triple 
fusion P15-bp26-P39 and aminopeptidase N) a box titration was performed using a pool of 
positive sera as a control. The best results were obtained at serum dilutions of 1:100, and all 
three antigens were still reacting properly at dilutions 1:5000.  
3.3.8 Comparison of antigens with existing serological methods  
A total of 200 sera from different groups of patients were studied. The first 100 sera were 
from a group of the Mongolian patients with confirmed brucellosis. The case definition for initial 
brucellosis diagnosis was a history of exposure to domestic animals, or consumption of un-
pasteurized milk or milk products, together with history of persisting fever, and symptoms and 
physical signs compatible with this infection, along with the positive results for RBT and SAT at 
dilutions =1/160. Only "true" positive serum samples were used in this ELISA, i.e. all samples 
had been tested before by PCR for the presence of Brucella DNA as described above. The 
second group of sera (50 samples) were derived from the individuals who had neither positive 
clinico-epidemiological nor laboratory evidence of the disease. The third group (50 samples) 
consisted of sera from individuals positive in serological tests (RBT and SAT), but negative in 
PCR and with no history of exposure to Brucella or any clinical signs of brucellosis. The results 
are summarised in Table 3.3. 
 
LP P15-BP26-P39 fusion Aminopeptidase N Study group 
Positive Negative Positive Negative Positive Negative 
True positive 
(n=100) 
97 
(97%) 
3 
(3%) 
99 
(99%) 
1 
(1%) 
90 
(90%) 
10 
(10%) 
True negative 
(n=50) 
0 
(0%) 
50 
(100%) 
0 
(0%) 
50 
(100%) 
0 
(0%) 
50 
(100%) 
Ambiguous 
(n=50) 
20 
(40%) 
30 
(60%) 
22 
(44%) 
28 
(56%) 
15 
30% 
35 
(70%) 
 
Table 3.3 Summary of results with the three new Brucella-specific ELISA tests. The table 
shows the number of positive and negative results obtained in ELISA with the three different 
antigens. The calculated percentage is given in parentheses.  
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All three recombinant antigens revealed a high specificity in the assay and did not lead 
to false positive results with the negative control sera. However, the sensitivity with the true 
positive samples was not 100 %. LP detected 97 out of the 100 positive samples and 
aminopeptidase N only 90. The best performance was seen with the P15-BP26-P39 fusion 
antigen reacting with 99 of the positive samples resulting in a sensitivity of 99 %.  
The recombinant antigens led to different results with the third group of patients which is 
is positive in RBT and SAT, but negative in PCR. From the 50 samples, 20 were positive with 
LP, 22 with the P15-BP26-P39 fusion, and 15 with Aminopeptidase N. The absence of reactivity 
of the antigen with the negative control group shows that there is no crossreaction with other 
bacteria. Positive RBT and SAT results can be due to either crossreaction or past infection.  
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4  DISCUSSION 
Brucellosis is a zoonosis transmittable to humans that shows a high degree of morbidity, 
both for animals and humans. Consequently, it causes significant financial loss and represents 
a serious public health problem in many countries. An appropriate diagnosis is the key for 
eradication and control of this disease. At present, several immunoassays are employed mainly 
to screen animal populations, but for humans such tests are usually applied when patients 
reveal clinical symptoms for confirmation of the disease. 
Generally, the immunoassays for brucellosis applied in the endemic areas and 
individuals professionally exposed to Brucella have limited sensitivity and specificity. At the one 
hand, this is due to missing resources for health care sector allowing the use of simple and 
inexpensive screening procedures only. The other reason is that many healthy individuals in 
these groups of population have high titres of antibodies against Brucella due to a previous 
unnoticed infection and being recovered. These methods also have limitations due to low 
antibody titres in the early phases of the disease and in patients with relapsing infection since it 
is generally very difficult to observe and monitor disease dynamics by immunoassays . Another 
essential limitation of the commonly used immunoassays is their cross-reactivity with other 
bacteria since Brucella spp. share common antigenic structures with other pathogens at the 
level of the O-chain polysaccharide S-LPS. Thus, the diagnostic tests based on the 
lipopolysaccharide O-side chain antibodies can generate false-positives due to cross-reaction 
with antigens from other Gram-negative bacteria (Weynants et al., 1996). On the other hand, 
infections caused by the rough form of B. canis are under-diagnosed by tests that employ LPS 
from smooth-Brucella strains (Polt et al., 1982; Lucero et al., 2005). 
One of the main goals of this work was to develop new diagnostic procedures that are 
not only more specific and sensitive compared to existing immunoassays, but also simple and 
cost-effective to perform in order to enable their routine use under the economically limited 
conditions of Mongolia. ELISA appeared to be the immunodiagnostic method of choice because 
in addition of being inexpensive and simple to perform it has the advantages of being fast and 
easily to be automated. Furthermore, it is applicable to different classes of immunoglobulins, 
allowing to monitor specific phases of the disease to a certain degree, at least.  
Since ELISA tests using LPS as antigen lack specificity, the new assays were based on 
recombinant proteins. Using appropriate recombinant antigens, specificity of immuno-assays is 
in general high, although sensitivity  is usually lower than in assays using whole cells or crude 
antigen preparations. Previous studies have shown that single recombinant proteins such as 
Omp31 (Cassatro et al., 2003), Omp25 (Cloeckaert, 1996), aminopeptidase N 
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(AminopeptidaseN), bp26 (Rosetti et al., 1996), P15 (Denoel et al., 1995), P17 (Hemmen, 
F., et al., 1995), and P39 (Denoel et al., 1997) carry immunogenic structures that could be 
useful for serological diagnosis of animal brucellosis. Higher sensitivities were obtained when 
several of these antigens were used in parallel, suggesting that their combination in a single-
well test could further improve the performance of the assay. A first step towards the 
development of a multi-protein diagnostic reagent was attempted by Letesson et al., 1997, 
suggesting that a good diagnostic reagent should contain more than one immunoreactive 
protein to cover a broader spectrum of protein-antibody interactions.  
During this work, more than ten different recombinant antigens have been produced and 
tested. In addition to the antigens described already, several new other immunoreactive 
proteins were detected by systematic screening of genomic data for potential surface antigens. 
The antigens omp852, Ompefflux, and LP found by this way turned out to react strongly with 
serum antibodies from brucellosis patients, thus representing new candidate antigens for 
ELISA. Optimal sensitivity was obtained by combining several of these antigens in fusion 
proteins.  
4.1 Patient samples 
The antisera used in this study were collected in Mongolia. Patients were  first screened 
by RBT and positive results confirmed by SAT assays, taking 1/160 dilution as threshold value 
for positivity as recommended for endemic areas (Young, 2005; Corbel, 1989). While the use of 
a higher titre as a positivity threshold decreases the sensitivity of SAT (Orduña et al., 2000), the 
lower SAT titres do not always exclude a Brucella infection (Young, 1991) because some acute 
brucellosis patients and those with a chronic or prolonged disease evolution can show very low 
titres of specific antibodies. In latter two cases the use of Coombs test and Brucellacapt assays 
proved to be appropriate leading to positive results. (Orduña et al., 2000). Thus, the SAT assay 
is prone not only to the false positive results, but also to false negative results, although the 
percentage of such cases is not highly significant (Mantecón et al., 2006). The criteria for true 
positive serum samples used in this study were positive results with RBT, SAT and genus-
specific PCR along with clinical manifestation.   
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4.2 Recombinant antigens 
To date, complete genome sequences have been established for eight different Brucella 
strains. These sequences can be taken from the internet from the collection of complete 
bacterial chromosomes in the NCBI GenBank (http://www.ncbi.nlm.nih. gov/genbank). They  
include two strains of B. melitensis (B. melitensis 16M and B. melitensis biovar abortus 2308), 
two strains of B. abortus ( B. abortus biovar 1 strain 9-941 and B. abortus S19), two strains of B. 
suis (B. suis ATCC 23445 and B. suis 1330) and the strains B. ovis ATCC 25840 and B. canis 
ATCC 23365. Most of these sequences have been finished only recently. For this work, mainly 
the sequences of B. melitensis biovar abortus 2308 and B. abortus biovar 1 strain 9-941 have 
been used to select candidates for recombinant test antigens.   
Vector pQE-30 was used as an efficient expression system in E. coli. It allows to induce 
protein expression upon induction with IPTG, warranting by this way the production of large 
amounts of protein without interference with the viability of the bacterium. In addition, it provides 
a histidine affinity tag to the N-terminus of the recombinant proteins allowing simple purification  
by affinity chromatography. All recombinant proteins, except  LP were expressed successfully. 
Since the low expression rate of LP was first assumed to be due to the presence of many “rare” 
E. coli codons, a synthetic gene was constructed avoiding these codons. However, the synthetic 
gene led to the same weak protein expression. Thus, the reason is rather a certain toxicity of 
the LP protein for E. coli.  
In standard protein purifications, approximately 1 to 2 milligrams of protein were 
obtained from one litre of culture. All single antigens as well as fusion antigens were 
successfully expressed and purified and all stages of the process were easily reproducible. The 
purified protein contained in average 1 mg per ml. Optimal dilutions of antigens for ELISA were 
determined empirically before testing them on a large number of samples.  
Protein purification using His-tag affinity chromatography results in relatively pure 
antigens.  However, it was not to be expected that the purified proteins would fold in native 
conformation. This depends mainly on the extreme over-expression leaving little time and/or 
space to gain the native three-dimensional structure. And this was also due to the denaturing 
conditions of the highly concentrated urea solution. The lack of native conformation to certain 
extent affects the reactivity with antibodies, and means to circumvent this problem are still to be 
studied. Recombinant proteins owing low antigenicity have to be used in relatively high 
concentrations, however the specificity of the assays could be also affected by parallel increase 
of residual bacterial lipopolysaccharide content which cannot be completely removed during 
simple affinity chromatography. This is an important issue in view of fact that the healthy 
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individuals have antibodies against lipopolysaccharide and other carbohydrate structures of 
many bacterial species colonizing the intestinal tract.  
It remains to be emphasized that cloning and expression of recombinant diagnostic 
antigens is feasible with reasonable effort and can lead to improvement of existing diagnostic 
systems. Inadequate diagnosis exists for many infectious diseases which are listed under the 
category "neglected diseases" according to the nomenclature of WHO. Except for the newly 
emerging zoonoses such as SARS and highly pathogenic avian influenza H5N1, the vast 
majority are not prioritized by health systems at national and international levels and are 
therefore labelled as neglected. The availability of the complete genomic sequences of most of 
these pathogens combined with useful computer programs for handling this large amount of 
structural information makes new diagnostic approaches based on recombinant antigens 
feasible not only in developed countries, but also under less privileged conditions of developing 
ones. The production and running costs of such assays are relatively low, and basic laboratory 
equipment such as centrifuges and ELISA readers are the sole investment, and which can be 
obtained also as a donation from a sponsor. Preparing missing specific diagnostic tests by this 
approach, many widespread diseases could be better recognized and controlled in the near 
future.  
4.3 Specificity 
Using recombinant proteins in immunoassays warrants relatively high specificity in 
general. High sequence homology of some of the cloned proteins has also been observed with 
two related bacteria of the class Alphaproteobacteria, O. anthropi and R. tropici. Rare cases of 
cross-reaction of Brucella-specific recombinant antigens with Orchobactrum anthropi have been 
described (Velasco et al., 1997). However, since very few human cases of infection by these 
bacteria were reported and they normally affect only individuals with immune deficiency leading 
to nosocomial infections (Ezzedine et al., 1994), this homology appears not to be relevant to 
affect diagnosis. Other taxonomically unrelated pathogens, such as Y. enterocoltitica 0:9 and E. 
coli O157:H7, also cause cross-reactions, however, only in case of using lipopolysacchaide or 
whole bacteria as antigens. A very weak background reactivity observed in our assays - only 
when high concentrations of recombinant antigen had to be used - derives mainly from O-
polysaccaride side chains of E. coli LPS which is present in low concentration in the antigen 
preparation (Wakelin et al., 2006). This problem can be circumvented either by using more 
diluted antigens, or by additional purification steps removing the residual (mainly LPS) 
contamination from the preparation (Colangeli et al., 1998). The latter step makes the 
preparation of the assays more demanding and expensive, thus the better way is to search for 
alternative more immunoreactive antigens. 
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The recombinant antigens LP and the P15-bp26-P39 triple fusion were tested in ELISA 
with sera of German blood donors and RBT as well as SAT-negative sera from Mongolian 
individuals. No false positive results were obtained in these assays. The antigens were also 
tested against the sera from the Mongolian patients with diagnosed bacterial pneumonia (H. 
influenzae, M. pneumoniae, S pneumoniae, N. meningitidis) and syphilis (T. pallidum). Few 
cases amongst this group of individuals were found to be positive not only by the recombinant 
antigen ELISA but also by SAT assays. This can be interpreted as suspected Brucella infection 
cases which need further confirmation by PCR. In brucellosis endemic areas such as Mongolia, 
due to its non-specific clinical manifestation Brucella infections can be overlooked on the 
background of another disease with either more severe or/and intense symptoms.  
4.4 Antibodies during the course of Brucella infection 
Recent studies on reactivity of cytosolic proteins (Mantecón et al., 2006) have shown 
differences in the evolution of the specific antibodies. A gradual decrease of IgM and IgA was 
observed, while IgG levels became elevated and persisted through 10 months of infection. 
Another study (Kwaasi et al., 2005) analysed the reactivity of different fractions of proteins with 
these antibodies during a course of infection. It is believed that the presence of the IgM 
generally indicates a recent infection, and it acts mainly against the LPS and the bacterial 
surface structures. IgG as an indicator of a past infection, also can show high titres in 
individuals in endemic areas. To our experience, both IgM and IgG antibodies display more or 
less similar behaviour independent of a phase (acute / chronic) of the disease, however, 
presence of higher levels of IgM was observed in majority of cases of recent infection (data not 
shown). It should be mentioned that complete history, i.e. determination of phase of the disease 
was not done for all patients. Our experiments also indicated that immunoassays with 
recombinant antigens using either only anti-IgM or anti-IgG antibody-conjugates in tests for 
human brucellosis could cause false negative results suggesting the use of both of them in 
immunological tests. Thus, the detection and a subsequent determination of the antibody profile 
on per case basis could be of clinical importance.  
4.5 ELISA 
Compared to alternative immunoassays, ELISA is a most versatile method, and results 
being available within in short time. It also has the advantage of being readily automated, thus 
enabling its use as a screening test with the results numerically quantifiable.  
Weak reactivity of antigens such as Ompefflux and omp852 in ELISA can be explained 
by their small size and consequently, by weak binding to the plastic surface of microtiterplates. 
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One of the ways to overcome it is to increase the size of protein either through fusion with 
another antigen, or chemical cross linking to a carrier protein. There are many other techniques 
that increase either the specificity or sensitivity of the ELISA including the use of various 
enzymes and washing methods. An important source of non-specific background is the use of 
phosphatase-conjugated second antibodies in ELISA. This non-specific background could be 
drastically reduced by using peroxidase-conjugated antibodies and including skim milk as a 
blocking reagent. Background with phosphatase assays easily arises from small contaminations 
because phosphatases are ubiquitous enzymes occurring in all body fluids including sweat on 
the finger tips.   
Even though performance of ELISA with Brucella specific antigens can still be improved, 
both LP and P15-bp26-P39 triple fusion from our initial experiments seem to have qualities of 
antigens highly useful for diagnostic purposes. The other new antigens Ompefflux and Omp852 
need to be improved further and are considered to express in full length (Ompefflux) or to be 
included in fusion protein designs (Omp852) in future studies. In any case, it is apparent that the 
new ELISA tests can serve as an extension of the generally used SAT assay in Mongolia, or 
even as a the only single method to diagnose Brucella infections. 
4.6 PCR 
Since serologically positive responses can occur in convalescent hosts or may arise 
from antigenically cross-reactive bacteria, characterization of cultured bacteria is suggested to 
be the “gold standard” for diagnosis of Brucella infections at present. However, beside the low 
yield due to fastidious nature of the organism, identification by culturing has many drawbacks 
such as time needed to culture, the bio-safety requirements, training of the personnel for 
complex procedures and the limited number of well-defined Brucella subtypes. PCR-based 
methods as a diagnostic tool for brucellosis have been proven to be faster and more sensitive 
than traditional methods. So far, the acceptance of molecular diagnostics has been slow, 
especially in developing countries. One of the purposes of this work was to develop a PCR 
assay that has the advantage of being rapid, specific, sensitive and inexpensive as compared to 
the currently practiced methods in Mongolia.  
4.7 Specimens and DNA extraction  
We have found that buffy coat isolated from minute amounts of blood is a good source 
for Brucella-specific DNA for PCR. The simple method for leukocyte isolation developed in this 
work appears to be the preferable method in clinical laboratory practice. Neither the extraction 
of DNA from whole blood nor the extraction of DNA from serum results in better yields. 
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Moreover, very little DNA was found in serum and corresponding few positive results were 
obtained with this DNA, which, according to some authors, is recommended specimen for the 
PCR assays (Zerva, 2001). Although the leukocytes are the target and the main place of 
localization of Brucella upon infection, their presence in plasma, especially in the acute phase of 
brucellosis, can not be ruled out. Whole blood specimen would be better, in principle, because 
they contain all possible forms of the bacteria, but they are not the optimal source of DNA. It is 
very demanding to extract pure DNA from the large amount of tissue represented by the 
erythrocytes. 2 ml volumes of coagulation-inhibited blood turned out to be ideal because it can 
be used in parallel for both, immunological tests as well as for harvesting of leukocytes for DNA 
extraction. The quantity of leukocytes obtained from this volume of blood was sufficient to detect 
Brucella DNA with high sensitivity, while lower volumes of 0-5-1.0 ml recommended by some 
authors (Queipo-Ortuño et al., 1997) led to reduced performance of PCR.  
In order to efficiently separate leukocytes it was tried to use a 2.5 % glutaraldehyde 
solution to clot and isolate the yellow layer of leukocytes and platelets (buffy coat) from the top 
of the sedimented erythrocytes. The method proved to be effective, but because it is a time- 
consuming procedure it was substituted by a method including red blood cell lysis buffer as 
described in the Materials and Methods section. In cases of focal complications such as 
neurobrucellosis, the specimen for the PCR assays can be cerebrospinal fluid, synovial fluid 
and purulent material as well. Both the leukocyte pellets and the whole blood specimens can be 
stored for long time at -20° C. An alternative method includes guanidinium hydrochloride to 
extract and conserve the DNA at the same time. In this case, the samples can be stored at 4°C.  
DNA extracted from our specimens was stable at -20° C  for at least three years when dissolved 
in a neutral buffer.  
The method for extraction and isloation of DNA used in this work combines leukocyte 
isolation procedure from whole blood by RBC lysis buffer (Kawasaki, 1990) and a newly 
developed guanidine-silica extraction protocol. This method turned out to be fast, inexpensive, 
and safer as compared to phenol-chloroform extraction, which employs hazardous organic 
solvents. Extraction can be carried out in a single tube, which is important in terms of avoiding 
cross-contamination, and can also be applied for the routine clinical diagnosis. Pre-treatment of 
samples by proteinase K as recommended by many authors, did not influence the DNA yield, 
but could be useful for extractions from other tissues, e.g. biopsy materials in focal 
complications of brucellosis.  
It is important to avoid contaminations with potential PCR-inhibitory substances, such as 
hemin and its derivatives. Other compounds such as the EDTA and heparin do not influence the 
PCR efficiency by applying the guanidinium-silica purification procedure. Thus, the various 
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washing steps are essential: the first wash with erythrocyte lysis solution to remove most of the 
hemoglobin derivatives and various other washings thereafter. On the other hand, the 
diagnostic PCR signal can be inhibited if the amount of DNA exceeds a certain threshold value 
(Cogswell et al., 1996). Accordingly, this work included evaluation of the effects of washing and 
empirical study of acceptable concentrations of the total DNA (bacterial plus host leukocytic) to 
obtain an optimal yield and to ensure the reliability of PCR signals for the diagnosis of Brucella 
spp. in human peripheral-blood samples.  
4.8 Primers. Design, PCR conditions, reaction mix, ready-to-use mixes  
Primers for PCR diagnosis were selected using DNA sequences available from Gene 
Bank Database and other resources. All computer programs needed for DNA manipulation were 
freely obtained from the internet. In order to increase specificity as well as sensitivity, nested 
primers were designed for each specific target sequence. The annealing temperatures were 
chosen universally at 60°C for convenience. The genus-specific primers were developed and 
tested first . Two sets of nested primers, first specific for 16SrRNA gene (Herman et al., 1992; 
Cetinkaya et al., 1999; Romero et al., 1995) and another for pcaC 4-carboximuconolactone 
decarboxylase gene (PCA) (Ratushna et al., 2006) were designed and successfully tested. 
Although primers specific for 16SrRNA gene had a slight sequence homology to that of O. 
anthropi, this fact was judged insignificant because this bacterium rarely causes disease in 
humans and the homology was not of a high degree. This set of four primers proved to be both 
sensitive and specific. The assays with these sets of primers were designed to result in different 
band sizes (247 bp for PCA and 606 bp for 16SrRNA primers), which is important in case of 
combining these primers in multiplex PCR assays. 
Species-specific primers were designed using a different approach. First, we designed 
set of primers where the reverse IS711 primer is located at 3' end of the IS711 element, 
whereas the reverse primers are derived from species-specific loci from B. abortus, B. 
melitensis and B. suis .  This multiplex approach has the advantage of enabling a simultaneous 
detection of several species, but establishing was more demanding than with normal PCR 
assay. It was required to adjust the concentrations for all three sets of primers very precisely to 
obtain reliable results for all species in a single reaction. Analogous approaches were described 
by several authors for B. suis (Bricker et al., 1994; Redkar et al., 2001). The published multiplex 
PCR does not detect all biovars of B. suis, covering only the biovar 1. By this reason, other sets 
of primers were designed in this work.  
To detect all potential Brucella species occurring in Mongolia, species-specific primers 
were designed that amplified only one specific region of each species at a time and resulted in a 
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particular size of the amplicon for each species. Species-specific primer sequences were 
selected targeting the following genes and regions: outer membrane transporter for B. abortus, 
transcriptional regulator, GNTR family gene encoding sequence for B. melitensis, and HlyD 
family secretion protein for B. suis (Ratushna et al., 2006). We attempted to combine these 
assays into a single multiplex reaction, but it turned out to be not feasible to adjust the 
concentration of all primers in a way that high sensitivity for all three species was warranted. 
The primers were therefore used in single species-specific PCR reactions.  
Thirdly, based on a size-specific polymorphism of immunoglobulin-binding protein EIBE, 
we selected primers which amplify different size products in each species, allowing 
differentiation of the species by the size of the amplified products (Ratushna et al., 2006).  
Reasonable results were obtained using these primers, but the coverage of all strains occurring 
worldwide should be questioned and has still to be confirmed for Mongolia, since the primer 
designs were based on the strains detected in the USA.  
In addition to Brucella-specific PCR, all samples were screened with Coxiella burnetii–
specific primers in order to reveal the presence of this pathogen in our samples (not shown in 
the Results section). The pathogen has the same route of transmission and similar pathogenetic 
features, necessitating a differential diagnosis. Multiplex PCRs were performed, with the C. 
burnetii- and each genus-specific Brucella primer pairs. The16SrRNA primers proved to be 
useful for the assay, since they had the same annealing temperatures. Amongst 20 patients 
being negative in Brucella-specific PCR but showing typical clinical signs of disease 5 cases of 
C. burnetii-infections were detected by this way. This shows that this disease is an important 
issue of the health sector of Mongolia in animal-human transmission of zoonoses and the 
disease caused by this agent needs further study and investigation.  
A frequently discussed disadvantage of the nested PCR assays is that they have a 
certain risk of carry-over contaminations which, however, can be avoided by careful handling. In 
order to adapt the PCR assays for laboratories with a limited experience or limited facilities for 
PCR, we have developed a method of preparation of off-the-shelf, pre-optimized, pre-mixed, 
pre-dispensed PCR reaction mixes using trehalose as a presevative. A reconstitution of the mix 
by water and the template DNA addition are the only things required. Previous experiments 
were made with sugars such as betaine and arabinose, but trehalose turned out to be of best 
for this purpose. According to our experience, this mixture is stable at least for three months at 
room temperature and helps enormously to prevent any kind of contamination. This method  
was already described (Klatser et al., 1998; Spiess et al., 2004) for detection of Mycobacteria 
and in the meantime such ready-to-use mixes are already commercially available for several 
pathogens.  
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4.9 Brucellosis in Mongolia 
Opposite to other published data and studies on epidemiology of brucellosis in Mongolia, 
results in this work show prevalence of B. abortus infection in patients. The apparent prevalence 
of B. abortus infection in Mongolian brucellosis patients, despite sheep and goat being a 
dominant livestock throughout the country is unexpected. It is in conflict with some statistical 
data and epidemiological transmission models developed by other researchers (Zinsstag et al., 
2005, Ebright et al., 2003), but agrees with data from other countries (Pappaset al., 2006; Reid, 
2005), where B. abortus is prevalent. It can be explained by change in the epidemiological 
pattern of brucellosis during the last decades like in some other regions of the world (Fosgate et 
al., 2002) such in California, due to immigration and altered socioeconomic structure of 
population. 
It is known that the main route of transmission of B. abortus from cattle to humans is the 
consumption of raw milk or its products. Mongolia, where traditional practices prevent this route 
of transmission (heating, transformation to foodstuff with low pH etc.) has experience of 
controlling and preventing the disease, however, a switch to the market economy along with 
reduction in the governmental regulatory policy influenced the re-emergence of the disease. 
Brucellosis in Mongolia in the last decades is probably widespread among the privately owned 
animals and the chances of the home-made milk products sold on the markets or bought from 
neighbours of not being adequately pasteurized are high. The spread of brucellosis in farm 
animals might be attributable to the privatization of collective (state-owned) farms as a result of 
the changed political and economic situation in the country. Collective farm animals were 
distributed to small private farms; families who own these animals might disregard or not be 
aware of sanitary and health requirements necessary to prevent transmission of brucellosis to 
humans. A probable consequence of privatization of the animal sector is an increased volume 
of home-made animal food products with inadequate sanitary control over production 
(Kozukeev, 2006). Referring to this fact, the increase in brucellosis transmission via this route in 
Mongolia cannot be ruled out although the cases of infection of cattle by B. melitensis seem to 
be emerging as an important problem in some southern European countries, e.g. in Israel, 
Kuwait and Saudi Arabia (Corbel, 1997). 
Another possibility is that the cases of B. abortus infection in Mongolia could be under-
reported, since infections with B. melitensis are generally considered more likely to be 
diagnosed than infection with other Brucella species due to its greater severity of the disease. 
Therefore, in most cases patients with only severe manifestation and complications of 
brucellosis seek medical help. It can be explained by some specific features or factors in 
Mongolia as the distance to the nearest health facility: Some households are far from hospitals 
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and poor infrastructure make accessibility to health care difficult. Even in areas where there is 
transportation, affordability of the costs of transport makes patients unable to present to 
hospitals in time as well. Due to these factors and conditions the percentage of reported B. 
melitensis infections could be higher than it is in reality. 
Studies carried out in the late 70s and 80s in Mongolia on the blood cultures for isolation 
and differentiation of Brucella species have shown the prevalence of B. melitensis in human 
brucellosis. Although blood cultures with further typing are “gold standard” for definite diagnosis 
of the disease, they have some drawbacks. In acute forms of infection produced by B. 
melitensis, the yield of blood cultures is usually high, reaching 70-80 % of cases (Ariza et al., 
1995). However, this figure is notably reduced in infections caused by B. abortus and B. suis, 
where the positive results rarely surpasses 30-50 % (Colmenero et al., 1996). These facts 
should not be ignored and could be a reason of under-diagnosing of the cases of B. abortus 
infections. 
Finally, this work was carried out with a set of samples collected in a short span of time 
from ambulatory outpatients coming mainly from Ulaanbaatar, the capital city. It is possible that 
the majority of them had a common source of infection caused by local outbreak on a milk farm 
near the city. 
Another possibility lays in different vaccination practices of or efficiencies of vaccinations 
on different kinds of livestock in Mongolia, causing the varied clearance of animals from 
Brucella, e.g. small livestock versus cattle. 
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5 CONCLUSION 
During this work two mayor principles for the diagnosis of Brucellosis, one of the major 
challenges of health in Mongolia, have been approached. First, a highly specific procedure for 
general immunodiagnosis was established. A set of protein antigens was selected to develop an 
indirect ELISA test for serological diagnosis of human brucellosis. The antigens were tested on 
various serum samples in order to evaluate their specificity and sensitivity in the diagnosis of 
this disease. Two of the generated antigens, namely the LP and a fusion polyprotein including 
three immunodominant proteins have proven to be useful. To our experience, the fusion protein 
antigen had much more enhanced specificity and sensitivity than single antigens. In principle, 
this fusion antigen is a great step forward to highly specific and sensitive immunodiagnosis 
leading to far more precise results than the diagnostic procedures applied to date. However 
including additional reactive antigen candidates could still enhance the quality of the assay.  
 Attempts were also made to develop fast, specific and sensitive PCR assays for 
diagnosis of Brucella spp. on the genus and species level. The PCR assays proved to be 
specific and sensitive enough to be a method of choice for definite diagnosis of Brucella 
infections in Mongolia and could be applicable in the routine clinical diagnosis. The genus-
specific PCR assays were confirmed to be appropriate in terms of simplicity and sensitivity. The 
16SrRNA as well as the PCA primers combined with other primers can be used for diagnosis of 
other pathogen with similar pathogenesis, e.g. C. burnetii. Contaminations can be drastically 
reduced by preparing ready-to-use mixes, enabling use by the laboratory personnel of limited 
training. Introduction of the PCR-based assays will be of great importance for comprehensive 
epidemiological analyses of brucellosis in Mongolia. 
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7 APPENDIX 
DNA, primers, and protein sequences of the recombinant antigens  
Recombinant proteins cloned and expressed in E.coli :  
B.abortus bacterioferritin, P15 
B.abortus 17-kDa protein, P17  
B.abortus 39-kDa cytoplasmic protein, P39 
B.abortus 26 kDa periplasmic protein, bp26 
B.melitensis Omp31outer membrane protein, omp31               
B.abortus Omp25 outer membrane protein, omp25 
B.melitensis 16M membrane alanine aminopeptidase, AminopepN              
B.abortus outer membrane lipoprotein-related protein, LP 
B. abortus hypothetical omp62289852 , Baomp852 
B.abortus outer membrane efflux protein, Baompeff 
P15-bp26 fusion 
P15-P39 fusion 
Bp26-Baomp852 fusion 
Bp26-P39 fusion 
P15-bp26-P39 fusion 
P15 
DNA sequence (gi|29423750|gb|AY229988.1|  Brucella melitensis biovar Abortus 
bacterioferritin (bfr) gene): 
        1 cgcggccgtt gctgtggctg cttcccaaat gtcgtagaaa ccatcataag ggtgactgaa 
       61 gaatactatc ttcgtcgcaa ccaaatggac gaaaacatta tccagttcat ggatcgtgtg 
      121 cgttctctac gagataaatt cgggagttca tggaatgaaa ggcgaaccaa aggtcatcga 
      181 gcggcttaac gaggcactgt ttcttgagct cggtgcggta aaccagtatt ggctgcacta 
      241 ccgtcttctc aacgattggg gttacacgcg ccttgcaaag aaggaacgcg aggaatccat 
      301 cgaggaaatg catcacgccg acaagctgat tgatcgcatt atcttccttg aaggctttcc 
      361 gaacctccag accgtttcgc cgttgcgcat tggccagaat gtgaaggaag ttctcgaagc 
      421 tgacctcaag ggtgaatatg acgctcgcgc ttcgtataag gaatcgcgcg aaatctgcga 
      481 caagctcggc gactatgtgt cgaagcagct tttcgacgaa cttctggccg atgaagaagg 
      541 ccatatcgac ttccttgaaa cccagcttga ccttctcgcc aagatcggcg gagaacgcta 
      601 tggccagctt aacgcggcgc ccgccgacga agctgagtaa gcctgtttca atctgtcttg 
      661 aaagccgggg cgcatcgctc cggctttttc tttgg 
 
Primers: 
BAp15-for: ATAGGATCCatgaaaggcgaaccaaaggt(BamHI) 
BAp15-rev: TATAAGCTTtaagctggccatagcgttct(HindIII) 
 
Sequence size: 457 bp. 
Protein sequence including His-tag:     
           94 
MRGSHHHHHHGSMKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREES 
IEEMHHADKLIDRIIFLEGFPNLQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREIC 
DKLGDYVSKQLFDELLADEEGHIDFLETQLDLLAKIGGERYGQL 
 
Molecular weight of recombinant protein: 19.1 kD. 
P17 
DNA sequence (gi|599653|emb|Z46864.1|BAORFP17  B.abortus gene for open reading 
frame): 
        1 gaattccgat cagtgcatag tttccgcgtg ctcgcgcaat ggtgcgcggg cttgttctcg 
       61 gggcggggtg aaactcccca ccggcggtat gaaaagcaat tttcaagccc gcgagcgcct 
      121 gaaatggaag ccgattcgca tgccatttca gggtcagcag atccggtgag atgccggagc 
      181 cgacggttaa agtccggatg gaagagagcg aatgagcgtc acgattgcgc cttccggcgt 
      241 cgttcttgcg ttcttttgtg cgccctgatt ctagtttcgt gaggaaccta tgaaccaaag 
      301 ctgtccgaac aagacatcct ttaaaatcgc attcattcag gcccgctggc acgccgacat 
      361 cgttgacgaa gcgcgcaaaa gctttgtcgc cgaactggcc gcaaagacgg gtggcagcgt 
      421 cgaggtagag atattcgacg tgccgggtgc atatgaaatt ccccttcacg ccaagacatt 
      481 ggccagaacc gggcgctatg cagccatcgt cggtgcggcc ttcgtgatcg acggcggcat 
      541 ctatcgtcat gatttcgtgg cgacggccgt tatcaacggc atgatgcagg tgcagcttga 
      601 aacggaagtg ccggtgctga gcgtcgtgct gacgccgcac catttccatg aaagcaagga 
      661 gcatcacgac ttcttccatg ctcatttcaa ggtgaagggc gtggaagcgg cccatgccgc 
      721 cttgcagatc gtgagcgagc gcagccgcat cgccgcgctt gtctgactaa ccctctataa 
      781 tacgcccgca atgggtataa atgtcgaatt c 
 
Primers: 
BAp17-for: ATAGGATCCcaaagctgtccgaacaagaca(BamHI) 
BAp17-rev: ATAGGTACCttgcgggcgtattatagagg (KpnI) 
 
Sequence size: 496 bp. 
 
Protein sequence, including His-tag:     
MRGSHHHHHHGSQSCPNKTSFKIAFIQARWHADIVDEARKSFVAELAAKTGGSVEVEIFDVPGAYEIPLH
AKTLARTGRYAAIVGAAFVIDGGIYRHDFVATAVINGMMQVQLETEVPVLSVVLTPHHFHESKEHHDFFH
AHFKVKGVEAAHAALQIVSERSRIAALV 
 
Molecular weight of recombinant protein: 18.51 kD. 
P39 
DNA sequence (gi|13936894|gb|AF360361.1|AF360361 Brucella melitensis 
biovar Abortus immunogenic 39-kDa protein(p39)and39UgpA1(39ugpa1)genes): 
        1 atgggcgcct gttgccaatg cgcaggaaaa gcagaatgtc gaggttctgc actggtgacg 
       61 tccggcggcg aagcgtccgc gcttgaagtt ttgaaaaaag atcttgaaag caagggcatt 
      121 agctggaccg atatgccggt tgcaggtggc ggcggcacgg aagccatgac cgttttgcgc 
      181 gcgcgcgtta ccgcaggcaa tgcgccaacc gcggtgcaga tgctgggttt tgacattcgc 
      241 gactgggcgg agcagggcgc actcggcaat ctcgatacgg ttgcttccaa ggaaggctgg 
      301 gaaaaggtta ttccggctcc cttgcaggaa tttgccaaat atgacggcca ctggattcgt 
      361 gcgcccgtca atattcactc caccaactgg atgtggatca acaaggctgc tctcgacaag 
      421 gctggcggca aggagccgac caattgggat gagctgattg cgcttctcga caatttcaag 
      481 gcgcagggca ttacgccgat cgcgcatggc ggccagccgt ggcaggatgc aaccattttc 
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      541 gatgcggttg ttctttcatt cggcccggat ttctacaaga aggccttcat cgatctcgac 
      601 ccggaagcac tgggcagcga taccatgaag caggccttcg accgcatgtc caagcttcgc 
      661 acctatgttg atgacaactt ctccggccgt gactggaacc ttgcttcggc catggttatc 
      721 gaaggcaagg ccggtgtcca gttcatgggc gactgggcga agggcgagtt cctcaaggcg 
      781 ggcaagaagc cgggtgagga tttcgtctgc atgcgttatc cgggcacgca gggtgctgtc 
      841 actttcaatt ccgacatgtt cgccatgttc aaggtttcgg aagacaaggt tcccgcacag 
      901 cttgaaatgg cttcggcgat tgaaagccct gccttccagt ctgcctttaa tgtggtgaag 
      961 gggtcggccc cggcacgcac ggatgtgccc gataccgctt tcgatgcctg tggcaagaag 
     1021 gccattgccg atgtcaagga agcaaacagc aagggcactc tgcttggctc catggcgcat 
     1081 ggctatgcca atccggctgc cgtgaagaat gcgatctacg acgtcgtgac ccgccagttc 
     1141 aacggccagc tttcttcgga agatgccgtc aaggaactcg ttgtggcggt tgaagccgca 
     1201 aaataa 
 
Primers: 
BAp39-for:ATAGGATCCgaaagcaagggcattagctg(BamHI) 
Bap39-rev: ATAGGTACCcttattttgcggcttcaacc(KpnI) 
 
Sequence size: 1102 bp. 
 
Protein sequence, including His-tag:       
MRGSHHHHHHGSESKGISWTDMPVAGGGGTEAMTVLRARVTAGNAPTAVQMLGFDIRDWAEQGALGNLDT
VASKEGWEKVIPAPLQEFAKYDGHWIRAPVNIHSTNWMWINKAALDKAGGKEPTNWDELIALLDNFKAQG
ITPIAHGGQPWQDATIFDAVVLSFGPDFYKKAFIDLDPEALGSDTMKQAFDRMSKLRTYVDDNFSGRDWN
LASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRYPGTQGAVTFNSDMFAMFKVSEDKVPAQLEM
ASAIESPAFQSAFNVVKGSAPARTDVPDTAFDACGKKAIADVKEANSKGTLLGSMAHGYANPAAVKNAIY
DVVTRQFNGQLSSEDAVKELVVAVEAAK 
 
Molecular weight of recombinant protein: 40.87 kD. 
BP26 
DNA sequence (gi|32699289|gb|AY166764.1|  Brucella melitensis biovar Abortus strain 
870 BP26 (bp26) gene): 
        1 atgaacactc gtgctagcaa ttttctcgca gcctcatttt ccacaatcat gctcgtcggc 
       61 gctttcagcc tgcccgcttt cgcacaggag aatcagatga cgacgcagcc cgcgcgcatc 
      121 gccgtcaccg gggaaggcat gatgacggcc tcgcccgata tggccattct caatctctcg 
      181 gtgctacgcc aggcaaagac cgcgcgcgaa gccatgaccg cgaataatga agccatgaca 
      241 aaagtgctcg atgccatgaa gaaggccggc atcgaagatc gcgatctcca gacaggcggc 
      301 atcaatatcc agccgattta tgtctatcct gacgacaaga acaacctgaa agagcctacc 
      361 atcaccggct attctgtatc caccagtctc acggttcgcg tgcgcgaact ggccaatgtt 
      421 ggaaaaattt tggatgaatc cgtcacgctc ggtgttaatc agggcggtga tttgaacctg 
      481 gtcaatgata atccctccgc cgtgatcaac gaggcgcgca agcgcgcagt ggccaatgcc 
      541 attgccaagg cgaagacgct tgccgacgct gcaggcgtgg ggcttggccg tgtggtggaa 
      601 atcagtgaac tgagccgccc gcccatgccg atgccaattg cgcgcggaca gttcagaacc 
      661 atgctagcag ccgcaccgga caattccgtg ccgattgccg caggcgaaaa cagctataac 
      721 gtatcggtca atgtcgtttt tgaaatcaag taa 
     
Primers: 
BMbp26-for: ATAGGATCCatgaacactcgtgctagcaattt (BamHI) 
BMbp26-rev: TATAAGCTTagctgctagcatggttctgaactg(HindIII)  
 
Sequence size: 671 bp. 
 
Protein sequence, including His-tag:   
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MRGSHHHHHHGSIGSMNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMA
ILNLSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYS
VSTSLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGL
GRVVEISELSRPPMPMPIARGQFRTMLA 
 
Molecular weight of recombinant protein: 25.42 kD. 
Omp31 
DNA sequence (gi|17982305|gb|AE009483.1| Brucella melitensis 16M chromosome I, 
section 40 of 195): 
        1 atgtttagct taaaagggac tgttatgaaa accgcacttc ttgcatccgt cgcaatgttg 
       61 ttcacaagct cggctatggc tgccgacatc atcgttgctg aaccggcacc cgttgcagtc 
      121 gacacgttct cttggactgg cggctatatt ggtatcaatg ctggttacgc tggcggcaag 
      181 ttcaagcatc cgttctcagg catcgagcag gatggggccc aagatttttc aggttcgctc 
      241 gacgtcacgg ccagcggctt tgttggcggc gttcaggccg gttataactg gcagcttgcc 
      301 aacggcctcg tgcttggtgg cgaagctgac ttccagggct cgacggttaa gagcaagctt 
      361 gttgacaacg gtgacctctc cgatatcggc gttgcaggca acctcagcgg cgacgaaagc 
      421 ttcggcctcg agaccaaggt tcagtggttt ggaacggtgc gtgcgcgcct cggcttcacc 
      481 ccgactgaac gcctgatggt ctatggtacc ggtggtttgg cctatggtaa ggtcaagacg 
      541 tcgcttagcg cctatgacga tggtgaatcg ttcagcgccg gaaactccaa gaccaaggct 
      601 ggctggacgc ttggtgcagg tgtagaatac gccgtcacca acaattggac cctgaagtcg 
      661 gaatacctct acaccgacct cggcaagcgt tccttcaatt acattgatga agaaaacgtc 
      721 aatattaaca tggaaaacaa ggtgaacttc cacaccgtcc gcctcggtct gaactacaag 
      781 ttc taa 
Primers: 
omp31-for: ATAGGATCCatgtttagcttaaaagggactgttat(BamHI)  
omp31-rev: ATACTGCAGttagaacttgtagttcagaccgag  (PstI) 
 
Sequence size: 786 bp. 
 
Protein sequence, including His-tag:   
MRGSHHHHHHGSMFSLKGTVMKTALLASVAMLFTSSAMAADIIVAEPAPVAVDTFSWTGGYIGINAGYAG
GKFKHPFSGIEQDGAQDFSGSLDVTASGFVGGVQAGYNWQLANGLVLGGEADFQGSTVKSKLVDNGDLSD
IGVAGNLSGDESFVLETKVQWFGTVRARLGFTPTERLMVYGTGGLAYGKVKTSLSAYDDGESFSAGNSKT
KAGWTLGAGVEYAVTNNWTLKSEYLYTDLGKRSFNYIDEENV 
NINMENKVNFHTVRLGLNYKF 
 
Molecular weight of recombinant protein: 29.18 kD. 
Omp25 
DNA sequence (gi|157310308|emb|AM712382.1| Brucella sp.CCM 4916 omp25 gene for 
outer membrane protein 25): 
        1 atgcgcactc ttaagtctct cgtaatcgtc tcggctgcgc tgctgccgtt ctctgcgacc 
       61 gcttttgctg ccgacgccat ccaggaacag cctccggttc cggctccggt tgaagtagct 
      121 ccccagtata gctgggctgg tggctatacc ggtctttacc ttggctacgg ctggaacaag 
      181 gccaagacca gcaccgttgg cagcatcaag cctgacgatt ggaaggctgg cgcctttgct 
      241 ggctggaact tccagcagga ccagatcgta tacggtgttg aaggtgatgc aggttattcc 
      301 tgggccaaga agtccaagga cggcctggaa gtcaagcagg gctttgaagg ctcgctgcgt 
      361 gcccgcgtcg gctacgacct gaacccggtt atgccgtacc tcacggctgg tattgccggt 
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      421 tcgcagatca agcttaacaa cggcttggac gacgaaagca agttccgcgt gggttggacg 
      481 gctggtgccg gtctcgaagc caagctgacg gacaacatcc tcggccgcgt tgagtaccgt 
      541 tacacccagt acggcaacaa gaactatgat ctggccggta cgactgttcg caacaagctg 
      601 gacacgcagg atatccgcgt cggcatcggc tacaagttct aa 
 
Primers: 
omp25-for: ATAGGATCCatgcgcactcttaagtctctcg(BamHI)   
omp25-rev: ATACTGCAGttagaacttgtagccgatgcc (PstI)    
 
Sequence size: 642 bp. 
 
Protein sequence, including His-tag:     
MRGSHHHHHHGSMRTLKSLVIVSAALLPFSATAFAADAIQEQPPVPAPVEVAPQYSWAGGYTGLYLGYGW
NKAKTSTVGSIKPDDWKAGAFAGWNFQQDQIVYGVEGDAGYSWAKKSKDGLEVKQGFEGSLRARVGYDLN
PVMPYLTAGIAGSQIKLNNGLDDESKFRVGWTAGAGLEAKLTDNILGRVEYRYTQYGNKNYDLAGTTVRN
KLDTQDIRVGIGYKF 
 
Molecular weight of recombinant protein: 24.55 kD. 
AminopepN 
DNA sequence (gi|17983309|gb|AE009570.1| Brucella melitensis 16M chromosome I, 
section 127 of 195): 
        1 atgcgtactg aaaccggcca tactttccgt ctcgaagatt atcgccagac accttacgcc 
       61 atacccgaaa cgaaactcga cttcacactg gagccggaaa aaaccatcgt gcgcgcaacg 
      121 ctcaccatag agcgccgctc cgatacgccc gccggtacgc cgctcgttct ccacggtgac 
      181 gaattgaagc tcgtgagcct tgccatcgac ggcaaggcgc tttccgacaa cagcttttcg 
      241 gccacgcccg accagttgac catcagcgat cttccgaaag atgtgcgctt caccttgcag 
      301 atcgtgaccg aggtgaaccc aacagccaat cgccagcttt ccggccttta ccgctccagc 
      361 ggcgtctatt gcacccaatg cgaggcggaa ggctttcgtc gcatcaccta tttttacgac 
      421 cgcccggacg tgctgtcggt ctatacggtg cgtgtcgatg ccgaccgcaa agccgctccc 
      481 atcctgcttt caaacggcaa ccctgtcgaa aacggcatgg tggagggcca gccggaacgg 
      541 cattttgccg tctggcacga cccgcatcca aaaccctcct atcttttcgc gctcgtcgcc 
      601 ggttcgctcg gcgtggtgaa agaccacttt acaacccgat ctggacggcc cgtcgatctc 
      661 gccatccatg tggaacatgg caaggagggc cgcgcgcttt atgcgatgga cgcgctgaaa 
      721 cgctccatga aatgggacga ggaaaaattc ggccgcgaat atgaccttaa cgttttcaat 
      781 atcgtcgccg tctccgattt caacatgggc gcgatggaga acaagggcct caatatcttc 
      841 aacgacaaat atgtgctggc cgatcctgaa accgtgaccg atgcggatta tgccggcatc 
      901 gaagccgtta tcgcgcatga atatttccac aactggaccg gcaaccgcat cacctgccgc 
      961 gactggttcc agctatgcct caaggaaggc ctgacggttt atcgcgatca cgaattttcc 
     1021 gccgaccagc gctcgcgccc tgtcaagcgc attgcggagg tgaaaatcct gaaagcgcag 
     1081 caattcccgg aggatgcagg ctcgcttgcc catccggtgc gccctcgcga atatcgcgag 
     1141 atcaataatt tctatacggc aaccgtctat gaaaaaggtt cggaagtcgt tcgcatgatc 
     1201 cgcaccatca tcgggccgga gctgttccgc aagggcatgg acctctattt cgagcgccat 
     1261 gacggcgatg cggcgaccat cgagaatttc atccaggttt ttgccgatgt ttccgggcag 
     1321 gatttctcgc aattcgcgct ctggtacgat caggccggta caccgaaggt ggaagccggg 
     1381 ttccatcatg acgcagccgc gaagacattc acgatcaagc tggaacagtc acttgcgccg 
     1441 acacccggcc agtcgatcag gaagcccatg catataccca ttgccttcgg cctgatcggg 
     1501 ccggacggca aggacatgca gccctcgtcg gtggaaggcg gcgaggtgcg cgacggcgta 
     1561 atccatttgc gccgcccatc cgaaaccatc gtcttccatg gcatcgaggc ccggcccgtg 
     1621 ccgtcgctgc tgcgcggctt ttcggcgcca gtcaatctcg ccgcgcctct cacggcggaa 
     1681 gaccgggttt tccttgccct gaacgatagc gaccccgttg cgcgctggca ggcgatgaac 
     1741 agcattttct ctgcgaccct tctggatggc gccaagcgtg tgcgcggcgg gcatcagccg 
     1801 gaaaccgatc cgaagatcgt cgcgctggcc ggaaaggtcg ccttcgatga aatgctggac 
     1861 ccggctttcc gggcgctttg cctgacgctg ccgagcgaaa gcgatatcgc gcgcgaaatg 
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     1921 ggtaacaatg tcgatccaga cgcaatcctc gccagccgca accatctgat tgcagcaatc 
     1981 gcttcaggct atgccgatgg atttgccggg ctctatgaca cgctgaagca ggaaggggcg 
     2041 ttttcacccg atgcggcccc ggcgggaaag cgtgccttgc gtagcgccct tctcgattat 
     2101 ctcagcgttc aggaaaagag ccctgaacgt gcagaaaggc aatttgtcga agccgacaac 
     2161 atgacggacc gcgccacggc gctggccgtt ctggtccatc gttttggcga tagcggcgaa 
     2221 gcccgtcagg cgctcgcaac cttcgagcaa acgttcggcc aggatgcgct cgtgatggac 
     2281 aaatggttca tcgtgcaggc gacacgcccc ggcgaaacgg cccttgaagc agtgagggaa 
     2341 ctgacccgcc atccgctctt ttctctcgac aatccaaatc gcgtgcgcgc gctcatcggc 
     2401 gcatttacgg cttccaaccc gaccgggttc aaccgccaag atggtgcagc ctatggtttc 
     2461 ctcgccgata cgcttctgac cattgatccg aaaaacccgc agctttccgc acggcttttg 
     2521 acggcaatgc gctcatggcg gtcgctggaa gaggtgcggc gcgaacatgc ccgcgcggca 
     2581 ctggcgcgca ttgcaggcgc aggcaaactc tccaccgatc tgcgcgacat catcgaccga 
     2641 acgctcgcct ga 
 
Primers: 
AminP-for: ATAGGATCCatgcgtactgaaaccggccatac(BamHI)   
AminP-rev: TATAAGCTTtcaggcgagcgttcggtc     (HindII)  
 
Sequence size: 2652 bp. 
 
Protein sequence, including His-tag:     
MRGSHHHHHHGSMRTETGHTFRLEDYRQTPYAIPETKLDFTLEPEKTIVRATLTIERRSDTPAGTPLVLH
GDELKLVSLAIDGKALSDNSFSATPDQLTISDLPKDVRFTLQIVTEVNPTANRQLSGLYRSSGVYCTQCE
AEGFRRITYFYDRPDVLSVYTVRVDADRKAAPILLSNGNPVENGMVEGQPERHFAVWHDPHPKPSYLFAL
VAGSLGVVKDHFTTRSGRPVDLAIHVEHGKEGRALYAMDALKRSMKWDEEKFGREYDLNVFNIVAVSDFN
MGAMENKGLNIFNDKYVLADPETVTDADYAGIEAVIAHEYFHNWTGNRITCRDWFQLCLKEGLTVYRDHE
FSADQRSRPVKRIAEVKILKAQQFPEDAGSLAHPVRPREYREINNFYTATVYEKGSEVVRMIRTIIGPEL
FRKGMDLYFERHDGDAATIENFIQVFADVSGQDFSQFALWYDQAGTPKVEAGFHHDAAAKTFTIKLEQSL
APTPGQSIRKPMHIPIAFGLIGPDGKDMQPSSVEGGEVRDGVIHLRRPSETIVFHGIEARPVPSLLRGFS
APVNLAAPLTAEDRVFLALNDSDPVARWQAMNSIFSATLLDGAKRVRGGHQPETDPKIVALAGKVAFDEM
LDPAFRALCLTLPSESDIAREMGNNVDPDAILASRNHLIAAIASGYADGFAGLYDTLKQEGAFSPDAAPA
GKRALRSALLDYLSVQEKSPERAERQFVEADNMTDRATALAVLVHRFGDSGEARQALATFEQTFGQDALV
MDKWFIVQATRPGETALEAVRELTRHPLFSLDNPNRVRALIGAFTASNPTGFNRQDGAAYGFLADTLLTI
DPKNPQLSARLLTAMRSWRSLEEVRREHARAALARIAGAGKLSTDLRDIIDRTLA 
 
Molecular weight of recombinant protein: 99.46 kD. 
LP 
DNA sequence (gi|62289568|ref|YP_221361.1| Brucella abortus biovar 1 str. 9-941outer 
membrane lipoprotein-related protein): 
        1 atgcgtgctg attgttatga aggccggttt gttatgatga tagtttccag gttttctcgc 
       61 cctgttccag ttatatcgat gatgtttgtc gtgtcgctgg cactgtcggc ctgcggcacg 
      121 acgggcggcg gcaaggggag cggttttcca tcgctgggcg gctcatcaca gaagccggaa 
      181 acgaacctgc tcgcttcgct tggcaacggc ctgcttggca attcggccag tcagttgagt 
      241 gcggctgatc gcaggaaggc gctggaagct gaatatcgcg cgcttgaata ttcgccagcg 
      301 gggaaatcgg ttttgtggag cggagccgga tcaaacgctg gcgacgtgac ggcggcgcaa 
      361 ccctatcagg tcggctcgca gaactgccgc caatattcgc atagtttcac cattggcggg 
      421 gatcagcaga cggtgcgtgg cacggcttgc cgcaatcccg acggtagctg gacaccgctg 
      481 acctga 
Primers:  
LP-for: ATAGGATCCatgcgtgctgattgttatgaag(BamHI) 
LP-rev: TATAAGCTTtcaggtcagcggtgtcca    (HindIII) 
 
Sequence size: 486 bp. 
Protein sequence, including His-tag: 
           99 
MRGSHHHHHHGSMRADCYEGRFVMMIVSRFSRPVPVISMMFVVSLALSACGTTGGGKGSGFPSLGGSSQK
PETNLLASLGNGLLGNSASQLSAADRRKALEAEYRALEYSPAGKSVLWSGAGSNAGDVTAAQPYQVGSQN
CRQYSHSFTIGGDQQTVRGTACRNPDGSWTPLT 
 
Molecular weight of recombinant protein: 18.21 kD. 
Baomp852 
DNA sequence (gi|62289852|ref|YP_221645.1| Brucella abortus biovar 1 str. 9-941 
outer membrane protein, hypothetical): 
       1 atgaaaaatg cggcttccat tacgatagcg agcggtatta tcggcttggt tgcgcatggt  
      61 atcggatatt gtgccggtac ggcgcgacag gcctccaagc ctgtacaggc tgcaacctcc  
     121 accgttgcct ttaacccgaa ggccgtcgaa aacatcgtgc gcaattatct gcttcagaac  
     181 ccggaactga tgctggaagt gcagaccgcg cttgaaacca aacaggctca tgcggcacag  
     241 gaacaggtga agcaggtact ggccgccaat cagagcgttc ttttcgaccc caagcatgat  
     301 gctgtctttg gcaacccgaa tggcgacgtg acggtctatg aattcttcga ttacaattgc  
     361 ggctattgca agcgcgcgct tcccgatatg gaagcgatcc tgaaaaaaga tccgaatgtt  
     421 cgttatgtcc tcaaggagtt cccgatcctg gggccggatt ccatgcgtgc gcatgtggtc  
     481 tcccaggctt tcaaggcgct gatgccggag aagtacccgg aatttcatga aatgctgctt  
     541 ggcgggcatg ggcgcgcaac ggaggaatcc gcgattgccg acgccgtaaa gctcggcgcc  
     601 gatgaagcta agcttcgtga aaaaatgaag gacccggcca tcaccggcgc tttccagcgg  
     661 acctaccagc ttgcgcaaca gctcaacatc accggcactc cgtcctatgt catcggcgac  
     721 gaactggtgc ccggcgctat tggtatcgat ggattgcggc agaggatcgc ggccgcccgg  
     781 gacgctgcaa agaagtaa         
 
Primers: 
Baomp852-for: ATAGGATCCTtacaggctgcaacctccac (BamHI) 
Baomp852-rev: ATACTGCAGcaatccatcgataccaatagc(PstI) 
Sequence size: 654 bp. 
 
Protein sequence, including His-tag:       
MRGSHHHHHHGSLQAATSTVAFNPKAVENIVRNYLLQNPELMLEVQTALETKQAHAAQEQVKQVLAANQS
VLFDPKHDAVFGNPNGDVTVYEFFDYNCGYCKRALPDMEAILKKDPNVRYVLKEFPILGPDSMRAHVVSQ
AFKALMPEKYPEFHEMLLGGHGRATEESAIADAVKLGADEAKLREKMKDPAITGAFQRTYQLAQQLNITG
TPSYVIGDELVPGAIGIDGL 
 
Molecular weight of recombinant protein: 25.39 kD. 
Baompeff 
DNA sequence (gi|62289884|ref|YP_221677.1| Brucella abortus biovar 1 str. 9-941outer 
membrane efflux family protein): 
        
 
       1 atgaggtaca cggtgttcaa agcgtgcaag gaactggtag cggccgcagt attgttgtct  
      61 ggcaccgttt taacggggca ggccgctctg tcggagacgc tgactggcgc tctcgtcaag  
     121 gcttacaaga ataatgcttc cctgaattcc tcgcgggcag gggtgcgcat tcaggacgaa  
     181 aacgtggcga ttgccaaatc tgcctaccgg ccacagatta ccggttctta taatatatcg  
     241 agaggcaaga cgccggccac cgattatcgt acgactggta cggttggcat ccagttgaac  
     301 cagatgcttt tcgacggttt tcagaccagg aacaatgttg ccgccgctga aacgcaagtc  
     361 ttcgcgcagc gcgaaaacct ccgcaatgat gagcagaaca cgctctatca ggcggtagcc  
     421 gcctatatgg atgtttacca gcttcgccag attgctgcac tgcgcgagaa gaaccttgcc  
           100 
     481 gccatgaacg agcaggtgcg tgccgcacgc gctcgccttg atgtgggtga ggggacgcgc  
     541 accgacgttg ctcaggcaga ggccagccgc tccacagcca tagccgctct caacgccgcg  
     601 cgtgcagacg tgaaaacggc ggaagccacc tatatgcagg tcgttggatc gctgccggac  
     661 aagcttaccc cggcttctgc ggccaggcat cttccccagt cgccgagcca ggcctatgcg  
     721 tctgcgctcg cttctcatcc cggcatcctc gccacgaaat atgccgtcaa tgccgccggt  
     781 tataatgtca aggccaagga aggcgcactg cttccgacca ttggcctgac ggcaagcgcc  
     841 agccagcttg acactatcgc agggacggat atgggcgacg gtaacacggc atcgatcggc  
     901 gttggcgtca gcattccgat ctacacgggc ggccgcacgt cagcgcagat ccgccagtcc  
     961 aaggaacagc ttggtcaggc gcgaatcgag gttgatgtcg tgcaggacaa ggttcgtcag  
    1021 gccatcagtt cagcctggtc gcagctggaa gctgcccgtg cctcggtcgc agcaaaccgt  
    1081 gatggtattg ccgccgcaca gcttgccctc gatggcgtca ttgaagaacg caaggttggc  
    1141 cagcgcacga cgcttgacgt gttgaatgcc cagaacgatc tcgtcgcagt gcagatcgct  
    1201 ctagttcagg ccgaacatga tgttgttgtg gcgagctatg ctcttctgaa tgccacgggc  
    1261 cgcatgactg ccgaccagct tggtttgcag gtggcccagt ataagccgga agagcactac  
    1321 aaggcggtga aagacaagtg gttcggcctg cgtacgcctg atggccgcta atcggctctg  
    1381 caaacaatat ttcgatggcg cctgtgggcg ccatttctgt ttgtggcgat tcgcatcgtc  
    1441 caatttctta ataaatccat aaagctgtga gtttggatga tgcgttatc   
 
Primers:  
BAompeff-for: ATAGGATCCatcgaggttgatgtcgtgcag (BamHI) 
BAompeff-rev: TATAAGCTTacgcatcatccaaactcaca (HindIII) 
 
Sequence size: 510 bp. 
 
Protein sequence, including His-tag:      
MRGSHHHHHHGSIEVDVVQDKVRQAISSAWSQLEAARASVAANRDGIAAAQLALDGVIEERKVGQRTTLD
VLNAQNDLVAVQIALVQAEHDVVVASYALLNATGRMTADQLGLQVAQYKPEEHYKAVKDKWFGLRTPDGR 
 
Molecular weight of recombinant protein: 15.31 kD. 
P15-bp26 fusion 
DNA sequence: 
       1 atgaaaggcg aaccaaaggt catcgagcgg cttaacgagg cactgtttct tgagctcggt  
      61 gcggtaaacc agtattggct gcactaccgt cttctcaacg attggggtta cacgcgcctt  
     121 gcaaagaagg aacgcgagga atccatcgag gaaatgcatc acgccgacaa gctgattgat  
     181 cgcattatct tccttgaagg ctttccgaac ctccagaccg tttcgccgtt gcgcattggc  
     241 cagaatgtga aggaagttct cgaagctgac ctcaagggtg aatatgacgc tcgcgcttcg  
     301 tataaggaat cgcgcgaaat ctgcgacaag ctcggcgact atgtgtcgaa gcagcttttc  
     361 gacgaacttc tggccgatga agaaggccat atcgacttcc ttgaaaccca gcttgacctt  
     421 ctcgccaaga tcggcggaga acgctatggc cagcttaaag ctattccgct gagcagatcc  
     481 atgaacactc gtgctagcaa ttttctcgca gcctcatttt ccacaatcat gctcgtcggc  
     541 gctttcagcc tgcccgcttt cgcacaggag aatcagatga cgacgcagcc cgcgcgcatc  
     601 gccgtcaccg gggaaggcat gatgacggcc tcgcccgata tggccattct caatctctcg  
     661 gtgctacgcc aggcaaagac cgcgcgcgaa gccatgaccg cgaataatga agccatgaca  
     721 aaagtgctcg atgccatgaa gaaggccggc atcgaagatc gcgatctcca gacaggcggc  
     781 atcaatatcc agccgattta tgtctatcct gacgacaaga acaacctgaa agagcctacc  
     841 atcaccggct attctgtatc caccagtctc acggttcgcg tgcgcgaact ggccaatgtt  
     901 ggaaaaattt tggatgaatc cgtcacgctc ggtgttaatc agggcggtga tttgaacctg  
     961 gtcaatgata atccctccgc cgtgatcaac gaggcgcgca agcgcgcagt ggccaatgcc  
    1021 attgccaagg cgaagacgct tgccgacgct gcaggcgtgg ggcttggccg tgtggtggaa  
    1081 atcagtgaac tgagccgccc gcccatgccg atgccaattg cgcgcggaca gttcagaacc  
    1141 atgctagcag c 
 
Sequence size: 1153 bp 
Adapter sequence, HindIII-BamHI-AD2 is underlined (see the sequence in RESULTS) 
Protein sequence, including His-tag: 
           101 
MRGSHHHHHHMKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREESIEEMHHADKLIDRIIFLEG
FPNLQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDELLADEEGHIDFLETQLDLLAKI
GGERYGQLKAIPLSRSMNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILNLSV
LRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELA
NVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMPMPIAR
GQFRTMLA 
 
Molecular weight of recombinant protein: 43.01 kDa 
P15-P39 fusion 
DNA sequence: 
       1 atgaaaggcg aaccaaaggt catcgagcgg cttaacgagg cactgtttct tgagctcggt  
      61 gcggtaaacc agtattggct gcactaccgt cttctcaacg attggggtta cacgcgcctt  
     121 gcaaagaagg aacgcgagga atccatcgag gaaatgcatc acgccgacaa gctgattgat  
     181 cgcattatct tccttgaagg ctttccgaac ctccagaccg tttcgccgtt gcgcattggc  
     241 cagaatgtga aggaagttct cgaagctgac ctcaagggtg aatatgacgc tcgcgcttcg  
     301 tataaggaat cgcgcgaaat ctgcgacaag ctcggcgact atgtgtcgaa gcagcttttc  
     361 gacgaacttc tggccgatga agaaggccat atcgacttcc ttgaaaccca gcttgacctt  
     421 ctcgccaaga tcggcggaga acgctatggc cagcttaaag ctattccgct gagcagatcc  
     481 gaaagcaagg gcattagctg gaccgatatg ccggttgcag gtggcggcgg cacggaagcc  
     541 atgaccgttt tgcgcgcgcg cgttaccgca ggcaatgcgc caaccgcggt gcagatgctg  
     601 ggttttgaca ttcgcgactg ggcggagcag ggcgcactcg gcaatctcga tacggttgct  
     661 tccaaggaag gctgggaaaa ggttattccg gctcccttgc aggaatttgc caaatatgac  
     721 ggccactgga ttcgtgcgcc cgtcaatatt cactccacca actggatgtg gatcaacaag  
     781 gctgctctcg acaaggctgg cggcaaggag ccgaccaatt gggatgagct gattgcgctt  
     841 ctcgacaatt tcaaggcgca gggcattacg ccgatcgcgc atggcggcca gccgtggcag  
     901 gatgcaacca ttttcgatgc ggttgttctt tcattcggcc cggatttcta caagaaggcc  
     961 ttcatcgatc tcgacccgga agcactgggc agcgatacca tgaagcaggc cttcgaccgc  
    1021 atgtccaagc ttcgcaccta tgttgatgac aacttctccg gccgtgactg gaaccttgct  
    1081 tcggccatgg ttatcgaagg caaggccggt gtccagttca tgggcgactg ggcgaagggc  
    1141 gagttcctca aggcgggcaa gaagccgggt gaggatttcg tctgcatgcg ttatccgggc  
    1201 acgcagggtg ctgtcacttt caattccgac atgttcgcca tgttcaaggt ttcggaagac  
    1261 aaggttcccg cacagcttga aatggcttcg gcgattgaaa gccctgcctt ccagtctgcc  
    1321 tttaatgtgg tgaaggggtc ggccccggca cgcacggatg tgcccgatac cgctttcgat  
    1381 gcctgtggca agaaggccat tgccgatgtc aaggaagcaa acagcaaggg cactctgctt  
    1441 ggctccatgg cgcatggcta tgccaatccg gctgccgtga agaatgcgat ctacgacgtc  
    1501 gtgacccgcc agttcaacgg ccagctttct tcggaagatg ccgtcaagga actcgttgtg  
    1561 gcggttgaag ccgcaaaata a     
 
Sequence size: 1581 bp 
 
Adapter sequence, HindIII-BamHI – AD2 is underlined (see the sequence in RESULTS) 
 
Protein sequence, including His-tag: 
MRGSHHHHHHGSMKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREESIEEMHHADKL
IDRIIFLEGFPNLQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDELLADEE
GHIDFLETQLDLLAKIGGERYGQLKAIPLSRSESKGISWTDMPVAGGGGTEAMTVLRARVTAGNAPTAVQ
MLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIRAPVNIHSTNWMWINKAALDKAGG
KEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPDFYKKAFIDLDPEALGSDTMKQAF
DRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRYPGTQGAVTFN
SDMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVVKGSAPARTDVPDTAFDACGKKAIADVKEANSKGT
LLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAAK 
 
Molecular weight of recombinant protein: 59.4 kDa 
           102 
BP26-P39 fusion 
DNA sequence: 
 
       1 atgaacactc gtgctagcaa ttttctcgca gcctcatttt ccacaatcat gctcgtcggc  
      61 gctttcagcc tgcccgcttt cgcacaggag aatcagatga cgacgcagcc cgcgcgcatc  
     121 gccgtcaccg gggaaggcat gatgacggcc tcgcccgata tggccattct caatctctcg  
     181 gtgctacgcc aggcaaagac cgcgcgcgaa gccatgaccg cgaataatga agccatgaca  
     241 aaagtgctcg atgccatgaa gaaggccggc atcgaagatc gcgatctcca gacaggcggc  
     301 atcaatatcc agccgattta tgtctatcct gacgacaaga acaacctgaa agagcctacc  
     361 atcaccggct attctgtatc caccagtctc acggttcgcg tgcgcgaact ggccaatgtt  
     421 ggaaaaattt tggatgaatc cgtcacgctc ggtgttaatc agggcggtga tttgaacctg  
     481 gtcaatgata atccctccgc cgtgatcaac gaggcgcgca agcgcgcagt ggccaatgcc  
     541 attgccaagg cgaagacgct tgccgacgct gcaggcgtgg ggcttggccg tgtggtggaa  
     601 atcagtgaac tgagccgccc gcccatgccg atgccaattg cgcgcggaca gttcagaacc  
     661 atgctagcag ctaagctgcc gagcctgagc agatccgaaa gcaagggcat tagctggacc  
     721 gatatgccgg ttgcaggtgg cggcggcacg gaagccatga ccgttttgcg cgcgcgcgtt  
     781 accgcaggca atgcgccaac cgcggtgcag atgctgggtt ttgacattcg cgactgggcg  
     841 gagcagggcg cactcggcaa tctcgatacg gttgcttcca aggaaggctg ggaaaaggtt  
     901 attccggctc ccttgcagga atttgccaaa tatgacggcc actggattcg tgcgcccgtc  
     961 aatattcact ccaccaactg gatgtggatc aacaaggctg ctctcgacaa ggctggcggc  
    1021 aaggagccga ccaattggga tgagctgatt gcgcttctcg acaatttcaa ggcgcagggc  
    1081 attacgccga tcgcgcatgg cggccagccg tggcaggatg caaccatttt cgatgcggtt  
    1141 gttctttcat tcggcccgga tttctacaag aaggccttca tcgatctcga cccggaagca  
    1201 ctgggcagcg ataccatgaa gcaggccttc gaccgcatgt ccaagcttcg cacctatgtt  
    1261 gatgacaact tctccggccg tgactggaac cttgcttcgg ccatggttat cgaaggcaag  
    1321 gccggtgtcc agttcatggg cgactgggcg aagggcgagt tcctcaaggc gggcaagaag  
    1381 ccgggtgagg atttcgtctg catgcgttat ccgggcacgc agggtgctgt cactttcaat  
    1441 tccgacatgt tcgccatgtt caaggtttcg gaagacaagg ttcccgcaca gcttgaaatg  
    1501 gcttcggcga ttgaaagccc tgccttccag tctgccttta atgtggtgaa ggggtcggcc  
    1561 ccggcacgca cggatgtgcc cgataccgct ttcgatgcct gtggcaagaa ggccattgcc  
    1621 gatgtcaagg aagcaaacag caagggcact ctgcttggct ccatggcgca tggctatgcc  
    1681 aatccggctg ccgtgaagaa tgcgatctac gacgtcgtga cccgccagtt caacggccag  
    1741 ctttcttcgg aagatgccgt caaggaactc gttgtggcgg ttgaagccgc aaaataa  
 
Sequence size: 1797 bp 
 
Adapter sequence, HindIII-BamHI – AD1 is underlined (see the sequence in RESULTS) 
 
Protein sequence, including His-tag: 
MRGSHHHHHHGSMNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAVTGEGMMTASPDMAILN
LSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVST
SLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRV
VEISELSRPPMPMPIARGQFRTMLAAKLPSLSRSESKGISWTDMPVAGGGGTEAMTVLRARVTAGNAPTA
VQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIRAPVNIHSTNWMWINKAALDKA
GGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPDFYKKAFIDLDPEALGSDTMKQ
AFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRYPGTQGAVT
FNSDMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVVKGSAPARTDVPDTAFDACGKKAIADVKEANSK
GTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAAK 
Molecular weight of recombinant protein: 64.16 kDa 
Baomp852-bp26 fusion 
DNA sequence:  
       1 ttacaggctg caacctccac cgttgccttt aacccgaagg ccgtcgaaaa catcgtgcgc  
      61 aattatctgc ttcagaaccc ggaactgatg ctggaagtgc agaccgcgct tgaaaccaaa  
     121 caggctcatg cggcacagga acaggtgaag caggtactgg ccgccaatca gagcgttctt  
     181 ttcgacccca agcatgatgc tgtctttggc aacccgaatg gcgacgtgac ggtctatgaa  
           103 
     241 ttcttcgatt acaattgcgg ctattgcaag cgcgcgcttc ccgatatgga agcgatcctg  
     301 aaaaaagatc cgaatgttcg ttatgtcctc aaggagttcc cgatcctggg gccggattcc  
     361 atgcgtgcgc atgtggtctc ccaggctttc aaggcgctga tgccggagaa gtacccggaa  
     421 tttcatgaaa tgctgcttgg cgggcatggg cgcgcaacgg aggaatccgc gattgccgac  
     481 gccgtaaagc tcggcgccga tgaagctaag cttcgtgaaa aaatgaagga cccggccatc  
     541 accggcgctt tccagcggac ctaccagctt gcgcaacagc tcaacatcac cggcactccg  
     601 tcctatgtca tcggcgacga actggtgccc ggcgctattg gtatcgatgg attgctgcat  
     661 ctgccgctga gcagatccat gaacactcgt gctagcaatt ttctcgcagc ctcattttcc  
     721 acaatcatgc tcgtcggcgc tttcagcctg cccgctttcg cacaggagaa tcagatgacg  
     781 acgcagcccg cgcgcatcgc cgtcaccggg gaaggcatga tgacggcctc gcccgatatg  
     841 gccattctca atctctcggt gctacgccag gcaaagaccg cgcgcgaagc catgaccgcg  
     901 aataatgaag ccatgacaaa agtgctcgat gccatgaaga aggccggcat cgaagatcgc  
     961 gatctccaga caggcggcat caatatccag ccgatttatg tctatcctga cgacaagaac  
    1021 aacctgaaag agcctaccat caccggctat tctgtatcca ccagtctcac ggttcgcgtg  
    1081 cgcgaactgg ccaatgttgg aaaaattttg gatgaatccg tcacgctcgg tgttaatcag  
    1141 ggcggtgatt tgaacctggt caatgataat ccctccgccg tgatcaacga ggcgcgcaag  
    1201 cgcgcagtgg ccaatgccat tgccaaggcg aagacgcttg ccgacgctgc aggcgtgggg  
    1261 cttggccgtg tggtggaaat cagtgaactg agccgcccgc ccatgccgat gccaattgcg  
    1321 cgcggacagt tcagaaccat gctagcagct a    
 
Sequence size: 1351 bp 
 
Adapter sequence, PstI -BamHI – AD1 is underlined (see the sequence in RESULTS) 
 
Protein sequence, including His-tag: 
MRGSHHHHHHGSLQAATSTVAFNPKAVENIVRNYLLQNPELMLEVQTALETKQAHAAQEQVKQVLAANQS
VLFDPKHDAVFGNPNGDVTVYEFFDYNCGYCKRALPDMEAILKKDPNVRYVLKEFPILGPDSMRAHVVSQ
AFKALMPEKYPEFHEMLLGGHGRATEESAIADAVKLGADEAKLREKMKDPAITGAFQRTYQLAQQLNITG
TPSYVIGDELVPGAIGIDGLLHLPLSRSMNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPARIAV
TGEGMMTASPDMAILNLSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDD
KNNLKEPTITGYSVSTSLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIA
KAKTLADAAGVGLGRVVEISELSRPPMPMPIARGQFRTMLAA 
 
Molecular weight of recombinant protein: 50.12 kDa 
P15-bp26-P39 fusion 
DNA sequence: 
       1 atgaaaggcg aaccaaaggt catcgagcgg cttaacgagg cactgtttct tgagctcggt  
      61 gcggtaaacc agtattggct gcactaccgt cttctcaacg attggggtta cacgcgcctt  
     121 gcaaagaagg aacgcgagga atccatcgag gaaatgcatc acgccgacaa gctgattgat  
     181 cgcattatct tccttgaagg ctttccgaac ctccagaccg tttcgccgtt gcgcattggc  
     241 cagaatgtga aggaagttct cgaagctgac ctcaagggtg aatatgacgc tcgcgcttcg  
     301 tataaggaat cgcgcgaaat ctgcgacaag ctcggcgact atgtgtcgaa gcagcttttc  
     361 gacgaacttc tggccgatga agaaggccat atcgacttcc ttgaaaccca gcttgacctt  
     421 ctcgccaaga tcggcggaga acgctatggc cagcttaaag ctattccgct gagcagatcc  
     481 atgaacactc gtgctagcaa ttttctcgca gcctcatttt ccacaatcat gctcgtcggc  
     541 gctttcagcc tgcccgcttt cgcacaggag aatcagatga cgacgcagcc cgcgcgcatc  
     601 gccgtcaccg gggaaggcat gatgacggcc tcgcccgata tggccattct caatctctcg  
     661 gtgctacgcc aggcaaagac cgcgcgcgaa gccatgaccg cgaataatga agccatgaca  
     721 aaagtgctcg atgccatgaa gaaggccggc atcgaagatc gcgatctcca gacaggcggc  
     781 atcaatatcc agccgattta tgtctatcct gacgacaaga acaacctgaa agagcctacc  
     841 atcaccggct attctgtatc caccagtctc acggttcgcg tgcgcgaact ggccaatgtt  
     901 ggaaaaattt tggatgaatc cgtcacgctc ggtgttaatc agggcggtga tttgaacctg  
     961 gtcaatgata atccctccgc cgtgatcaac gaggcgcgca agcgcgcagt ggccaatgcc  
    1021 attgccaagg cgaagacgct tgccgacgct gcaggcgtgg ggcttggccg tgtggtggaa  
    1081 atcagtgaac tgagccgccc gcccatgccg atgccaattg cgcgcggaca gttcagaacc  
    1141 atgctagcag ctaagctgcc gagcctgagc agatccgaaa gcaagggcat tagctggacc  
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    1201 gatatgccgg ttgcaggtgg cggcggcacg gaagccatga ccgttttgcg cgcgcgcgtt  
    1261 accgcaggca atgcgccaac cgcggtgcag atgctgggtt ttgacattcg cgactgggcg  
    1321 gagcagggcg cactcggcaa tctcgatacg gttgcttcca aggaaggctg ggaaaaggtt  
    1381 attccggctc ccttgcagga atttgccaaa tatgacggcc actggattcg tgcgcccgtc  
    1441 aatattcact ccaccaactg gatgtggatc aacaaggctg ctctcgacaa ggctggcggc  
    1501 aaggagccga ccaattggga tgagctgatt gcgcttctcg acaatttcaa ggcgcagggc  
    1561 attacgccga tcgcgcatgg cggccagccg tggcaggatg caaccatttt cgatgcggtt  
    1621 gttctttcat tcggcccgga tttctacaag aaggccttca tcgatctcga cccggaagca  
    1681 ctgggcagcg ataccatgaa gcaggccttc gaccgcatgt ccaagcttcg cacctatgtt  
    1741 gatgacaact tctccggccg tgactggaac cttgcttcgg ccatggttat cgaaggcaag  
    1801 gccggtgtcc agttcatggg cgactgggcg aagggcgagt tcctcaaggc gggcaagaag  
    1861 ccgggtgagg atttcgtctg catgcgttat ccgggcacgc agggtgctgt cactttcaat  
    1921 tccgacatgt tcgccatgtt caaggtttcg gaagacaagg ttcccgcaca gcttgaaatg  
    1981 gcttcggcga ttgaaagccc tgccttccag tctgccttta atgtggtgaa ggggtcggcc  
    2041 ccggcacgca cggatgtgcc cgataccgct ttcgatgcct gtggcaagaa ggccattgcc  
    2101 gatgtcaagg aagcaaacag caagggcact ctgcttggct ccatggcgca tggctatgcc  
    2161 aatccggctg ccgtgaagaa tgcgatctac gacgtcgtga cccgccagtt caacggccag  
    2221 ctttcttcgg aagatgccgt caaggaactc gttgtggcgg ttgaagccgc aaaataa  
 
Sequence size: 2277 bp 
 
Adapter sequences, HindIII-BamHI – AD1 is underlined and HindIII-BamHI – AD2 marked by 
bold face and underlined (see the sequence in RESULTS) 
 
Protein sequence, including His-tag: 
MRGSHHHHHHGSMKGEPKVIERLNEALFLELGAVNQYWLHYRLLNDWGYTRLAKKEREESIEEMHHADKL
IDRIIFLEGFPNLQTVSPLRIGQNVKEVLEADLKGEYDARASYKESREICDKLGDYVSKQLFDELLADEE
GHIDFLETQLDLLAKIGGERYGQLKAIPLSRSMNTRASNFLAASFSTIMLVGAFSLPAFAQENQMTTQPA
RIAVTGEGMMTASPDMAILNLSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYV
YPDDKNNLKEPTITGYSVSTSLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVA
NAIAKAKTLADAAGVGLGRVVEISELSRPPMPMPIARGQFRTMLAAKLPSLSRSESKGISWTDMPVAGGG
GTEAMTVLRARVTAGNAPTAVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVIPAPLQEFAKYDGHWIRA
PVNIHSTNWMWINKAALDKAGGKEPTNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPDF
YKKAFIDLDPEALGSDTMKQAFDRMSKLRTYVDDNFSGRDWNLASAMVIEGKAGVQFMGDWAKGEFLKAG
KKPGEDFVCMRYPGTQGAVTFNSDMFAMFKVSEDKVPAQLEMASAIESPAFQSAFNVVKGSAPARTDVPD
TAFDACGKKAIADVKEANSKGTLLGSMAHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAAK 
 
Molecular weight of recombinant protein: 84.09 kDa 
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